AU2008261325B2 - Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators - Google Patents
Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators Download PDFInfo
- Publication number
- AU2008261325B2 AU2008261325B2 AU2008261325A AU2008261325A AU2008261325B2 AU 2008261325 B2 AU2008261325 B2 AU 2008261325B2 AU 2008261325 A AU2008261325 A AU 2008261325A AU 2008261325 A AU2008261325 A AU 2008261325A AU 2008261325 B2 AU2008261325 B2 AU 2008261325B2
- Authority
- AU
- Australia
- Prior art keywords
- ethylamino
- butoxyphenyl
- dimethylacetamide
- disorder
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000011734 sodium Substances 0.000 title claims abstract description 60
- 108090000312 Calcium Channels Proteins 0.000 title claims abstract description 40
- 102000003922 Calcium Channels Human genes 0.000 title claims abstract description 40
- 108010052164 Sodium Channels Proteins 0.000 title claims abstract description 37
- 102000018674 Sodium Channels Human genes 0.000 title claims abstract description 37
- 229910052708 sodium Inorganic materials 0.000 title claims abstract description 36
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 title claims abstract description 35
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 title claims description 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 29
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 22
- 230000001575 pathological effect Effects 0.000 claims abstract description 19
- 230000007246 mechanism Effects 0.000 claims abstract description 16
- 208000020016 psychiatric disease Diseases 0.000 claims abstract description 15
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 13
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 13
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 13
- 230000007170 pathology Effects 0.000 claims abstract description 13
- 208000025609 Urogenital disease Diseases 0.000 claims abstract description 12
- 230000001149 cognitive effect Effects 0.000 claims abstract description 11
- 230000000926 neurological effect Effects 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 215
- 230000000694 effects Effects 0.000 claims description 68
- 238000011282 treatment Methods 0.000 claims description 62
- 239000003814 drug Substances 0.000 claims description 61
- 238000000034 method Methods 0.000 claims description 61
- 208000002193 Pain Diseases 0.000 claims description 55
- 125000000217 alkyl group Chemical group 0.000 claims description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 46
- 230000036407 pain Effects 0.000 claims description 46
- 230000002829 reductive effect Effects 0.000 claims description 46
- 208000035475 disorder Diseases 0.000 claims description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims description 45
- 239000001257 hydrogen Substances 0.000 claims description 45
- 201000006417 multiple sclerosis Diseases 0.000 claims description 44
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 31
- -1 2-[2-(3-Pentyloxyphenyl)-ethylamino]-acetamide 2-[2-(3-Hexyloxyphenyl)-ethylamino]-acetamide 2-[2-(3-Butoxyphenyl)-ethylamino]-N-methylacetamide 2-[2-(3-Pentyloxyphenyl)-ethylamino]-N-methylacetamide Chemical compound 0.000 claims description 23
- 230000002401 inhibitory effect Effects 0.000 claims description 20
- 208000004296 neuralgia Diseases 0.000 claims description 18
- 208000021722 neuropathic pain Diseases 0.000 claims description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- 201000000980 schizophrenia Diseases 0.000 claims description 13
- 208000006011 Stroke Diseases 0.000 claims description 12
- 230000004054 inflammatory process Effects 0.000 claims description 12
- GRHBODILPPXVKN-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC=CC(CCNCC(=O)N(C)C)=C1 GRHBODILPPXVKN-UHFFFAOYSA-N 0.000 claims description 11
- 208000018737 Parkinson disease Diseases 0.000 claims description 11
- 208000028017 Psychotic disease Diseases 0.000 claims description 11
- 206010015037 epilepsy Diseases 0.000 claims description 11
- 208000019901 Anxiety disease Diseases 0.000 claims description 10
- 206010026749 Mania Diseases 0.000 claims description 10
- 208000019695 Migraine disease Diseases 0.000 claims description 10
- 230000003287 optical effect Effects 0.000 claims description 10
- 208000011580 syndromic disease Diseases 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 208000020925 Bipolar disease Diseases 0.000 claims description 9
- 230000001154 acute effect Effects 0.000 claims description 9
- 206010027599 migraine Diseases 0.000 claims description 9
- 206010065390 Inflammatory pain Diseases 0.000 claims description 8
- 239000000164 antipsychotic agent Substances 0.000 claims description 8
- 230000036506 anxiety Effects 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 201000006474 Brain Ischemia Diseases 0.000 claims description 7
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 7
- 206010008118 cerebral infarction Diseases 0.000 claims description 7
- 208000000094 Chronic Pain Diseases 0.000 claims description 6
- 206010012335 Dependence Diseases 0.000 claims description 6
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 5
- 208000010643 digestive system disease Diseases 0.000 claims description 5
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims description 4
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims description 4
- 208000005298 acute pain Diseases 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 230000002917 arthritic effect Effects 0.000 claims description 3
- 150000001721 carbon Chemical group 0.000 claims description 3
- 230000004064 dysfunction Effects 0.000 claims description 3
- 230000002124 endocrine Effects 0.000 claims description 3
- 229960003878 haloperidol Drugs 0.000 claims description 3
- 125000002950 monocyclic group Chemical group 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- 229960001534 risperidone Drugs 0.000 claims description 3
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 2
- NUAHCZNEPOUXAO-UHFFFAOYSA-N 2-[2-(3-butoxy-2,6-difluorophenyl)ethylamino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC=C(F)C(CCNCC(=O)N(C)C)=C1F NUAHCZNEPOUXAO-UHFFFAOYSA-N 0.000 claims description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
- JTTWLNNOMMGAGB-UHFFFAOYSA-N C(CCC)OC=1C(=C(C=CC1)CCNCC(=O)N(C)C)F.C(CCC)OC=1C(=C(C=CC1)CCNCC(=O)N(C)C)Cl.C(CCC)SC=1C=C(C=CC1)CCNCC(=O)N(C)C Chemical compound C(CCC)OC=1C(=C(C=CC1)CCNCC(=O)N(C)C)F.C(CCC)OC=1C(=C(C=CC1)CCNCC(=O)N(C)C)Cl.C(CCC)SC=1C=C(C=CC1)CCNCC(=O)N(C)C JTTWLNNOMMGAGB-UHFFFAOYSA-N 0.000 claims description 2
- DALQTPVCQMVNNL-UHFFFAOYSA-N C(CCC)OC=1C=C(C=C(C1)C(F)(F)F)CCNCC(=O)N(C)C.C(CCC)OC=1C=C(C=CC1C(F)(F)F)CCNCC(=O)N(C)C Chemical compound C(CCC)OC=1C=C(C=C(C1)C(F)(F)F)CCNCC(=O)N(C)C.C(CCC)OC=1C=C(C=CC1C(F)(F)F)CCNCC(=O)N(C)C DALQTPVCQMVNNL-UHFFFAOYSA-N 0.000 claims description 2
- RKBZDLPXBNLJAB-UHFFFAOYSA-N C(CCCC)OC=1C=C(C=CC1)CCNCC(=O)N1CCCC1.C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N1CCCC1.C(CCCCC)OC=1C=C(C=CC1)CCNCC(=O)N(C)C Chemical compound C(CCCC)OC=1C=C(C=CC1)CCNCC(=O)N1CCCC1.C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N1CCCC1.C(CCCCC)OC=1C=C(C=CC1)CCNCC(=O)N(C)C RKBZDLPXBNLJAB-UHFFFAOYSA-N 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims description 2
- 229960004170 clozapine Drugs 0.000 claims description 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- PEFUSHFQQPUGQX-UHFFFAOYSA-N n,n-dimethyl-2-[2-[3-(4,4,4-trifluorobutoxy)phenyl]ethylamino]acetamide Chemical compound CN(C)C(=O)CNCCC1=CC=CC(OCCCC(F)(F)F)=C1 PEFUSHFQQPUGQX-UHFFFAOYSA-N 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 2
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 claims 2
- IRPKKGLOGMXKDX-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dibutylacetamide N,N-dimethyl-2-[2-(3-pentoxyphenyl)ethylamino]acetamide Chemical compound CCCCCOC1=CC=CC(CCNCC(=O)N(C)C)=C1.CCCCOC1=CC=CC(CCNCC(=O)N(CCCC)CCCC)=C1 IRPKKGLOGMXKDX-UHFFFAOYSA-N 0.000 claims 1
- RYVJELATBDCMNB-UHFFFAOYSA-N C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)COC.C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)CO Chemical compound C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)COC.C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)CO RYVJELATBDCMNB-UHFFFAOYSA-N 0.000 claims 1
- UOUSPOHEYLJZJG-UHFFFAOYSA-N C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N(CCC)CCC.C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N(CC)CC.C(CCC)OC=1C=C(C=CC1OC)CCNCC(=O)N(C)C Chemical compound C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N(CCC)CCC.C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N(CC)CC.C(CCC)OC=1C=C(C=CC1OC)CCNCC(=O)N(C)C UOUSPOHEYLJZJG-UHFFFAOYSA-N 0.000 claims 1
- MBQVGFDQYDCDLJ-QZCDQQELSA-N C(CCC)OC=1C=C(C=CC1)CCN[C@H](C(=O)NC)C.C(CCC)OC=1C=C(C=CC1)CCN[C@H](C(=O)N)C.C(CCCCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)(C)C Chemical compound C(CCC)OC=1C=C(C=CC1)CCN[C@H](C(=O)NC)C.C(CCC)OC=1C=C(C=CC1)CCN[C@H](C(=O)N)C.C(CCCCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)(C)C MBQVGFDQYDCDLJ-QZCDQQELSA-N 0.000 claims 1
- WZOFNFHSLGILIU-UHFFFAOYSA-N C(CCCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)(C)C.C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)(C)C.C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)COCCC Chemical compound C(CCCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)(C)C.C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)(C)C.C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)COCCC WZOFNFHSLGILIU-UHFFFAOYSA-N 0.000 claims 1
- VRLSELRYHHSXAL-UHFFFAOYSA-N n,n-dimethyl-2-[2-(3-pentoxyphenyl)ethylamino]acetamide Chemical compound CCCCCOC1=CC=CC(CCNCC(=O)N(C)C)=C1 VRLSELRYHHSXAL-UHFFFAOYSA-N 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 abstract description 5
- 238000012360 testing method Methods 0.000 description 99
- 241000700159 Rattus Species 0.000 description 70
- 239000000243 solution Substances 0.000 description 51
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 48
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 45
- 241001465754 Metazoa Species 0.000 description 44
- 241000699670 Mus sp. Species 0.000 description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 38
- 229940079593 drug Drugs 0.000 description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 37
- 230000004044 response Effects 0.000 description 35
- 102000010909 Monoamine Oxidase Human genes 0.000 description 32
- 108010062431 Monoamine oxidase Proteins 0.000 description 32
- 235000015424 sodium Nutrition 0.000 description 31
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- 238000005481 NMR spectroscopy Methods 0.000 description 28
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 24
- 230000006977 prepulse inhibition Effects 0.000 description 24
- 239000002904 solvent Substances 0.000 description 24
- 239000007924 injection Substances 0.000 description 23
- 238000002347 injection Methods 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 22
- BHJIBOFHEFDSAU-LBPRGKRZSA-N ralfinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC=C1F BHJIBOFHEFDSAU-LBPRGKRZSA-N 0.000 description 22
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 21
- 239000003112 inhibitor Substances 0.000 description 21
- 239000003981 vehicle Substances 0.000 description 20
- 239000012458 free base Substances 0.000 description 19
- 239000000523 sample Substances 0.000 description 19
- 239000011780 sodium chloride Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 229940025084 amphetamine Drugs 0.000 description 18
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 17
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 17
- 208000004454 Hyperalgesia Diseases 0.000 description 17
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 17
- 210000004556 brain Anatomy 0.000 description 17
- 238000007912 intraperitoneal administration Methods 0.000 description 17
- NEMGRZFTLSKBAP-LBPRGKRZSA-N safinamide Chemical compound C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 NEMGRZFTLSKBAP-LBPRGKRZSA-N 0.000 description 17
- 229960002646 scopolamine Drugs 0.000 description 17
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 14
- 208000010340 Sleep Deprivation Diseases 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 229960003920 cocaine Drugs 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- 230000006742 locomotor activity Effects 0.000 description 14
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 14
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 14
- DXNSJWVLSBMXNR-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n,n-dimethylacetamide;hydrochloride Chemical compound Cl.CCCCOC1=CC=CC(CCNCC(=O)N(C)C)=C1 DXNSJWVLSBMXNR-UHFFFAOYSA-N 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 229950002652 safinamide Drugs 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 12
- 230000003542 behavioural effect Effects 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- 239000003208 petroleum Substances 0.000 description 12
- DZGWFCGJZKJUFP-UHFFFAOYSA-N tyramine Chemical compound NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 12
- 108091006146 Channels Proteins 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 11
- 239000001961 anticonvulsive agent Substances 0.000 description 11
- 229960004782 chlordiazepoxide Drugs 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 206010010904 Convulsion Diseases 0.000 description 10
- 238000000540 analysis of variance Methods 0.000 description 10
- 239000000935 antidepressant agent Substances 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 239000011575 calcium Substances 0.000 description 10
- 230000000284 resting effect Effects 0.000 description 10
- 229940127291 Calcium channel antagonist Drugs 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 230000033001 locomotion Effects 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 208000009935 visceral pain Diseases 0.000 description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 8
- 229910052791 calcium Inorganic materials 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 231100000869 headache Toxicity 0.000 description 8
- 229940098779 methanesulfonic acid Drugs 0.000 description 8
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 8
- 230000036278 prepulse Effects 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 239000003195 sodium channel blocking agent Substances 0.000 description 8
- 230000001256 tonic effect Effects 0.000 description 8
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 102000004129 N-Type Calcium Channels Human genes 0.000 description 7
- 108090000699 N-Type Calcium Channels Proteins 0.000 description 7
- XMMFBEWONDCTLD-UHFFFAOYSA-N acetyl(dimethyl)azanium;chloride Chemical compound Cl.CN(C)C(C)=O XMMFBEWONDCTLD-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 229940005513 antidepressants Drugs 0.000 description 7
- 239000000480 calcium channel blocker Substances 0.000 description 7
- 210000003618 cortical neuron Anatomy 0.000 description 7
- 230000006735 deficit Effects 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000377 silicon dioxide Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 229960003732 tyramine Drugs 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 208000000044 Amnesia Diseases 0.000 description 6
- 208000031091 Amnestic disease Diseases 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 241000700157 Rattus norvegicus Species 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 230000006986 amnesia Effects 0.000 description 6
- 230000001430 anti-depressive effect Effects 0.000 description 6
- 230000006399 behavior Effects 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 229960004397 cyclophosphamide Drugs 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 208000013403 hyperactivity Diseases 0.000 description 6
- 230000004941 influx Effects 0.000 description 6
- 238000001802 infusion Methods 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 230000001537 neural effect Effects 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 210000001032 spinal nerve Anatomy 0.000 description 6
- 238000010561 standard procedure Methods 0.000 description 6
- 229960004793 sucrose Drugs 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010005052 Bladder irritation Diseases 0.000 description 5
- 206010052804 Drug tolerance Diseases 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 239000004743 Polypropylene Substances 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 230000002411 adverse Effects 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- 230000026781 habituation Effects 0.000 description 5
- 125000005843 halogen group Chemical group 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 230000002427 irreversible effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 229960002715 nicotine Drugs 0.000 description 5
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000008313 sensitization Effects 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 238000001356 surgical procedure Methods 0.000 description 5
- HGDKMPFGWLNLNM-UHFFFAOYSA-N tert-butyl 2-(3-butoxyphenyl)-3-[[2-(dimethylamino)-2-oxoethyl]amino]propanoate Chemical compound CCCCOC1=CC=CC(C(CNCC(=O)N(C)C)C(=O)OC(C)(C)C)=C1 HGDKMPFGWLNLNM-UHFFFAOYSA-N 0.000 description 5
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 5
- 229950010357 tetrodotoxin Drugs 0.000 description 5
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 4
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 206010001497 Agitation Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 208000035154 Hyperesthesia Diseases 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 238000013019 agitation Methods 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 210000003050 axon Anatomy 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 description 4
- 229960000623 carbamazepine Drugs 0.000 description 4
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 4
- 210000000080 chela (arthropods) Anatomy 0.000 description 4
- DMLFJMQTNDSRFU-UHFFFAOYSA-N chlordiazepoxide hydrochloride Chemical compound Cl.O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 DMLFJMQTNDSRFU-UHFFFAOYSA-N 0.000 description 4
- 229960004725 chlordiazepoxide hydrochloride Drugs 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical group C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 4
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229940127237 mood stabilizer Drugs 0.000 description 4
- 239000004050 mood stabilizer Substances 0.000 description 4
- 230000000803 paradoxical effect Effects 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 229940076279 serotonin Drugs 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- 208000014001 urinary system disease Diseases 0.000 description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 3
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 3
- CNMUBJSRKQDUFE-UHFFFAOYSA-N 2-[2-(3-butylsulfanylphenyl)ethylamino]-n,n-dimethylacetamide;hydrochloride Chemical compound Cl.CCCCSC1=CC=CC(CCNCC(=O)N(C)C)=C1 CNMUBJSRKQDUFE-UHFFFAOYSA-N 0.000 description 3
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 208000004547 Hallucinations Diseases 0.000 description 3
- 206010019196 Head injury Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 3
- 229920005372 Plexiglas® Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010046543 Urinary incontinence Diseases 0.000 description 3
- 208000026723 Urinary tract disease Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 230000001773 anti-convulsant effect Effects 0.000 description 3
- 230000009016 anticipatory response Effects 0.000 description 3
- 229960003965 antiepileptics Drugs 0.000 description 3
- 206010003119 arrhythmia Diseases 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000009460 calcium influx Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 3
- 229960000632 dexamfetamine Drugs 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 3
- 229960001848 lamotrigine Drugs 0.000 description 3
- 229960005015 local anesthetics Drugs 0.000 description 3
- 210000003141 lower extremity Anatomy 0.000 description 3
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 3
- 229960004644 moclobemide Drugs 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 230000007823 neuropathy Effects 0.000 description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 3
- 229960002748 norepinephrine Drugs 0.000 description 3
- 210000001331 nose Anatomy 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 229960000964 phenelzine Drugs 0.000 description 3
- 125000003395 phenylethylamino group Chemical group [H]N(*)C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 239000004926 polymethyl methacrylate Substances 0.000 description 3
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 3
- 229960003946 selegiline Drugs 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000007958 sleep Effects 0.000 description 3
- 229910001415 sodium ion Inorganic materials 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000007492 two-way ANOVA Methods 0.000 description 3
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 2
- YKOCHIUQOBQIAC-YDALLXLXSA-N (2s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC(CN[C@@H](C)C(N)=O)=CC=C1OCC1=CC=CC(F)=C1 YKOCHIUQOBQIAC-YDALLXLXSA-N 0.000 description 2
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- NEQLCGUSTOFEFD-UHFFFAOYSA-N 2,2-dimethylpropanoylazanium;chloride Chemical compound Cl.CC(C)(C)C(N)=O NEQLCGUSTOFEFD-UHFFFAOYSA-N 0.000 description 2
- AHBUNJHJPGYIIE-UHFFFAOYSA-N 2-(3-butoxy-4-methylphenyl)acetonitrile Chemical compound CCCCOC1=CC(CC#N)=CC=C1C AHBUNJHJPGYIIE-UHFFFAOYSA-N 0.000 description 2
- ZYGSFFRTJZACEL-UHFFFAOYSA-N 2-(3-butylsulfanylphenyl)acetonitrile Chemical compound CCCCSC1=CC=CC(CC#N)=C1 ZYGSFFRTJZACEL-UHFFFAOYSA-N 0.000 description 2
- QAOJXZSPCDKVBM-UHFFFAOYSA-N 2-(3-hydroxy-4-methylphenyl)acetonitrile Chemical compound CC1=CC=C(CC#N)C=C1O QAOJXZSPCDKVBM-UHFFFAOYSA-N 0.000 description 2
- YMUMJIHZRRIBPK-UHFFFAOYSA-N 2-(3-methoxyphenyl)-2-methylpropanenitrile Chemical compound COC1=CC=CC(C(C)(C)C#N)=C1 YMUMJIHZRRIBPK-UHFFFAOYSA-N 0.000 description 2
- LXKNAUOWEJWGTE-UHFFFAOYSA-N 2-(3-methoxyphenyl)acetonitrile Chemical compound COC1=CC=CC(CC#N)=C1 LXKNAUOWEJWGTE-UHFFFAOYSA-N 0.000 description 2
- SLNNONQJXBRLKM-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-3-hydroxy-n,n-dimethylpropanamide;hydrochloride Chemical compound Cl.CCCCOC1=CC=CC(CCNC(CO)C(=O)N(C)C)=C1 SLNNONQJXBRLKM-UHFFFAOYSA-N 0.000 description 2
- LGUGPXRQOMPBED-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n,n-dimethylethanethioamide;hydrochloride Chemical compound Cl.CCCCOC1=CC=CC(CCNCC(=S)N(C)C)=C1 LGUGPXRQOMPBED-UHFFFAOYSA-N 0.000 description 2
- JMPHGYJSDLSUDQ-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n,n-dimethylpropanamide;hydrochloride Chemical compound Cl.CCCCOC1=CC=CC(CCNC(C)C(=O)N(C)C)=C1 JMPHGYJSDLSUDQ-UHFFFAOYSA-N 0.000 description 2
- KZUXGKZWVDBSGE-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n-methylacetamide Chemical compound CCCCOC1=CC=CC(CCNCC(=O)NC)=C1 KZUXGKZWVDBSGE-UHFFFAOYSA-N 0.000 description 2
- CSLSNPVDHCCYIU-UHFFFAOYSA-N 2-[2-(3-butylsulfonylphenyl)ethylamino]-n,n-dimethylacetamide;hydrochloride Chemical compound Cl.CCCCS(=O)(=O)C1=CC=CC(CCNCC(=O)N(C)C)=C1 CSLSNPVDHCCYIU-UHFFFAOYSA-N 0.000 description 2
- OUMBHBKKMAMFNQ-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2-methylpropyl]amino]-n,n-dimethylacetamide;hydrochloride Chemical compound Cl.CCCCOC1=CC=CC(C(C)(C)CNCC(=O)N(C)C)=C1 OUMBHBKKMAMFNQ-UHFFFAOYSA-N 0.000 description 2
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 2
- AMQIPHZFLIDOCB-UHFFFAOYSA-N 3-(2-hydroxyethyl)phenol Chemical compound OCCC1=CC=CC(O)=C1 AMQIPHZFLIDOCB-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 238000011767 DBA/2J (JAX™ mouse strain) Methods 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 208000005872 Diffuse Esophageal Spasm Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010020802 Hypertensive crisis Diseases 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 238000012347 Morris Water Maze Methods 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 229910021586 Nickel(II) chloride Inorganic materials 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 206010030184 Oesophageal spasm Diseases 0.000 description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 2
- 102000004316 Oxidoreductases Human genes 0.000 description 2
- 108090000854 Oxidoreductases Proteins 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- 240000007643 Phytolacca americana Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 238000010162 Tukey test Methods 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000009692 acute damage Effects 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 230000003109 amnesic effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000001949 anaesthesia Methods 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 230000003496 anti-amnesic effect Effects 0.000 description 2
- 230000000454 anti-cipatory effect Effects 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 230000003727 cerebral blood flow Effects 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 230000002999 depolarising effect Effects 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- 229940016681 dipropylacetamide Drugs 0.000 description 2
- LBOJYSIDWZQNJS-CVEARBPZSA-N dizocilpine Chemical compound C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 LBOJYSIDWZQNJS-CVEARBPZSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 208000024732 dysthymic disease Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000001952 enzyme assay Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- KERMLSZDRZAXKG-UHFFFAOYSA-N ethyl 2-[2-(3-butoxyphenyl)ethylamino]-2-methylpropanoate Chemical compound CCCCOC1=CC=CC(CCNC(C)(C)C(=O)OCC)=C1 KERMLSZDRZAXKG-UHFFFAOYSA-N 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000010304 firing Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 230000035863 hyperlocomotion Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000003447 ipsilateral effect Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 229960001078 lithium Drugs 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- CMGIBGQOOLCMCQ-UHFFFAOYSA-N n,n-dimethyl-2-[2-(3-pentoxyphenyl)ethylamino]acetamide;hydrochloride Chemical compound Cl.CCCCCOC1=CC=CC(CCNCC(=O)N(C)C)=C1 CMGIBGQOOLCMCQ-UHFFFAOYSA-N 0.000 description 2
- 229960005016 naphazoline Drugs 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000002981 neuropathic effect Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- 230000003957 neurotransmitter release Effects 0.000 description 2
- QMMRZOWCJAIUJA-UHFFFAOYSA-L nickel dichloride Chemical compound Cl[Ni]Cl QMMRZOWCJAIUJA-UHFFFAOYSA-L 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 208000020629 overactive bladder Diseases 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 239000005022 packaging material Substances 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000012402 patch clamp technique Methods 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 229960000786 propylhexedrine Drugs 0.000 description 2
- JCRIVQIOJSSCQD-UHFFFAOYSA-N propylhexedrine Chemical compound CNC(C)CC1CCCCC1 JCRIVQIOJSSCQD-UHFFFAOYSA-N 0.000 description 2
- 229940127250 psychostimulant medication Drugs 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 229940075993 receptor modulator Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000011808 rodent model Methods 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 210000001044 sensory neuron Anatomy 0.000 description 2
- 230000002295 serotoninergic effect Effects 0.000 description 2
- 230000037322 slow-wave sleep Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 229940125794 sodium channel blocker Drugs 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 238000013223 sprague-dawley female rat Methods 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 230000024188 startle response Effects 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- UTNZNEKGOIVHJX-UHFFFAOYSA-N tert-butyl 2-(3-butoxyphenyl)-3-[[1-(dimethylamino)-1-oxopropan-2-yl]amino]propanoate Chemical compound CCCCOC1=CC=CC(C(CNC(C)C(=O)N(C)C)C(=O)OC(C)(C)C)=C1 UTNZNEKGOIVHJX-UHFFFAOYSA-N 0.000 description 2
- BCDJEPRTBNSTLC-UHFFFAOYSA-N tert-butyl 2-(3-butoxyphenyl)-3-[[2-(dimethylamino)-2-sulfanylideneethyl]amino]propanoate Chemical compound CCCCOC1=CC=CC(C(CNCC(=S)N(C)C)C(=O)OC(C)(C)C)=C1 BCDJEPRTBNSTLC-UHFFFAOYSA-N 0.000 description 2
- MGUUNJBVMVIXNB-UHFFFAOYSA-N tert-butyl 2-(3-butylsulfonylphenyl)-3-[[2-(dimethylamino)-2-oxoethyl]amino]propanoate Chemical compound CCCCS(=O)(=O)C1=CC=CC(C(CNCC(=O)N(C)C)C(=O)OC(C)(C)C)=C1 MGUUNJBVMVIXNB-UHFFFAOYSA-N 0.000 description 2
- YVCAFLLYIWNAKZ-UHFFFAOYSA-N tert-butyl 3-[[3-acetyloxy-1-(dimethylamino)-1-oxopropan-2-yl]amino]-2-(3-butoxyphenyl)propanoate Chemical compound CCCCOC1=CC=CC(C(CNC(COC(C)=O)C(=O)N(C)C)C(=O)OC(C)(C)C)=C1 YVCAFLLYIWNAKZ-UHFFFAOYSA-N 0.000 description 2
- UYVNHBSYQVREHW-UHFFFAOYSA-N tert-butyl 3-amino-2-(3-butoxyphenyl)propanoate Chemical compound CCCCOC1=CC=CC(C(CN)C(=O)OC(C)(C)C)=C1 UYVNHBSYQVREHW-UHFFFAOYSA-N 0.000 description 2
- SLHAKXCWWIMCLP-UHFFFAOYSA-N tert-butyl 3-amino-2-(3-hydroxyphenyl)propanoate Chemical compound CC(C)(C)OC(=O)C(CN)C1=CC=CC(O)=C1 SLHAKXCWWIMCLP-UHFFFAOYSA-N 0.000 description 2
- CTRQONISPPUQOM-UHFFFAOYSA-N tert-butyl n-[2-(3-butoxy-4-methylphenyl)ethyl]carbamate Chemical compound CCCCOC1=CC(CCNC(=O)OC(C)(C)C)=CC=C1C CTRQONISPPUQOM-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 229960003741 tranylcypromine Drugs 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000009529 traumatic brain injury Effects 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- 210000000427 trigeminal ganglion Anatomy 0.000 description 2
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 2
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 238000012762 unpaired Student’s t-test Methods 0.000 description 2
- 229940102566 valproate Drugs 0.000 description 2
- OMOMUFTZPTXCHP-UHFFFAOYSA-N valpromide Chemical compound CCCC(C(N)=O)CCC OMOMUFTZPTXCHP-UHFFFAOYSA-N 0.000 description 2
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 2
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 229960000833 xylometazoline Drugs 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- VVVBEZQPVJOPON-KSLSDJDQSA-N (2R)-2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylpropanamide 2-[2-[3-butoxy-2-(trifluoromethyl)phenyl]ethylamino]-N,N-dimethylacetamide Chemical compound C(CCC)OC=1C(=C(C=CC1)CCNCC(=O)N(C)C)C(F)(F)F.C(CCC)OC=1C=C(C=CC1)CCN[C@@H](C(=O)N(C)C)C VVVBEZQPVJOPON-KSLSDJDQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- CFJMRBQWBDQYMK-UHFFFAOYSA-N 1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester Chemical compound C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 CFJMRBQWBDQYMK-UHFFFAOYSA-N 0.000 description 1
- DXUWLPMQHNMSOZ-UHFFFAOYSA-N 1-pyrrolidin-1-ylethanone;hydrochloride Chemical compound Cl.CC(=O)N1CCCC1 DXUWLPMQHNMSOZ-UHFFFAOYSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- WCFOZBGIIGPILD-UHFFFAOYSA-N 2-(2,6-difluoro-3-methoxyphenyl)acetonitrile Chemical compound COC1=CC=C(F)C(CC#N)=C1F WCFOZBGIIGPILD-UHFFFAOYSA-N 0.000 description 1
- KHBKENHNQPJSCV-UHFFFAOYSA-N 2-(3-butoxyphenyl)acetaldehyde Chemical compound CCCCOC1=CC=CC(CC=O)=C1 KHBKENHNQPJSCV-UHFFFAOYSA-N 0.000 description 1
- LUQPODGESQYULH-UHFFFAOYSA-N 2-(3-butoxyphenyl)ethanamine;hydrochloride Chemical compound Cl.CCCCOC1=CC=CC(CCN)=C1 LUQPODGESQYULH-UHFFFAOYSA-N 0.000 description 1
- RFCPEALMBGPMED-UHFFFAOYSA-N 2-(3-butoxyphenyl)ethanol Chemical compound CCCCOC1=CC=CC(CCO)=C1 RFCPEALMBGPMED-UHFFFAOYSA-N 0.000 description 1
- LVOKGAHCTHNWIL-UHFFFAOYSA-N 2-(3-iodophenyl)acetonitrile Chemical compound IC1=CC=CC(CC#N)=C1 LVOKGAHCTHNWIL-UHFFFAOYSA-N 0.000 description 1
- KRGXHARSWLJCGO-UHFFFAOYSA-N 2-(3-methoxy-4-methylphenyl)acetonitrile Chemical compound COC1=CC(CC#N)=CC=C1C KRGXHARSWLJCGO-UHFFFAOYSA-N 0.000 description 1
- WJBMRZAHTUFBGE-UHFFFAOYSA-N 2-(3-methoxyphenyl)ethanamine Chemical compound COC1=CC=CC(CCN)=C1 WJBMRZAHTUFBGE-UHFFFAOYSA-N 0.000 description 1
- MGUCUSVCMVPQMD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)ethanamine;hydrochloride Chemical compound Cl.NCCC1=CC=CC(OCC=2C=CC=CC=2)=C1 MGUCUSVCMVPQMD-UHFFFAOYSA-N 0.000 description 1
- YAIQLSGJDFUANQ-UHFFFAOYSA-N 2-(benzylamino)propanamide Chemical class NC(=O)C(C)NCC1=CC=CC=C1 YAIQLSGJDFUANQ-UHFFFAOYSA-N 0.000 description 1
- XIKQSTNYYHSCAJ-UHFFFAOYSA-N 2-[2-(3-butoxy-2,6-difluorophenyl)ethylamino]-n,n-dimethylacetamide;hydrochloride Chemical compound Cl.CCCCOC1=CC=C(F)C(CCNCC(=O)N(C)C)=C1F XIKQSTNYYHSCAJ-UHFFFAOYSA-N 0.000 description 1
- BPIZDRCSEOVMQU-UHFFFAOYSA-N 2-[2-(3-butoxy-2-fluorophenyl)ethylamino]-n,n-diethylacetamide Chemical compound CCCCOC1=CC=CC(CCNCC(=O)N(CC)CC)=C1F BPIZDRCSEOVMQU-UHFFFAOYSA-N 0.000 description 1
- JGHYMAWEPWZQKP-UHFFFAOYSA-N 2-[2-(3-butoxy-2-fluorophenyl)ethylamino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC=CC(CCNCC(=O)N(C)C)=C1F JGHYMAWEPWZQKP-UHFFFAOYSA-N 0.000 description 1
- LIJGBTHMSJZSSZ-UHFFFAOYSA-N 2-[2-(3-butoxy-4-fluorophenyl)ethylamino]-n,n-dimethylacetamide;hydrochloride Chemical compound Cl.CCCCOC1=CC(CCNCC(=O)N(C)C)=CC=C1F LIJGBTHMSJZSSZ-UHFFFAOYSA-N 0.000 description 1
- ZEBKYEICOYLYGX-UHFFFAOYSA-N 2-[2-(3-butoxy-4-methoxyphenyl)ethylamino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC(CCNCC(=O)N(C)C)=CC=C1OC ZEBKYEICOYLYGX-UHFFFAOYSA-N 0.000 description 1
- XDUKDZAIPPBDQO-UHFFFAOYSA-N 2-[2-(3-butoxy-4-methoxyphenyl)ethylamino]-n,n-dimethylacetamide;hydrochloride Chemical compound Cl.CCCCOC1=CC(CCNCC(=O)N(C)C)=CC=C1OC XDUKDZAIPPBDQO-UHFFFAOYSA-N 0.000 description 1
- MLGNOVVGMAGHFI-UHFFFAOYSA-N 2-[2-(3-butoxy-4-methylphenyl)ethylamino]-n,n-dimethylacetamide;hydrochloride Chemical compound Cl.CCCCOC1=CC(CCNCC(=O)N(C)C)=CC=C1C MLGNOVVGMAGHFI-UHFFFAOYSA-N 0.000 description 1
- IQUSCAXHSGWPDE-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-1-pyrrolidin-1-ylethanone Chemical compound CCCCOC1=CC=CC(CCNCC(=O)N2CCCC2)=C1 IQUSCAXHSGWPDE-UHFFFAOYSA-N 0.000 description 1
- LJGNZNWEJNBYPC-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n,n,2-trimethylpropanamide;hydrochloride Chemical compound Cl.CCCCOC1=CC=CC(CCNC(C)(C)C(=O)N(C)C)=C1 LJGNZNWEJNBYPC-UHFFFAOYSA-N 0.000 description 1
- ZXAADSNJEVLUSJ-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n,n-dibutylacetamide Chemical compound CCCCOC1=CC=CC(CCNCC(=O)N(CCCC)CCCC)=C1 ZXAADSNJEVLUSJ-UHFFFAOYSA-N 0.000 description 1
- MSINBBWQHNNTQA-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n,n-dibutylacetamide;hydrochloride Chemical compound Cl.CCCCOC1=CC=CC(CCNCC(=O)N(CCCC)CCCC)=C1 MSINBBWQHNNTQA-UHFFFAOYSA-N 0.000 description 1
- YRUDJGIBRALGGB-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n,n-diethylacetamide Chemical compound CCCCOC1=CC=CC(CCNCC(=O)N(CC)CC)=C1 YRUDJGIBRALGGB-UHFFFAOYSA-N 0.000 description 1
- QQLRZUYGUPTTNV-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n,n-diethylacetamide;hydrochloride Chemical compound Cl.CCCCOC1=CC=CC(CCNCC(=O)N(CC)CC)=C1 QQLRZUYGUPTTNV-UHFFFAOYSA-N 0.000 description 1
- UGYMDVZYADOSEF-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n,n-dimethylpropanamide Chemical compound CCCCOC1=CC=CC(CCNC(C)C(=O)N(C)C)=C1 UGYMDVZYADOSEF-UHFFFAOYSA-N 0.000 description 1
- XHAHBSNMOPQNHO-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n,n-dipropylacetamide Chemical compound CCCCOC1=CC=CC(CCNCC(=O)N(CCC)CCC)=C1 XHAHBSNMOPQNHO-UHFFFAOYSA-N 0.000 description 1
- VPZOLYDGSFTZQR-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n,n-dipropylacetamide;hydrochloride Chemical compound Cl.CCCCOC1=CC=CC(CCNCC(=O)N(CCC)CCC)=C1 VPZOLYDGSFTZQR-UHFFFAOYSA-N 0.000 description 1
- QKWLNDBBBXMKPV-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]-n-methylacetamide;hydrochloride Chemical compound Cl.CCCCOC1=CC=CC(CCNCC(=O)NC)=C1 QKWLNDBBBXMKPV-UHFFFAOYSA-N 0.000 description 1
- PNVRSMDUIBNKRC-UHFFFAOYSA-N 2-[2-(3-butoxyphenyl)ethylamino]acetamide;hydrochloride Chemical compound Cl.CCCCOC1=CC=CC(CCNCC(N)=O)=C1 PNVRSMDUIBNKRC-UHFFFAOYSA-N 0.000 description 1
- HEBZOZGBZXKENA-UHFFFAOYSA-N 2-[2-(3-butylsulfonylphenyl)ethylamino]-n,n-dimethylacetamide Chemical compound CCCCS(=O)(=O)C1=CC=CC(CCNCC(=O)N(C)C)=C1 HEBZOZGBZXKENA-UHFFFAOYSA-N 0.000 description 1
- LNCDVUPCGOSSRO-UHFFFAOYSA-N 2-[2-(3-hexoxyphenyl)ethylamino]-n,n-dimethylacetamide;hydrochloride Chemical compound Cl.CCCCCCOC1=CC=CC(CCNCC(=O)N(C)C)=C1 LNCDVUPCGOSSRO-UHFFFAOYSA-N 0.000 description 1
- XJPQMIBDTHHLMM-UHFFFAOYSA-N 2-[2-(3-pentoxyphenyl)ethylamino]-n,n-dipropylacetamide;hydrochloride Chemical compound Cl.CCCCCOC1=CC=CC(CCNCC(=O)N(CCC)CCC)=C1 XJPQMIBDTHHLMM-UHFFFAOYSA-N 0.000 description 1
- XPEOTZMXIWGSAB-UHFFFAOYSA-N 2-butylhexanamide Chemical compound CCCCC(C(N)=O)CCCC XPEOTZMXIWGSAB-UHFFFAOYSA-N 0.000 description 1
- ZUURTFDLYSRYHS-UHFFFAOYSA-N 2-methylpropanethioamide;hydrochloride Chemical compound Cl.CC(C)C(N)=S ZUURTFDLYSRYHS-UHFFFAOYSA-N 0.000 description 1
- 229940124125 5 Lipoxygenase inhibitor Drugs 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000000187 Abnormal Reflex Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000242762 Anemonia sulcata Species 0.000 description 1
- 108010087765 Antipain Proteins 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 206010003628 Atonic seizures Diseases 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 206010056948 Automatic bladder Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010069918 Bacterial prostatitis Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 208000021465 Brief psychotic disease Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- XKWQDYZTNXSRHA-UHFFFAOYSA-N C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)CO.C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)C.C(CCCCC)OC=1C=C(C=CC1)CCNCC(=O)N1CCCC1 Chemical compound C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)CO.C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)C.C(CCCCC)OC=1C=C(C=CC1)CCNCC(=O)N1CCCC1 XKWQDYZTNXSRHA-UHFFFAOYSA-N 0.000 description 1
- RGPKUICXURJUPW-UHFFFAOYSA-N C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)COCCC.C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)COC Chemical compound C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)COCCC.C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)COC RGPKUICXURJUPW-UHFFFAOYSA-N 0.000 description 1
- TVAFNNNSGGKCTH-UHFFFAOYSA-N C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N(CC)CC.C(CCC)OC=1C=C(C=CC1OC)CCNCC(=O)N(C)C Chemical compound C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N(CC)CC.C(CCC)OC=1C=C(C=CC1OC)CCNCC(=O)N(C)C TVAFNNNSGGKCTH-UHFFFAOYSA-N 0.000 description 1
- OHPMYRGVAKIWAS-UHFFFAOYSA-N C(CCC)OC=1C=C(C=CC1)CCNCC(=O)NC.C(CCCCC)OC=1C=C(C=CC1)CCNCC(=O)N.C(CCCC)OC=1C=C(C=CC1)CCNCC(=O)N.C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N Chemical compound C(CCC)OC=1C=C(C=CC1)CCNCC(=O)NC.C(CCCCC)OC=1C=C(C=CC1)CCNCC(=O)N.C(CCCC)OC=1C=C(C=CC1)CCNCC(=O)N.C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N OHPMYRGVAKIWAS-UHFFFAOYSA-N 0.000 description 1
- WVUUVEHFPDUDFH-JAVZBQFESA-N C(CCC)OC=1C=C(C=CC1)CCN[C@@H](C(=O)NC)C.C(CCC)OC=1C=C(C=CC1)CCN[C@@H](C(=O)N)C.C(CCC)OC=1C=C(C=CC1)CCN[C@H](C(=O)N(C)C)C Chemical compound C(CCC)OC=1C=C(C=CC1)CCN[C@@H](C(=O)NC)C.C(CCC)OC=1C=C(C=CC1)CCN[C@@H](C(=O)N)C.C(CCC)OC=1C=C(C=CC1)CCN[C@H](C(=O)N(C)C)C WVUUVEHFPDUDFH-JAVZBQFESA-N 0.000 description 1
- DKUALDOQQKXBML-IMECTCCJSA-N C(CCC)OC=1C=C(C=CC1)CCN[C@H](C(=O)NC)C.C(CCC)OC=1C=C(C=CC1)CCN[C@H](C(=O)N)C Chemical compound C(CCC)OC=1C=C(C=CC1)CCN[C@H](C(=O)NC)C.C(CCC)OC=1C=C(C=CC1)CCN[C@H](C(=O)N)C DKUALDOQQKXBML-IMECTCCJSA-N 0.000 description 1
- JTKUZBJYSGIQNR-UHFFFAOYSA-N C(CCC)SC=1C=C(C=CC1)CCNCC(=O)N(C)C.C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N(C)C.C(CCCCC)OC=1C=C(C=CC1)CCNCC(=O)NC Chemical compound C(CCC)SC=1C=C(C=CC1)CCNCC(=O)N(C)C.C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N(C)C.C(CCCCC)OC=1C=C(C=CC1)CCNCC(=O)NC JTKUZBJYSGIQNR-UHFFFAOYSA-N 0.000 description 1
- PAHUZOPJBQGVKJ-UHFFFAOYSA-N C(CCCC)OC=1C=C(C=CC1)CCNCC(=O)N(C)C.C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N(CCCC)CCCC.C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N(CCC)CCC Chemical compound C(CCCC)OC=1C=C(C=CC1)CCNCC(=O)N(C)C.C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N(CCCC)CCCC.C(CCC)OC=1C=C(C=CC1)CCNCC(=O)N(CCC)CCC PAHUZOPJBQGVKJ-UHFFFAOYSA-N 0.000 description 1
- HKYSEAKPVJCLBF-UHFFFAOYSA-N C(CCCCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)(C)C.C(CCCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)(C)C.C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)(C)C Chemical compound C(CCCCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)(C)C.C(CCCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)(C)C.C(CCC)OC=1C=C(C=CC1)CCNC(C(=O)N(C)C)(C)C HKYSEAKPVJCLBF-UHFFFAOYSA-N 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 208000001387 Causalgia Diseases 0.000 description 1
- 101150047856 Cav2 gene Proteins 0.000 description 1
- 101150110214 Cav3 gene Proteins 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010056874 Chemical cystitis Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
- 229940086562 Cyclooxygenase 1 inhibitor Drugs 0.000 description 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 208000032538 Depersonalisation Diseases 0.000 description 1
- 238000006646 Dess-Martin oxidation reaction Methods 0.000 description 1
- 206010051153 Diabetic gastroparesis Diseases 0.000 description 1
- RPNUMPOLZDHAAY-UHFFFAOYSA-N Diethylenetriamine Chemical compound NCCNCCN RPNUMPOLZDHAAY-UHFFFAOYSA-N 0.000 description 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
- 206010013470 Dissociative states Diseases 0.000 description 1
- 206010013486 Distractibility Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- BKISUIVCTANPFV-UHFFFAOYSA-N FC(CCCOC=1C=C(C=CC1)CCNCC(=O)N(C)C)(F)F.C(CCC)OC=1C=C(C=CC1)C(CNCC(=O)N(C)C)(C)C.C(CCC)OC=1C=C(C=CC1)CCNCC(=S)N(C)C Chemical compound FC(CCCOC=1C=C(C=CC1)CCNCC(=O)N(C)C)(F)F.C(CCC)OC=1C=C(C=CC1)C(CNCC(=O)N(C)C)(C)C.C(CCC)OC=1C=C(C=CC1)CCNCC(=S)N(C)C BKISUIVCTANPFV-UHFFFAOYSA-N 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000037767 Gallbladder pain Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 229940086575 Glutamate release inhibitor Drugs 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010019075 Hallucination, visual Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 101000935123 Homo sapiens Voltage-dependent N-type calcium channel subunit alpha-1B Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- 206010021030 Hypomania Diseases 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 208000030990 Impulse-control disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000005615 Interstitial Cystitis Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 1
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229940123379 Methyltransferase inhibitor Drugs 0.000 description 1
- 208000037039 Monarthritis Diseases 0.000 description 1
- 208000002472 Morton Neuroma Diseases 0.000 description 1
- 208000020059 Morton neuralgia Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010073713 Musculoskeletal injury Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010065673 Nephritic syndrome Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029315 Neuromuscular blockade Diseases 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- 102400001103 Neurotensin Human genes 0.000 description 1
- 101800001814 Neurotensin Proteins 0.000 description 1
- 229940123925 Nicotinic receptor agonist Drugs 0.000 description 1
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 1
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 239000012425 OXONE® Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 206010034703 Perseveration Diseases 0.000 description 1
- 206010034759 Petit mal epilepsy Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 206010035104 Pituitary tumour Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 208000002389 Pouchitis Diseases 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 208000017143 Secondary Headache disease Diseases 0.000 description 1
- 208000019568 Shared Paranoid disease Diseases 0.000 description 1
- 206010040703 Simple partial seizures Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 201000002661 Spondylitis Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 description 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 206010043220 Temporomandibular joint syndrome Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 208000012981 Traumatic Stress disease Diseases 0.000 description 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- FVECELJHCSPHKY-UHFFFAOYSA-N Veratridine Natural products C1=C(OC)C(OC)=CC=C1C(=O)OC1C2(O)OC34CC5(O)C(CN6C(CCC(C)C6)C6(C)O)C6(O)C(O)CC5(O)C4CCC2C3(C)CC1 FVECELJHCSPHKY-UHFFFAOYSA-N 0.000 description 1
- 102100025342 Voltage-dependent N-type calcium channel subunit alpha-1B Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 101100514842 Xenopus laevis mtus1 gene Proteins 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 208000028311 absence seizure Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000036982 action potential Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 239000003449 adenosine A2 receptor antagonist Substances 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 206010053552 allodynia Diseases 0.000 description 1
- 102000003802 alpha-Synuclein Human genes 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- QSIYTPCKNAPAJY-UHFFFAOYSA-N aluminum;ethoxy-oxido-oxophosphanium;2-(trichloromethylsulfanyl)isoindole-1,3-dione Chemical compound [Al+3].CCO[P+]([O-])=O.CCO[P+]([O-])=O.CCO[P+]([O-])=O.C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1 QSIYTPCKNAPAJY-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003561 anti-manic effect Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 230000000648 anti-parkinson Effects 0.000 description 1
- 230000001663 anti-spastic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 229940125684 antimigraine agent Drugs 0.000 description 1
- 239000002282 antimigraine agent Substances 0.000 description 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 208000025748 atypical depressive disease Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- NHYXMAKLBXBVEO-UHFFFAOYSA-N bromomethyl acetate Chemical compound CC(=O)OCBr NHYXMAKLBXBVEO-UHFFFAOYSA-N 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940125400 channel inhibitor Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 208000028502 clonic seizure Diseases 0.000 description 1
- BTFHLQRNAMSNLC-UHFFFAOYSA-N clorgyline Chemical compound C#CCN(C)CCCOC1=CC=C(Cl)C=C1Cl BTFHLQRNAMSNLC-UHFFFAOYSA-N 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 208000008609 collagenous colitis Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 208000026725 cyclothymic disease Diseases 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003479 dental cement Substances 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 210000002451 diencephalon Anatomy 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229950004794 dizocilpine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical class CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- IOLQWGVDEFWYNP-UHFFFAOYSA-N ethyl 2-bromo-2-methylpropanoate Chemical compound CCOC(=O)C(C)(C)Br IOLQWGVDEFWYNP-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000025561 forward locomotion Effects 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 208000001288 gastroparesis Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000028326 generalized seizure Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000002430 glycine receptor antagonist Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- XNXVOSBNFZWHBV-UHFFFAOYSA-N hydron;o-methylhydroxylamine;chloride Chemical compound Cl.CON XNXVOSBNFZWHBV-UHFFFAOYSA-N 0.000 description 1
- 125000006289 hydroxybenzyl group Chemical group 0.000 description 1
- 206010020745 hyperreflexia Diseases 0.000 description 1
- 230000035859 hyperreflexia Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229940023568 magnesium valproate Drugs 0.000 description 1
- LKLLHOIUJVEAGU-UHFFFAOYSA-L magnesium;2-propylpentanoate Chemical compound [Mg+2].CCCC(C([O-])=O)CCC.CCCC(C([O-])=O)CCC LKLLHOIUJVEAGU-UHFFFAOYSA-L 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 125000005905 mesyloxy group Chemical group 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000003697 methyltransferase inhibitor Substances 0.000 description 1
- 208000008275 microscopic colitis Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001730 monoaminergic effect Effects 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000028492 myoclonic seizure Diseases 0.000 description 1
- AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 description 1
- VYZREHLHXNYBKX-UHFFFAOYSA-N n,n-dimethyl-2-[2-(3-propan-2-yloxyphenyl)ethylamino]acetamide;hydrochloride Chemical compound Cl.CC(C)OC1=CC=CC(CCNCC(=O)N(C)C)=C1 VYZREHLHXNYBKX-UHFFFAOYSA-N 0.000 description 1
- JJVBOCIUQDAEHK-UHFFFAOYSA-N n,n-dimethyl-2-[2-[3-(4,4,4-trifluorobutoxy)phenyl]ethylamino]acetamide;hydrochloride Chemical compound Cl.CN(C)C(=O)CNCCC1=CC=CC(OCCCC(F)(F)F)=C1 JJVBOCIUQDAEHK-UHFFFAOYSA-N 0.000 description 1
- MYWUZJCMWCOHBA-UHFFFAOYSA-N n-methyl-1-phenylpropan-2-amine Chemical compound CNC(C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-UHFFFAOYSA-N 0.000 description 1
- LSEVRAVOFBBAEX-UHFFFAOYSA-N n-methyl-2-[2-(3-pentoxyphenyl)ethylamino]acetamide Chemical compound CCCCCOC1=CC=CC(CCNCC(=O)NC)=C1 LSEVRAVOFBBAEX-UHFFFAOYSA-N 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
- 239000000842 neuromuscular blocking agent Substances 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 1
- 208000025319 neurotic depression Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- GWWNCLHJCFNTJA-UHFFFAOYSA-N nicandrenone-2 Natural products C12OC2C2(O)CC=CC(=O)C2(C)C(CCC23C)C1C3CCC2(O)C(C)C1OC(O)C2(C)OC2(C)C1 GWWNCLHJCFNTJA-UHFFFAOYSA-N 0.000 description 1
- LAIZPRYFQUWUBN-UHFFFAOYSA-L nickel chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ni+2] LAIZPRYFQUWUBN-UHFFFAOYSA-L 0.000 description 1
- 239000000181 nicotinic agonist Substances 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000000966 norepinephrine reuptake Effects 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002746 orthostatic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 238000007833 oxidative deamination reaction Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 description 1
- 229960005457 pancuronium Drugs 0.000 description 1
- 229960003379 pancuronium bromide Drugs 0.000 description 1
- NPIJXCQZLFKBMV-YTGGZNJNSA-L pancuronium bromide Chemical compound [Br-].[Br-].C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 NPIJXCQZLFKBMV-YTGGZNJNSA-L 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 208000007777 paroxysmal Hemicrania Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 229960003436 pentoxyverine Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- OKBMCNHOEMXPTM-UHFFFAOYSA-M potassium peroxymonosulfate Chemical compound [K+].OOS([O-])(=O)=O OKBMCNHOEMXPTM-UHFFFAOYSA-M 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000010880 proctocolectomy Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 239000003196 psychodysleptic agent Substances 0.000 description 1
- 230000001696 purinergic effect Effects 0.000 description 1
- 206010037628 pylorospasm Diseases 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- SZVWBINNBHRDJG-UHFFFAOYSA-N pyridin-2-amine;sodium Chemical compound [Na].NC1=CC=CC=N1 SZVWBINNBHRDJG-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005932 reductive alkylation reaction Methods 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 230000004617 sleep duration Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000003890 substance P antagonist Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- YYTBHQKYNIQVNJ-UHFFFAOYSA-N tert-butyl 2-(3-butoxyphenyl)-3-[[1-(dimethylamino)-3-hydroxy-1-oxopropan-2-yl]amino]propanoate Chemical compound CCCCOC1=CC=CC(C(CNC(CO)C(=O)N(C)C)C(=O)OC(C)(C)C)=C1 YYTBHQKYNIQVNJ-UHFFFAOYSA-N 0.000 description 1
- AJKMDWBHPPPVRA-UHFFFAOYSA-N tert-butyl 3-amino-2-(3-phenylmethoxyphenyl)propanoate Chemical compound CC(C)(C)OC(=O)C(CN)C1=CC=CC(OCC=2C=CC=CC=2)=C1 AJKMDWBHPPPVRA-UHFFFAOYSA-N 0.000 description 1
- 208000012720 thalamic disease Diseases 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- 206010048627 thoracic outlet syndrome Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 208000028500 tonic seizure Diseases 0.000 description 1
- 208000028325 tonic-clonic seizure Diseases 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000000105 vanilloid receptor agonist Substances 0.000 description 1
- 239000000085 vanilloid receptor antagonist Substances 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- FVECELJHCSPHKY-JLSHOZRYSA-N veratridine Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)O[C@@H]1[C@@]2(O)O[C@]34C[C@@]5(O)[C@H](CN6[C@@H](CC[C@H](C)C6)[C@@]6(C)O)[C@]6(O)[C@@H](O)C[C@@]5(O)[C@@H]4CC[C@H]2[C@]3(C)CC1 FVECELJHCSPHKY-JLSHOZRYSA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 1
- 229960002811 ziconotide Drugs 0.000 description 1
- KNJNGVKTAFTUFL-OCMUWRIYSA-N ω-conotoxin Chemical compound N([C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1C(N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CO)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CSSC1)C(N)=O)=O)=O)C(=O)[C@@H]1CSSC[C@@H](N)C(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1 KNJNGVKTAFTUFL-OCMUWRIYSA-N 0.000 description 1
- 108091058550 ω-conotoxin Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/08—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
- C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
- C07C321/26—Thiols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C327/42—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C327/44—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
Abstract
Substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives of formula (I) wherein X, Y, Z, R, R, R, R, R', R, R, R, R have the meanings defined in the specification and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them as active ingredient and their use as sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies, including, but not limited to, neurological, cognitive, psychiatric, inflammatory, urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role.
Description
WO 2008/151702 PCT/EP2008/003848 SUBSTITUTED 2- [2- (PHENYL) ETHYLAMINO] ALKANEAMIDE DERIVATIVES AND THEIR USE AS SODIUM AND/OR CALCIUM CHANNEL MODULATORS The present invention relates to substituted 2-[2-(phenyl)ethylamino]alkaneamide derivatives, 5 pharmaceutically acceptable salts thereof, pharmaceutical compositions containing them and their use as sodium and/or calcium channel modulators. The derivatives, object of the invention, are active as sodium and/or calcium channel modulators and therefore are useful in preventing alleviating and curing a wide range of pathologies, including, but not limited to neurological, cognitive, psychiatric, inflammatory, 10 urogenital and gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role. The compounds of this invention are substantially free of monoamine oxidase (MAO) inhibitory effect, especially at dosages that are therapeutically effective in preventing, alleviating and/or curing said affections. 15 Background of the invention Chemical Background 20 The GB 586,645 patent describes the synthesis of amino acid derivatives of the following general formula
R
5 R X 4 R6 n N R2 13 R R 0
R
7 25 In particular it describes the synthesis of N-hydroxyalkylamides having stimulating uterine smooth muscle properties. The patent application WO 90/14334 describes mono-substituted N-phenylalkyl alpha-amino carboxamide derivatives of the following general formula 30 2 R R 0 1 1 2 N NR 5 R-A I
R
3 R' 3
R
6 wherein R is a (Ci-Cs)alkyl, (C 3 -Cs)cycloalkyl, furyl, thienyl, pyridyl or a phenyl ring optionally 5 substituted by I to 4 substituents independently selected from halo, (CI-C 6 )alkyl, (Ci
C
6 )alkoxy and trifluoromethyl; A is a -(CH 2 )m-, -(CH 2 )p-X-(CH 2 )q- group wherein m is an integer of I to 4, one of p and q is zero and the other is zero or an integer of 1 to 4, X is -0-, -S- or -NR4- in which R 4 is hydrogen or (Ci-C 4 )alkyl; n is 0 or 1; each of R, and R 2 independently is hydrogen or (CI-C 4 )alkyl; R 3 is hydrogen, (Ci-C 4 )alkyl optionally 10 substituted by hydroxy or phenyl optionally substituted as above; R 3 ' is hydrogen or R 3 and
R
3 taken together form a (C 3
-C
6 )cycloalkyl ring; each of R 5 and R 6 independently is hydrogen or (Ci-C 6 ) alkyl, with the proviso that when R is (Ci-C 8 )alkyl, then A is a -(CH2)p
X-(CH
2 )q- group in which p and q are both zero and X is -0-, -S- or -NR 4 -, in which R 4 is hydrogen or Ci-C 4 alkyl for use as anti-epileptic, anti-Parkinson, neuroprotective, anti 15 depressant, anti-spastic and/or hypnotic agents. None of derivatives synthesized in our patent application is specifically disclosed and prepared in WO 90/14334. In other patent applications, selected compounds falling in WO 90/14334 general formula, are 20 claimed for use in compositions having other activities, specifically: WO 99/35125 Alpha-aminoamide derivatives useful as analgesic agents WO 03/020273 Pharmaceutical composition comprising gabapentin or analogue thereof and an alpha aminoamide and its analgesic use WO 04/062655 Alpha-aminoamide derivatives useful as antimigraine agents 25 WO 05/018627 Alpha-aminoamide derivatives useful as anti-inflammatory agents WO 05/070405 Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders WO 05/102300 Alpha-aminoamide derivatives useful in the treatment of Restless Legs Syndrome and additive disorders 30 WO 06/027052 Use of (halobenzyloxy) benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective 21349941 (GHMatters)24/12/2009 WO 2008/151702 3 PCT/EP2008/003848 modulators EP Apple. N* 06012352.8 a-Aminoamide Derivatives Useful in the Treatment of Cognitive Disorders. 5 In the patent application WO 98/35957 amide derivatives of the following general formula are described R4 R3 N R 5 N,R 1 0 10 and are claimed to be useful against obesity and eating disorders. None of the compounds synthesized in our patent application has been actually synthesized or specifically listed in this WO 98/35957. 15 - In WO 2004/087125, compounds of the following general formula are described: R R,' O1 'R0K3 I R2 A sodium channels blocking mechanism and many pharmacological activities are claimed, in 20 particular anti-pain and anti bladder disfunction activities. It must be underlined that when X 2 is an alkylene, it cannot be -CH 2
-CH
2 - but only -CH 2 -, so none of the 2-[2-(phenyl)ethylamino]alkaneamide derivatives of this application falls within the general formula reported above. - Eleonora Ghidini et al., in Bioorganic & Medicinal Chemistry 2006, 14, 3263-3274 25 describe compounds of the following general formula: WO 2008/151702 PCT/EP2008/003848 RI H RN NR2 R3 0 These compounds have been tested for an anticonvulsant activity. 5 None of the compounds disclosed and synthesized in this patent application falls within the general formula described above. - The co-pending application PCT/EP 2006/011443 (WO 2007/071311) filed on November 2 9 th, 2006, refers to 2-phenylethylamino derivatives of the following general formula: 10 R 0 W N R 3 0 2 14 R R2 R (J), R None of the compounds claimed in this application falls within the PCT/EP 2006/011443 (WO 2007/071311). 15 Biological Background Sodium channels play an important role in the neuronal network by transmitting electrical impulses rapidly throughout cells and cell networks, thereby coordinating higher processes ranging from locomotion to cognition. These channels are large transmembrane proteins, 20 which are able to switch between different states to enable selective permeability for sodium ions. For this process an action potential is needed to depolarize the membrane, and hence these channels are voltage-gated. In the past few years a much better understanding of sodium channels and drugs interacting with them has been developed. Voltage-gated sodium channels were originally classified based on their sensitivity to 25 tetrodotoxin, from low nanomolar (Tetrodotoxin sensitive, TTXs) to high micromolar (Tetrodotoxin resistant, TTXr). So far, 9 different sodium channel a subunits have been identified and classified as Nav 1.1 to Nav 1.9. Navl.1 to Navl.4, Navl.6 and Navl.7 are TTXs, whereas Navl.5, Navl.8 and Nav.1.9 are TTXr, with different degrees of sensitivity. NavI.1 to Navl.3 and Navl.6, are primarily 5 expressed in the CNS, whereas Navl.4 and Navl.5 are mainly expressed in muscle (skeletal and heart respectively) and Navl.7, Navl.8 and Navl.9 are predominantly expressed in DRG sensory neurons. 5 It has become clear that a number of drugs having an unknown mechanism of action actually act by modulating sodium channel conductance, including local anaesthetics, class I antiarrhythmics and anticonvulsants. Neuronal sodium channel blockers have found application with their use in the treatment of epilepsy (phenytoin and carbamazepine), bipolar 10 disorder (lamotrigine), preventing neurodegeneration, and in reducing neuropathic pain. Various anti-epileptic drugs that stabilize neuronal excitability are effective in neuropathic pain (e.g. carbamazepine). In addition, an increase in sodium channel expression or activity has also been observed in 15 several models of inflammatory pain, suggesting a role of sodium channels in inflammatory pain. Calcium channels are membrane-spanning, multi-subunit proteins that allow controlled entry of calcium ions into cells from the extracellular fluid. Commonly, calcium channels are 20 voltage dependent and are referred to as voltage-gated calcium channels (VGCC). VGCCs are found throughout the mammalian nervous system, where they regulate the intracellular calcium ions levels that are important for cell viability and function. Intracellular calcium ion concentrations are implicated in a number of vital processes in animals, such as neurotransmitter release, muscle contraction, pacemaker activity and secretion of hormones. 25 All "excitable" cells in animals, such as neurons of the central nervous system (CNS), peripheral nerve cells, and muscle cells, including those of skeletal muscles, cardiac muscles and venous and arterial smooth muscles, have voltage dependent calcium channels. Calcium channels are a large family with many genetically, physiologically, and 30 pharmacologically distinct subtypes. Based on the biophysical properties of calcium currents recorded from individual neurons, two super-families have been described: High Voltage Activated (HVA) and Low Voltage Activated (LVA) calcium channels. Calcium currents referred as L-Type, P-Type, Q-Type, N-Type, R-Type are HVA while T-Type are LVA. From the molecular identity, ten distinct calcium channels subtypes have been identified, cloned 2134994.1 (GHMatters)24/122009 5a and expressed and grouped in three families: Cavl family (Cav 1.1, 1.2, 1.3, 1.4) is functionally related to the L-type Ca current; Cav2 family (Cav 2.1, 2.2, 2.3) is functionally related to the P/Q, N, R-type currents and Cav3 (Cav 3.1, 3.2, 3.3) family is functionally 5 related to the T 2134994_1 (GHMatters)24/12/2009 WO 2008/151702 6 PCT/EP2008/003848 type current. It is believed that calcium channels are relevant in certain disease states. A number of compounds useful in treating various cardiovascular diseases in mammals, including humans, 5 are thought to exert their beneficial effects by modulating functions of voltage dependant calcium channels present in cardiac and/or vascular smooth muscle. Compounds with activity against calcium channels have also been implicated for the treatment of pain. In particular N type calcium channels (Cav2.2), responsible for the regulation of neurotransmitter release, are thought to play a significant role in nociceptive transmission, both due to their tissue 10 distribution as well as from the results of several pharmacological studies. N-type calcium channels were found up-regulated in the ipsilateral dorsal horn in neuropathic pain models of injury (Cizkova D., Marsala J., Lukacova N., Marsala M., , Jergova S., Orendacova J., Yaksh T. L. Exp. Brain Res. (2002) 147: 456-463). Specific N-type calcium channel blockers were shown to be effective in reducing pain responses in neuropathic pain models (Mattews E. A., 15 Dickenson A. H. Pain (2001) 92: 235-246), in the phase II of the formalin test (Diaz A., Dickenson A. H. Pain (1997) 69: 93-100) and the hyperalgesia initiated by knee joint inflammation (Nebe J., Vanegas H., Schaible H. G. Exp.Brain Res. (1998) 120: 61-69). Mutant mice, lacking the N-type calcium channels, were found to have a decreased response to persistent pain as seen by a decrease in pain response during phase II of the formalin test 20 (Kim C., Jun K., Lee T., Kim S. S., Mcenery M. W., Chin H., Kim H. L, Park J. M., Kim D. K., Jung S. J., Kim J., Shin H. S. Mol. Cell Neurosci. (2001) 18: 235-245; Hatakeyama S., Wakamori M, Ino M., Miyamoto N., Takahashi E., Yoshinaga T., Sawada K., Imoto K., Tanaka I., Yoshizawa T., Nishizawa Y., Mori Y., Nidome T., Shoji S. Neuroreport (2001) 12: 2423-2427) as well as to neuropathic pain, assessed by a decrease in mechanical allodynia and 25 thermal hyperalgesia in the spinal nerve ligation model. Interestingly, these mice also showed lower levels of anxiety when compared to wild type (Saegusa H., Kurihara T., Zong S., Kazuno A., Matsuda Y. Nonaka T., Han W., Toriyama H., Tanabe T., EMBO J. (2001) 20: 2349-2356). The involvement of N-type calcium channels in pain has been further validated in the clinic by ziconotide, a peptide derived from the venom of the marine snail, Conus 30 Magnus. A limitation in the therapeutic use of this peptide is that it has to be administered intrathecally in humans (Bowersox S. S. and Luther R. Toxicon, (1998) 36: 1651-1658). All together these findings indicate that compounds with sodium and/or calcium channel blockade have a high therapeutic potential in preventing, alleviating and curing a wide range 35 of pathologies, including neurological, psychiatric, urogenital and gastrointestinal diseases, WO 2008/151702 7 PCT/EP2008/003848 where the above mechanisms have been described as playing a pathological role. There are many papers and patents which describe sodium channel and/or calcium channel modulators or antagonists for the treatment or modulation of a plethora of disorders, such as 5 their use as local anaesthetics, antimanic anti-depressants, agents for the treatment of unipolar depression, urinary incontinence, diarrhoea, inflammation, epilepsy, neurodegenerative conditions, nerve cell death, neuropathic pain, migraine, acute hyperalgesia and inflammation, renal disease, allergy, asthma, bronchospasm, dysmenorrhea, esophageal spasm, glaucoma, urinary tract disorders, gastrointestinal motility disorders. 10 A non-exhaustive list of such papers and patents/patent applications describing sodium and/or calcium channels blockers and uses thereof includes the references shown below: C. Alzheimer describes in Adv. Exp. Med. Biol. 2002, 513, 161-181, sodium and calcium channels as targets of neuroprotective substances. 15 Vanegas e Schaible (Pain 2000, 85, 9-18) discuss effects of antagonists of calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia. WO 03/057219 relates to sodium channel blockers useful as agents for treating or modulating a central nervous system disorder, such as neuropathic pain, inflammatory pain, inflammation-related pain or epilepsy. 20 W099/14199 discloses substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines-10 oles as potent sodium channel blockers useful for the treatment of several diseases, such as stroke, neurodegenerative disorders, Alzheimer's Disease, Parkinson's Disease and cardiovascular disorders. WO01/74779 discloses new aminopyridine sodium channel blockers and their use as 25 anticonvulsants, local anaesthetics, as antiarrythmics, for the treatment or prevention of neurodegenerative conditions, such as amyotrophic lateral sclerosis (ALS), for the treatment or prevention of both, acute or chronic pain, and for the treatment or prevention of diabetic neuropathy. W004/087125 discloses amino acid derivatives as inhibitors of mammalian sodium channels, 30 useful in the treatment of chronic and acute pain, tinnitus, bowel disorders, bladder dysfunction and demyelinating diseases. U.S. Patent 5,051,403 relates to a method of reducing neuronal damage associated with an ischemic condition, such as stroke, by administration of binding/inhibitory omega-conotoxin 35 peptide wherein the peptide is characterized by specific inhibition of voltage-gated calcium WO 2008/151702 8 PCT/EP2008/003848 channel currents selectively in neuronal tissues. U.S. Patent 5,587,454 relates to compositions and methods of producing analgesia particularly in the treatment of pain and neuropathic pain. 5 U.S. Patent 5,863,952 relates to calcium channel antagonists for the treatment of ischaemic stroke. U.S. Patent 6,011,035 relates to calcium channel blockers, useful in the treatment of conditions such as stroke and pain. U.S. Patent 6,117,841 relates to calcium channel blockers and their use in the treatment of 10 stroke, cerebral ischemia, pain, head trauma or epilepsy. U.S. Patent 6,362,174 relates to N-type calcium channel blockers in the treatment of stroke, cerebral ischemia, pain, epilepsy, and head trauma. U.S. Patent 6,420,383 and U.S. Patent 6,472,530 relate to novel calcium channel blockers, useful for treating and preventing a number of disorders such as hypersensitivity, allergy, 15 asthma, bronchospasm, dysmenorrhea, esophageal spasm, glaucoma, premature labor, urinary tract disorders, gastrointestinal motility disorders and cardiovascular disorders. U.S. Patent 6,458,781 relates to compounds that act to block calcium channels and their use to treat stroke, cerebral ischemia, pain, head trauma or epilepsy. U.S. Patent 6,521,647 relates to the use of calcium channel blockers in the treatment of renal 20 disease in animals, especially chronic renal failure. WO 97/10210 relates to tricyclic heterocyclic derivatives, and their use in therapy, in particular as calcium channel antagonists, e.g. for the treatment of ischaemia, in particular ischaemic stroke. WO 03/018561 relates to quinoline compounds as N-type calcium channel antagonists and 25 methods of using such compounds for the treatment or prevention of pain or nociception. Monoamine oxidase (MAO) is an enzyme present in the outer mitochondrial membrane of neuronal and non-neuronal cells. Two isoforms of MAO exist: MAO-A and MAO-B. MAO enzymes are responsible for the oxidative deamination of endogenous and xenobiotic amines, 30 and have a different substrate preference, inhibitor specificity, and tissue distribution. Serotonin, noradrenaline and adrenaline are preferential substrates for MAO-A, and clorgyline is a selective MAO-A inhibitor; whereas MAO-B prefers p-phenylethylamine as a substrate, and is inhibited by selegiline. Dopamine, tyramine and tryptamine are oxidized by both MAO-A and MAO-B, in particular in human brain dopamine is deaminated by 80% by 35 MAO-B.
9 MAO inhibition allows endogenous and exogenous substrates to accumulate and may thereby, when almost fully inhibited (>90%), alter the dynamics of regular monoamine transmitters. MAO regulate the concentrations in the brain of the most important neurotransmitters such as 5 noradrenaline, serotonin and dopamine which are related to emotion, anxiety and movement. Thus, it is thought that MAO be closely involved in various psychiatric and neurological disorders such as depression, anxiety and Parkinson's disease (PD). MAO-A inhibitors are mainly used in psychiatry for the treatment of major, refractory and 10 atypical depression as a consequence of their ability to increase the reduced serotonin and noradrenaline brain levels. More recently, MAO-A inhibitors have been used to treat patients with anxiety disorders such as social phobia, panic disorders, post-traumatic stress disorders and obsessive compulsive disorders. 15 MAO-B inhibitors are mainly used in neurology for the treatment of PD. There is also recent evidence and interest in the role of MAO-B in other pathological conditions such as Alzheimer disease (AD). So far no evidence have been reported on MAO B involvement in the metabolism of co-transmitters, such as colecystokinin, substance P, 20 somatostatin and neurotensin, which are involved in the modulation of pain sensation. For this reason there is no scientific rationale for the use of MAO-B inhibitors in pain syndromes. Adverse drug reactions during clinical practice with MAO inhibitors have been reported. First generation of non-selective and irreversible MAO inhibitors, such as tranylcypromine and 25 phenelzine, have serious side effects, including hepatotoxicity, orthostatic hypotension and, most importantly, hypertensive crisis that occurs following the ingestion of foods containing tyramine (Cooper AJ.-Tyramine and irreversible monoamine oxidase inhibitors in clinical practice.- Br J Psych Suppi 1989:38-45). 30 When these non-selective and irreversible MAO inhibitors are used, a strict tyramine-reduced diet must be observed. The pressor sensitivity towards tyramine is normalized 4 weeks after cessation of tranylcypromine therapy and more than 11 weeks after cessation of phenelzine therapy. 2134994_1 (GHMatters)24/12/2009 10 Selegiline, an irreversible MAO-B inhibitor, especially when used in combination with levodopa, can cause anorexia/nausea, dry mouth, dyskinesia and orthostatic hypotension in patients with PD, the latter being most problematic (Volz H.P. and Gleiter C.H.- Monoamine 5 oxidase inhibitors. A perspective on their use in the elderly.- Drugs Aging 13 (1998), pp. 341 355). In monotherapy, anorexia/nausea, musculoskeletal injuries, and cardiac arrhythmias occurred more often in patients receiving selegiline compared with those receiving placebo. Apart from 10 these adverse effects, increased rates of elevated serum AST and ALT levels were noted. The most frequently reported adverse effect of moclobemide, a selective and reversible MAO A inhibitor, are sleep disturbances, increased anxiety, restlessness, and headache. The combination of selective serotonin reuptake inhibitors (SSRIs) and moclobemide has 15 good efficacy in cases of refractory depression, but has created controversy as to whether toxic side effects, such as serotoninergic syndrome, result from this combination (Baumann P.- Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31 (1996), pp 444-469). Because of cardiac arrhythmias and increased liver enzyme levels, electrocardiogram and laboratory values should be checked 20 regularly. Many types of physiologic changes that occur with aging affect the pharmacodynamics and pharmacokinetics of MAO inhibitors. Indeed, pharmacokinetic variables in the elderly are markedly different form those in younger patients. These variables including absorption, 25 distribution, metabolism and excretion have to be taken into account to avoid or minimize certain adverse effects and drug-drug interactions. Elderly patients are generally more susceptible than younger patients to side effects, including adverse drug reactions. Hypertensive crisis may occur more frequently in elderly than in younger patients, because cardiovascular systems of the elderly are already compromised by age. 30 The use of sympathomimetic drugs in combination with MAO inhibitors may also elevate blood pressure. In addition, compared with placebo, phenelzine was associated with a significantly higher incidence of drowsiness, tremor, dyskinesia, diarrhea, micturition difficulties, orthostatic effects, and adverse dermatological effects. It is interesting to note that 2134994_1 (GHMatters)24112009 10a in the elderly, headache is reported with a higher frequency than in younger patients during treatment with moclobemide (Volz H.P. and Gleiter C.H.- Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging 13 (1998), pp. 341-355). 5 MAO inhibitors (preferentially MAO-A, but also non selective MAO-A/MAO-B) are sometimes prescribed for depression. Because of the potential risk of suicide, adverse drug reactions and toxicity due to overdose are important factors to consider when choosing an antidepressant. In addition, when MAO inhibitors are used in high dosage, adverse 10 cardiovascular effects seem to increase considerably; and because MAO selectivity is lost with such high doses, tyramine can induce potentially dangerous hypertensive reactions. Acute overdose with MAO inhibitors causes agitation, hallucinations, hyperpyrexia, hyperreflexia and convulsions. Abnormal blood pressure is also a toxic sign, so that gastric lavage and maintenance of cardiopulmonary function may be required. Overdose of 15 traditional non-selective and irreversible MAO inhibitors are considerably dangerous and 2134994_1 (GHMatters)24/12/2009 WO 2008/151702 11 PCT/EP2008/003848 sometimes fatal (Yamada and Richelson, 1996. Pharmacology of antidepressants in the elderly. In: David JR, Snyder L., editors. Handbook of pharmacology of aging. Boca Raton: CRC Press 1996). 5 In the treatment of the affections wherein sodium and calcium channels mechanism(s) play(s) a pathological role, the inhibition of MAO enzymes is of no benefits. Moreover MAO inhibitory side effects may impose at least two types of negative limitations: 1) Dietary: eating food with high tyramine content may cause severe, even life threatening increase of systemic blood pressure (the so called "cheese-effect"). 10 2) Pharmacological: as an example, pain is often treated with a combination of drugs such as opioid derivatives and tricyclic antidepressant. With MAO inhibitors such association is dangerous as it may cause the serotoninergic syndrome (agitation, tremors, hallucination, hyperthermia and arrhythmias). Thus, eliminating or significantly reducing MAO inhibitory activity in medicaments active as 15 sodium and/or calcium channel modulators useful in preventing, alleviating and curing a wide range of pathologies where said mechanism(s) play(s) a pathological role, including neurological, psychiatric, inflammatory, urogenital and gastrointestinal diseases, is an unexpected and substantial therapeutic improvement versus compounds of similar efficacy but with the above mentioned side effects. 20 Taken into account these findings on MAO inhibitors and, in particular, lacking any evidence on MAO-B role in pathological affections like pain, migraine, inflammatory, urogenital and gastrointestinal diseases, it might be conceivable that MAO-B inhibition should not be an essential feature for compounds indicated for the above pathologies, avoiding any possible side effects during chronic and/or long-term treatments. 25 An advantageous solution to the above described problem would consist in providing medicaments which are "selectively active as sodium and/or calcium modulators" or are useful for the "selective treatment" of affections, disorders or diseases wherein the sodium and/or calcium channel mechanism(s) play(s) a pathological role. With this expression are intended medicaments which, when administered to a patient in need thereof in amounts that 30 are effective in the treatment of the above said affections wherein the above said mechanism(s) play(s) pathological role, do not exhibit any MAO inhibitory activity or exhibit a significantly reduced MAO inhibitory activity, thus resulting in avoidance of side effects due to accumulation of endogenous and exogenous monoamine transmitters. It is a primary object of this invention the use of 2-[2-(phenyl)ethylamino]alkaneamide 35 derivatives for the manufacture of a medicament active as sodium and/or calcium channel 12 modulator for the treatment of pathologies where the above said mechanism(s) play(s) a pathological role, which is a neurological, cognitive, psychiatric, inflammatory, urogenital or gastrointestinal disorder, said medicaments being substantially free from any MAO inhibitory 5 activity or having significantly reduced MAO inhibitory activity and, therefore, having a reduced potential for unwanted side effects. Accordingly, a main object of this invention is to provide 2-[2-(phenyl)ethylamino]alkaneamide derivatives for use as medicaments for treating the above described pathologies, characterized in that said medicaments are substantially free from any MAO inhibitory activity or present a significantly reduced MAO inhibitory activity 10 and, therefore, have a reduced potential for unwanted side effects. Said use provides an improved selective resource for the prevention, alleviation and/or cure of the above said pathological affections, in particular, in patients who are particularly sensitive to unwanted side-effects due to MAO inhibitory activity, such as those hereinabove described. 15 A further aspect of this invention is to provide a method for treating a patient affected by a disorder caused by dysfunctions of voltage-gated sodium and/or calcium channels which comprises the administration to said patient of an effective amount of a 2-[2 (phenyl)ethylamino]alkaneamide derivative. 20 The above mentioned neurological disorders include pain of both chronic and acute type, in particular neuropathic and inflammatory pain, headaches, migraine, spasms; neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, epilepsy, restless legs syndrome, stroke and cerebral ischemia; cognitive disorders such as Mild Cognitive Impairment (MCI) and psychiatric disorders including depression, bipolar 25 disorders, mania, schizophrenia, psychoses, anxiety and addiction. The above mentioned inflammatory disorders include inflammatory processes affecting all body systems, e.g. inflammatory processes of the muscle-skeletal system, arthritic conditions, disorders affecting skin and related tissues; disorders of the respiratory system as well as disorders of immune and endocrinological system. A more detailed explanation of all above mentioned pathologies 30 is given hereinafter in the following. It is to be understood that, if any prior art publication is referred to herein, such reference does not constitute an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country. 2134994_1 (GHMattes)24/11209 12a Description of the invention The object of this application is a new class of 2-[2-(phenyl)ethylamino]alkaneamide derivatives highly potent as sodium and/or calcium channel modulators and substantially free 5 from any MAO inhibitory activity or having significantly reduced MAO inhibitory activity and, thus, having potentially reduced side effects in preventing, alleviating and curing a wide range of pathologies, including but not limited to neurogical, cognitive, psychiatric, 2134994 _ (GHMatters)24/12r2009 WO 2008/151702 13 PCT/EP2008/003848 inflammatory, urogenital and gastrointestinal diseases where the above mechanisms have been described as playing a pathological role. In this description and claims, the expression "sodium and/or calcium channel modulator(s)" 5 means compounds able to block sodium and/or calcium currents in a voltage dependent manner. Therefore, object of the present invention is a compound of general formula (I)
R'
3 IRZ N R R3 I 3 1R5 117 10 (I) wherein: X is -0-, -S- or -S02-; Y is hydrogen, OH or O(Ci-C 4 )alkyl; Z is =O or =S; 15 R is (C 3 -Cio)alkyl; co-trifluoro(C 3 -Cio)alkyl; R, and R 2 are, independently, hydrogen, hydroxy, (CI-Cs)alkoxy, (Ci-C 8 ) alkylthio, halo, trifluoromethyl or 2,2,2-trifluoroethyl; or one of R 1 and
R
2 is in ortho position to R-X- and, taken together with the same R-X-, represents a 0- group where Ro is (C 2
-C
9 )alkyl; 20 R 3 and R' 3 are, independently, hydrogen or (CI-C 4 )alkyl; R4 and R 5 are, independently, hydrogen, (C 1
-C
4 )alkyl; or R 4 is hydrogen and R 5 is a group selected from -CH 2 -OH, -CH 2 -0-(Ci-C 6 )alkyl, -CH(CI-1 3 )-OH,
-(CH
2
)
2
-S-CH
3 , benzyl and 4-hydroxybenzyl; or R 4 and R 5 , taken together with the adjacent carbon atom, form a (C 3
-C
6 )cycloalkyl 25 residue;
R
6 and R 7 are independently hydrogen or (C 1
-C
6 )alkyl; or taken together with the adjacent nitrogen atom form a 5-6 membered monocyclic saturated heterocycle, optionally containing one additional heteroatom chosen among -0-, -S- and -NR 8 - where R 8 is hydrogen or (CI-C 6 ) alkyl; 30 with the proviso that when X is -S-or -S0 2 -,then Y is not OH or O(CI-C 4 ) alkyl; if the case, either as single optical isomer in the isolated form or mixture thereof in any WO 2008/151702 14 PCT/EP2008/003848 proportion and its pharmaceutically acceptable salts. Although some of the compounds specifically described in this application are falling within the general formula of WO 90/14334, none of them has been specifically described in said 5 application. None of the compounds defined by the general formula (I) of this application is specifically described or mentioned in WO 90/14334. In fact only few 2-(2-phenyl ethylamino)alkaneamide derivatives are identified in said prior document which, however, have a benzyloxy, benzylamino or benzyl substituent in the 4-position of the phenyl portion. Moreover, the following selected classes of compounds of formula (I) of this application do 10 not fall within the general formula of WO 90/14334: a) compounds where X is -SO 2 -; b) compounds where Y is OH or O(Ci-C 4 )alkyl; c) compounds where Z is =S; d) compounds where Ris (Cq-CIO)alkyl or co-trifluoro(C 3 -Cio)alkyl; 15 e) compounds where R 1 and/or R 2 are different from hydrogen; f) compounds where both R 3 and R' 3 are different from hydrogen g) compounds where both R 4 and R 5 are different from hydrogen, but do not form a
(C
3
-C
6 )cycloalkyl residue when taken together with the adjacent carbon atom; h) compounds where R6 and R 7 , taken together with the adjacent nitrogen atom form 20 a monocyclic 5-6 membered saturated heterocycle, optionally containing one additional heteroatom chosen among -0-, -S- and -NR 8 -, where R 8 is hydrogen or
(CI-C
6 ) alkyl. The term "alkyl" used in this description and claims, where no otherwise specified, identifies 25 a straight or branched alkyl radical; examples of said radicals or moieties include: methyl, ethyl, propyl, isopropryl, butyl, isobutyl, pentyl, isopentyl, hexyl, heptyl, octyl, nonyl, decyl and their isomers. The term "alkoxy" used in this description and claims identifies a straight or branched alkoxy radical; examples of said radicals include: methoxy, ethoxy, propoxy, isopropoxy, butoxy, 30 isobutoxy, tert-butoxy, pentyloxy, isopentyloxy, hexyloxy, isohexyloxy, heptyloxy, octyloxy and their isomers. The term "(C3-C 6 )cycloalkyl" identifies a cycloaliphatic ring; examples of said rings include: cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. The term "halo" means an halogen atom radical such as fluoro, chloro, bromo and iodo. 35 Examples of a monocyclic 5 or 6 membered saturated heterocycles, optionally containing one WO 2008/151702 15 PCT/EP2008/003848 additional heteroatom, chosen among -0-, -S- or -NR 8 -, where R 8 is hydrogen or (Ci-C 6 ) alkyl are, for instance, pyrrolidine, pyrazolidine, imidazolidine, oxazolidine, isoxazolidine, piperidine, piperazine, N-methylpiperazine, morpholine and thiomorpholine. 5 When the compounds of this invention contain one or more asymmetric carbon atoms and, therefore, they can exist as single optical isomers or a mixture thereof, the invention includes within its scope all the possible single optical isomers, (e.g. enantiomers, diastereoisomers) of said compounds in the isolated form and the mixtures thereof in any proportion, including racemic mixtures. 10 Examples of pharmaceutically acceptable salts of the compounds of formula (I) are salts with organic and inorganic acids such as hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, phosphoric, acetic, propionic, tartaric, fumaric, citric, benzoic, succinic, cinnamic, mandelic, salicylic, glycolic, lactic, oxalic, malic, maleic, malonic, fumaric, tartaric, p-toluenesulfonic, methanesulfonic, glutaric acid and other acids which, for instance, can be found in : P. 15 Heinrich Stahl, Camille G. Wermuth "Handbook of pharmaceutical salts: properties, selection and use ", WILEY-VCH, 2002. The compounds of formula (I) are active as sodium and/or calcium channel modulators and therefore, are useful in preventing, alleviating and curing a wide range of pathologies, including but not limited to neurological, cognitive, psychiatric, inflammatory, urologic, and 20 gastrointestinal diseases, where the above mechanisms have been described as playing a pathological role. Preferred compounds of formula (I) are the compounds wherein: X is -0-, -S-; 25 Y is hydrogen, OH or O(Ci-C 3 )alkyl; Z is = or =S; R is (C 4
-C
7 )alkyl or co-trifluoro(C 4
-C
6 )alkyl; R, and R 2 are, independently, hydrogen, (CI-C 4 )alkoxy, halo, trifluoromethyl or 2,2,2-trifluoroethyl; or one of R 1 and R 2 is in ortho position to R-X 30 and, taken together with the same R-X-, represent a 0- group where Ro is (C 2
-C
5 )alkyl;
R
3 and R' 3 are, independently, hydrogen or (Ci-C 3 )alkyl;
R
4 and R 5 are, independently, hydrogen or (Ci-C 4 )alkyl; or R 4 is hydrogen and R 5 is a group selected from -CH 2 -OH, -CH 2 -O-(Ci-C 3 )alkyl, -(CH 2
)
2
-S
35 CH 3 , benzyl and 4-hydroxybenzyl; - 16 R 6 and R 7 are, independently, hydrogen or (CI-C 4 )alkyl; or taken together with the adjacent nitrogen atom form a 5-6 membered monocyclic saturated heterocycle, optionally containing one additional heteroatom chosen among -0- and -NR 8 - where R 8 is hydrogen or (CI-C 3 ) alkyl; 5 with the proviso that when X is -S-, then Y is not OH or O(CI-C 3 ) alkyl if the case, either as single optical isomers in the isolated form or mixture thereof in any proportion and their pharmaceutically acceptable salts. More preferred compounds of formula (I) are the compounds wherein: X is -0-, -S-; 10 Y is hydrogen or O(CI-C 3 )alkyl; Z is =0 or =S; R is (C 4
-C
7 )alkyl or co-trifluoro(C 4 -CW)alkyl; R, and R 2 are, independently, hydrogen, (CI-C 3 )alkoxy, fluoro, chloro, trifluoromethyl or 2,2,2-trifluoroethyl; or one of R, and R 2 is in ortho 15 position to R-X- and taken together with the same R-X-, represents a R- 0 0- group where R 0 is (C 3
-C
4 )alkyl;
R
3 and R' 3 are, independently, hydrogen or (Ci-C 3 )alkyl;
R
4 and R 5 are, independently, hydrogen or (CI-C 4 )alkyl; or R 4 is hydrogen and R 5 is a group selected from -CH 2 -OH, -CH 2 -0-(CI-C 3 )alkyl, benzyl and 4 20 hydroxybenzyl;
R
6 and R 7 are, independently, hydrogen or (CI-C 3 )alkyl; or taken together with the adjacent nitrogen atom form a 5-6 membered monocyclic saturated heterocycle, optionally containing one additional heteroatom chosen among -0- and -NR-, where R 8 is hydrogen or (C-C 3 ) alkyl; 25 with the proviso that when X is -S-, then Y is not O(CI-C 3 ) alkyl; if the case, either as single optical isomers in the isolated form or mixture thereof in any proportion and their pharmaceutically acceptable salts. Even more preferred compounds of formula (I) are those compounds wherein: 30 X is -O-; Y is hydrogen; Z is =0; R is (C 4
-C
6 )alkyl; R, and R 2 are, independently, hydrogen or halo, preferably fluoro; 2930290_1 (GHMatters) P82528.AU 3/11/11 17
R
3 , R' 3 , R 4 and R 5 are hydrogen;
R
6 and R 7 are, independently, hydrogen or (Ci-C 3 )alkyl; 5 if the case, either as single optical isomers in the isolated form or mixture thereof in any proportion and their pharmaceutically acceptable salts; Most preferably, a compound of formula (I) according to this invention is selected from the group consisting of: 10 2-[2-(3-Butoxyphenyl)-ethylamino]-acetamide 2-[2-(3-Pentyloxyphenyl)-ethylamino]-acetamide 2-[2-(3-Hexyloxyphenyl)-ethylamino]-acetamide 2-[2-(3-Butoxyphenyl)-ethylamino]-N-methylacetamide 2-[2-(3-Pentyloxyphenyl)-ethylamino]-N-methylacetamide 15 2-[2-(3-Hexyloxyphenyl)-ethylamino]-N-methylacetamide 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butylthiophenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butylsulfonylphenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxyphenyl)-(N'-hydroxy)ethylamino]-N,N-dimethylacetamide 20 2-[2-(3-Butoxyphenyl)-(N'-methoxy)ethylamino ]-N,N-dimethylacetamide 2-[2-(3-Butoxyphenyl)-(N'-propoxy)ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethyl-thioacetamide 2-[2-(3-Butoxyphenyl)-2-methylpropylamino]-N,N-dimethylacetamide 2-(2-[3-(4,4,4-Trifluorobutoxy)phenyl]-ethylamino}-N,N-dimethylacetamide 25 2-[2-(3-Butylthiophenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxy-2-chlorophenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxy-2-fluorophenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxy-4-methoxyphenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-diethylacetamide 30 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dipropylacetamide 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dibutylacetamide 2-[2-(3-Pentyloxyphenyl)-ethylamino]-N,N-dimethylacetamide 2134994_1 (GHMatters)24/1122009 WO 2008/151702 18 PCT/EP2008/003848 2-[2-(3-Hexyloxyphenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxyphenyl)-ethylamino]- 1 -pyrrolidin- 1 -yl-ethan- 1-one 2-[2-(3-Pentyloxyphenyl)-ethylamino]- I -pyrrolidin- 1 -yl-ethan- 1-one 5 2-[2-(3-Hexyloxyphenyl)-ethylamino] -1 -pyrrolidin-1 -yl-ethan- 1-one 2-[2-(3-Butoxyphenyl)-ethylamino]- N,N-dimethylpropanamide 2-[2-(3-Butoxyphenyl)-ethylamino]-3-hydroxy-N,N-dimethylpropanamide 2-[2-(3-Butoxyphenyl)-ethylamino]-3-methoxy-N,N-dimethylpropanamide 2-[2-(3-Butoxyphenyl)-ethylamino]-3-propoxy-N,N-dimethylpropanamide 10 2-[2-(3-Butoxyphenyl)-ethylamino]-2,N,N-trimethylpropanamide 2-[2-(3-Pentyloxyphenyl)-ethylamino]-2,N,N-trimethylpropanamide 2-[2-(3-Hexyloxyphenyl)-ethylamino]-2,N,N-trimethylpropanamide (S)-2-[2-(3-Butoxyphenyl)-ethylamino]-propanamide (S)-2-[2-(3-Butoxyphenyl)-ethylamino]-N-methylpropanamide 15 (S)-2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethylpropanamide (R)-2-[2-(3-Butoxyphenyl)-ethylamino]-propanamide (R)-2-[2-(3-Butoxyphenyl)-ethylamino]-N-methylpropanamide (R)-2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethylpropanamide 2-[2-(3-Butoxy-2-trifluoromethylphenyl)-ethylamino]-N,N-dimethylacetamide 20 2-[2-(3-Butoxy-4-trifluoromethylphenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxy-5-trifluoromethylphenyl)-ethylamino]-N,N-dimethylacetamide if the case, either as single optical isomers in the isolated form or mixtures thereof in any proportion and their pharmaceutically acceptable salts, preferably their salts with hydrochloric 25 or methanesulfonic acid. The compounds of this invention are prepared according to conventional procedures which are described in more detail in the Experimental Part. In particular most of the compounds of formula (I) , where X is -0- and Y is hydrogen, object 30 of the present invention, are prepared according to a synthetic process shown in the following Scheme I: WO 2008/151702 19 PCT/EP2008/003848 Scheme I R R boc (Ph, H) O NH 2 Method A (Ph) HO NH R3 1) boc 2 0 2) H 2 ,R Method B (H) R, R2 1) HBr 2) boc 2 O R, R2 0 R-EWG 3 boc o EWG "R R boc 11 N N R 6 _ R5_ R7 R O NH R I R 3 115 1173 R, R 2 R1 R2 1) Lawesson s HCI 2) HCI R O R 3S HRH RN R R R O R R RR N 3 R IN I ~R R1 ~17 11 15 R 7 5 R, R2 R R2 wherein: R, R 1 , R 2 , R 3 , R' 3 , R4, R 5 , R6 and R 7 have the same meanings defined in formula (I) above, 10 Ph means a phenyl radical, boc is a tert-butoxycarbonyl group and EWG stays for "Electron Withdrawing Group" such as, for example, a halogen or a mesyloxy or a tosyloxy or a trifluoromethanesulfonate group. Lawessons's reagent is 2,4-bis(4-methoxyphenyl)-1,3,2,4 dithiadiphosphetane-2,4-disulfide (The Merck Index, 13h Ed., 5408, page 966). According to a preferred embodiment of the invention the alkylation reactions with R-EWG 15 are carried out in the presence of a base and, more preferably, said base is selected from
K
2 C0 3 , triethylamine and diisopropylethylamine. An alternative method for the preparation of the compounds of formula (I) where R, R1, R 2 , R3, R' 3 , R 4 , R5, R 6 and R7 have the same meanings as in formula (I), X is 0 and Y is hydrogen 20 consists in submitting an aldehyde of the formula
R'
3 R CHO
R
3 R1 R2 to a reductive alkylation with an x-aminoalkaneamide of formula 5 0
H
2 N R
NR
6
R
5 R 7 The reducing agent may be selected from NaBH 4 , NaBH 3 CN and (polystyrylmethyl) trimethylammonium cyanoborohydride. 10 The resulting 2-[2-(phenyl)ethylamino]alkaneamide compounds of formula (I) wherein Z is =O can be transformed into the corresponding compounds where Z is =S by protecting the NH- group with boc 2 0, reacting the N-boc protected derivative with Lawesson's reagent, and finally deprotecting with HCI as show in Scheme I. 15 As a further alternative to these methods, an amine of formula R13 '.O NH2 R 2 R R, R 2 is alkylated by reaction with an ester of an alkanoic acid of formula 0 EWG
O(C,-C
3 )alkyl 20 R 5 in the presence of a base (e.g. triethylamine) and the resulting alkanoic ester derivatives of formula 2190192_ I (GHMatters) WO 2008/151702 21 PCT/EP2008/003848 R H R N (C,-C 3 )alkyl RR R, R is reacted with an amine of formula HNR 6
R
7 , optionally in the presence of an amidation 5 catalyst (e.g. trimethylaluminium), to yield the compound formula (I) where Y is hydrogen. The compounds of formula (I) where R 5 is hydrogen, optionally can be transformed into the corresponding compounds of formula (I) wherein R 5 is (Ci-C 4 )alkyl, -CH 2 OH, -CH 2 -0-(C 1 C 6 ) alkyl, -CH(CH 3 )-OH, -(CH 2
)
2
-S-CH
3 , benzyl, or 4-hydroxybenzyl by submitting a N protected derivative of the above said compound of formula (I) to a C-alkylation procedure 10 with an alkylating agent of formula EWGR 5 wherein EWG has the same meaning as above and R 5 represents one of the group listed hereinabove. In this case, when a end compound of formula (I) is desired where the group R 5 contain a hydroxy moiety, a reagent EWGR 5 is usually employed where the corresponding hydroxy moiety is protected, e.g. by acetylation. All protecting groups are then removed from the resulting C-alkylated compounds. 15 If desired, when a compound of formula (I) is obtained in a form of a free base it may be converted into a salt thereof (e.g., with hydrochloric acid) by common procedures. The compounds of formula (I) , where X is S or SO 2 and Y is hydrogen are prepared according to a synthetic process shown in the following Scheme 11: WO 2008/151702 22 PCT/EP2008/003848 Scheme II
CH
3 COSR R N R, R N 11 3 N R, R2 R, R2 NiC 2 NaB 4 boc,O R' boc EWG NR6 R 3 oc 13 ~b1 0
R
5 17 RAS N R R 7 R S N H RI R2 R, R2 1) Lawesson's oxone 2) HCI boc '3 HR13 1114 R S NR6 RS2 N R R 13 R5 I1 3 R R1 17 1.14 117 R, R 2 R, R2 H C 1) Lawesson's 2) HC
RW
3 s 3 H 0 R7 SO 2 0R S 2 NR
R
3 Rn11R13 R7 R2 R7 R, 112 R, R12 5 wherein R, R 1 , R 2 , R 3 , R' 3 , R 4 , R 5 , R 6 and R 7 have the same meanings as defined in formula (I), boc is a tert-butoxycarbonyl group and EWG has the same meaning as above, "oxone" stays for potassium peroxymonosulfate and Lawessons's reagent is 2,4-bis(4-methoxyphenyl)-1,3,2,4 dithiadiphosphetane-2,4-disulfide. 10 The compounds of formula (I) , where X is -0- and Y is OH or O(Ci-C 4 )alkyl, are prepared WO 2008/151702 23 PCT/EP2008/003848 according to a synthetic process shown in the following Scheme III: Scheme III 5 3 R'3 R7 0 CHO R OH Dess-Martin R3 R3 periodinane R1 R2 R, R 2
(C
1
-C
4 )alk-ONH 2 NaBH 3 CN or PhCH 2
-ONH
2 0 R' Y O EWG -R6 R'3 0
,(C
1
-C
4 )alkor 3 N | -CH 2 -Ph R" N N" R6 R5R7 R:"'O NH R3 II R3 R5 R7 R, R2 R R2 Y O-(CI-C 4 )alk,or -CH 2 Ph H2 '3 Y 0 111 R1 O N N R6 K \~3 I
R
5 17 R, R 2 Y=OH wherein R, R 1 , R 2 , R 3 , R' 3 , R 4 , R 5 , R 6 and R 7 have the same meanings as defined in formula (I), Ph means a phenyl group, and EWG has the same meaning as above. Dress-Martin periodinane, 10 see: Dess, D.B.; Martin, J.C. J.Am.Chem.Soc., 1991, 113, 7277. The intermediates used in Schemes I, II and III are commercially available or are prepared from commercially available compounds according to well-known methods. The evaluation of the usefulness of the optional protection as well as the selection of the 15 suitable protecting agent, according to the reaction carried out in the preparation of the 24 compounds of the invention and the functional group to be protected, are within the common knowledge of the skilled person. 5 The removal of the optional protective groups is carried out according to conventional techniques. For a general reference to the use of protective groups in organic chemistry see Theodora W. Greene and Peter G.M. Wuts "Protective groups in organic synthesis", John Wiley & Sons, 10 Inc., II Ed., 1991. The preparation of the salts of the compounds of formula (I) is carried out according to known methods. 15 For the preparation of a single optical isomer of a compound of formula (I) said compound may be obtained through a sterically controlled synthesis or by using reagents having the appropriate chirality or separating the desired isomer from the enantiomeric mixture thereof, according to conventional procedures. 20 Pharmacology The compounds of the invention may be used for the manufacture of a medicament active as sodium and/or calcium channel modulator against disorders caused by dysfunctions of voltage gated sodium and/or calcium channels. 25 Such compounds are voltage-dependent blockers of the sodium and/or calcium channels with potency in the low micromolar range as demonstrated by the blockade of the sodium and/or calcium influx (fluorescence assays) and by the voltage-dependent blockade of the currents (patch clamp techniques). 30 The activity of the compounds representative of this invention was compared with that of compounds known from WO 90/14334, which have been clinically developed for therapeutical applications such as "ralfinamide" (S)-(+)-2-[4-(2-fluorobenzyloxy) benzylamino]-propanamide and/or "safinamide" (S)-(+)-2-[4-(3-fluorobenzyloxy) benzylamino]-propanamide. 2134994_1 (GHMatters)24/12/2009 24a Safinamide (NW-1015, FCE-26743A, PNU-151774E) is a sodium channel blocker, a calcium channel modulator, a monoamino oxidase B (MAO-B) inhibitor, a glutamate release inhibitor and a dopamine metabolism modulator. 5 Safinamide is useful in the treatment of CNS disorders, in particular of epilepsy, Parkinson's disease, Alzheimer's disease, restless legs syndrome (WO 90/14334, WO 04/089353, WO 05/102300) and cognitive disorders (EP Appl. N* 06/012352.8). 213494_1 (GHMatters)24112/2009 WO 2008/151702 25 PCT/EP2008/003848 Ralfinamide (NW-1029, FCE-26742A, PNU-0154339E) is a sodium and calcium channel inhibitor and NMDA receptor modulator useful in the treatment of pain conditions, including neuropathic and inflammatory pain of both acute and chronic type, migraine, depressions, 5 cardiovascular, inflammatory, urogenital, metabolic and gastrointestinal disorders (WO 99/35125, WO 03/020273, WO 04/062655, WO 05/018627, WO 05/070405, WO 06/02705). The sodium channel modulating activity of the 2-[2-(phenyl)ethylamino]alkaneamide derivatives was measured through a fluorescence-based sodium influx assay in ND7/23 cell 10 line (Table 1) and through the electrophysiological patch clamp technique in rat cortical neurons (Table 3) and in ND7/23 cell line (Table 4) respectively. The calcium channel modulating activity of the 2-[2-(phenyl)ethylamino]alkaneamide derivatives was measured through a fluorescence-based calcium influx assays (Table 2) in AtT20 cell line. 15 The MAO-B activity of the above compounds was measured by using a radioenzymatic assay (Table 5) in rat brain mitochondria. The in vivo analgesic activity of the above compounds was assessed in the "formalin test" in mice (Table 6) and in the "Spinal nerve ligation model of neuropathic pain (SNL)" in rats (Figure 1). The anti-inflammatory pain activity was measured using the "Complete Freund's 20 adjuvant model (CFA)" in rats. The anti-visceral pain activity was measured using the "acetic acid-induced visceral pain" model in mice (Figure 2). The anticonvulsant activity was measured using the "Maximal electroshock test" in mice (Table 7 and Table 8). 25 The anti mania activity was measured using the "Amphetamine and chlordiazepoxide-induced hyperlocomotion in mice" model (Figure 3) and in the "paradoxical sleep deprivation" rat model. The antiamnesic activity was assessed using the "Morris Water Maze test " in which amnesia is induced by scopolamine in rats and in the "Novel Object Recognition test" in rats. 30 To investigate the antidepressant activity of the compounds the "Tail suspension test" model in mice was used. The anti-schizophrenia activity was assessed using the "test of cognitive impairment in schizophrenia" and the "Prepulse inhibition of startle (PPI)" in mice and in rats (Figure 4). The "Cocaine-induced behavioural sensitization test" in rats was used to assess the anti 35 addiction activities of the compounds.
WO 2008/151702 26 PCT/EP2008/003848 "Acute bladder irritation by acetic acid in rats" and "Intermediate bladder irritation by cyclophosphamide in rats" tests were used as models for urological diseases. The anti migraine activity was measured using the "migraine test" in rats. 5 In electrophysiological patch clamp studies, such substances exhibit also "use and frequency dependency", i.e. an enhancement of the block during a high frequency stimulation when there is a large accumulation of channels in the inactivated state, such as in neuronal pathological conditions. Functionally, the use-dependent block results in depression of 10 neuronal activity at high frequency firing and with lower blocking capacity at normal firing rate suggesting that the compounds of this invention may selectively depress abnormal activity of the sodium and/or calcium channels, leaving unaffected the physiological activity, thus having limited CNS depressant effects (W. A. Catterall, Trends Pharmacol. Sci. (1987) 8: 57-65). 15 One of the most representative compounds of this invention is 2-[2-(3-Butoxyphenyl) ethylamino]-N,N-dimethylacetamide hydrochloride (NW-3509) that was found very active in almost all experimental in vitro and in vivo models. The compounds of the invention are active in vivo when orally, intraperitoneally or intravenously administered in the range of 0.1 to 100 mg/kg in different animal models here 20 following described. In view of the above described mechanisms of action, the compounds of the present invention are useful in the prevention or treatment of neuropathic pain. Neuropathic pain syndromes include, and are not limited to: diabetic neuropathy; sciatica; non-specific lower back pain; multiple sclerosis pain; fibromyalgia; HIV-related neuropathy; neuralgia, such as post 25 herpetic neuralgia and trigeminal neuralgia, Morton's neuralgia, causalgia; and pain resulting from physical trauma, amputation, phantom limb, cancer, toxins or chronic inflammatory conditions; central pain such as the one observed in thalamic syndromes, mixed central and peripheral forms of pain such as complex regional pain syndromes (CRPS) also called reflex sympathetic dystrophies. 30 The compounds of the invention are also useful for the treatment of chronic pain. Chronic pain includes, and is not limited to, chronic pain caused by inflammation or an inflammatory related condition, ostheoarthritis, rheumatoid arthritis, acute injury or trauma, upper back pain or lower back pain (resulting from systematic, regional or primary spine disease such as radiculopathy), bone pain (due to osteoarthritis, osteoporosis, bone metastasis or unknown 35 reasons), pelvic pain, spinal cord injury-associated pain, cardiac chest pain, non-cardiac chest WO 2008/151702 27 PCT/EP2008/003848 pain, central post-stroke pain, myofascial pain, sickle cell pain, cancer pain, Fabry's disease, AIDS pain, geriatric pain or pain caused by headache, temporomandibular joint syndrome, gout, fibrosis or thoracic outlet syndromes, in particular rheumatoid arthritis and 5 osteoarthritis. The compounds of the invention are also useful in the treatment of acute pain (caused by acute injury, illness, sports-medicine injuries, carpal tunnel syndrome, bums, musculoskeletal sprains and strains, musculotendinous strain, cervicobrachial pain syndromes, dyspepsis, gastric ulcer, duodenal ulcer, dysmenorrhoea, endometriosis or surgery (such as open heart or 10 bypass surgery), post operative pain, kidney stone pain, gallbladder pain, gallstone pain, obstetric pain or dental pain. The compounds of the invention are also useful in the treatment of headaches, migraine, tension type headache, transformed migraine or evolutive headache, cluster headache, as well as secondary headache disorders, such as the ones derived from infections, metabolic 15 disorders or other systemic illnesses and other acute headaches, paroxysmal hemicrania and the like, resulting from a worsening of the above mentioned primary and secondary headaches. The compounds of the invention are also useful for the treatment of neurological conditions such as epilepsy including simple partial seizure, complex partial seizure, secondary 20 generalized seizure, further including absence seizure, myoclonic seizure, clonic seizure, tonic seizure, tonic clonic seizure and atonic seizure. The compounds of the invention are also useful for the treatment of neurodegenerative disorders of various origins including Alzheimer Disease, Parkinson Disease and other dementia conditions such as Lewys body, fronto temporal dementia and taupathies; amyotrophic lateral sclerosis and other parkinsonian 25 syndromes; other spino cerebellar degeneration and Charcot-Marie-Toot neuropathy, traumatic brain injury, stroke and cerebral ischemia. The compounds of the invention are also useful for the treatment of cognitive disorders and of psychiatric disorders. Examples of cognitive disorders are Mild Cognitive Impairment (MCI) and those associated to autism, dyslexia, attention deficit hyperactivity disorders, 30 schizophrenia, obsessive compulsive disorders, psychosis, bipolar disorders, depression, Tourette's syndrome, and disorders of learning in children, adolescent and adults, Age Associated Memory Impairment, Age Associated Cognitive Decline, Alzheimer's Disease, Parkinson's Disease, Down's Syndrome, traumatic brain injury, Huntington's Disease, Progressive Supranuclear Palsy (PSP), HIV, stroke, vascular diseases, Pick's or Creutzfeldt 35 Jacob disease, multiple sclerosis (MS) and other white matter disorders and drug-induced WO 2008/151702 28 PCT/EP2008/003848 cognitive worsening. Psychiatric disorders include, and are not limited to major depression, apathy, dysthymia, mania, bipolar disorder (such as bipolar disorder type 1, bipolar disorder type II), cyclothymic disorder, rapid cycling, ultradian cycling, mania, hypomania, 5 schizophrenia, schizophreniform disorders, schizoaffective disorders, personality disorders, attention disorders with or without hyperactive behaviour, delusional disorders, brief psychotic disorders, shared psychotic disorders, psychotic disorder due to a general medical condition, substance-induced psychotic disorders or a psychotic disorder not otherwise specified, anxiety disorders such as generalised anxiety disorder, panic disorders, post 10 traumatic stress disorder, impulse control disorders, phobic disorders, dissociative states and moreover in smoke and drug addiction and alcoholism. In particular bipolar disorders, schizophrenia, psychosis, anxiety and addiction. The compounds of the invention inhibit inflammatory processes affecting all body systems. Therefore are useful in the treatment of inflammatory processes of the muscular-skeletal 15 system of which the following is a list of examples but it is not comprehensive of all target disorders: arthritic conditions such as alkylosing spondylitis, cervical arthritis, fibromyalgia, gut, juvenile rheumatoid arthritis, lumbosacral arthritis, osteoarthritis, osteoporosis, psoriatic arthritis, rheumatic disease; disorders affecting skin and related tissues: eczema, psoriasis, dermatitis and inflammatory conditions such as sunburn; disorders of the respiratory system: 20 asthma, allergic rhinitis and respiratory distress syndrome, lung disorders in which inflammation is involved such as asthma and bronchitis; chronic obstructive pulmonary disease; disorders of the immune and endocrinological systems: periarthritis nodosa, thyroiditis, aplastic anaemia, sclerodoma, myasthenia gravis, multiple sclerosis and other demyclinizating disorders, encephalomyelitis, sarcoidosis, nephritic syndrome, Bechet's 25 syndrome, polymyositis, gingivitis. Compounds of the invention are also useful in the treatment of gastrointestinal (GI) tract disorders such as inflammatory bowel disorders including but not limited to ulcerative colitis, Crohn's disease, ileitis, proctitis, celiac disease, enteropathies, microscopic or collagenous colitis, eosinophilic gastroenteritis, or pouchitis resulting after proctocolectomy and post 30 ileonatal anastomosis, and irritable bowel syndrome including any disorders associated with abdominal pain and/or abdominal discomfort such as pylorospasm, nervous indigestion, spastic colon, spastic colitis, spastic bowel, intestinal neurosis, functional colitis, mucous colitis, laxative colitis and functional dyspepsia; but also for treatment of atrophic gastritis, gastritis varialoforme, ulcerative colitis, peptic ulceration, pyresis, and other damage to the GI 35 tract, for example, by Helicobacter pylori, gastroesophageal reflux disease, gastroparesis, WO 2008/151702 29 PCT/EP2008/003848 such as diabetic gastroparesis; and other functional bowel disorders, such as non-ulcerative dyspepsia (NUD); emesis, diarrhoea, and visceral inflammation. Compounds of the invention are also useful in the treatment of disorders of the genito-urinary 5 tract such as overactive bladder, prostatitis (chronic bacterial and chronic non-bacterial prostatitis), prostadynia, interstitial cystitis, urinary incontinence and benign prostatic hyperplasia, annexities, pelvic inflammation, bartholinities and vaginitis. In particular overactive bladder and urinary incontinence. It will be appreciated that the compounds of the invention may advantageously be used in 10 conjunction with one or more other therapeutic agents. Examples of suitable agents for adjunctive therapy include a serotonin receptor modulator including a 5HTlB/lD agonist, such as a triptan (e.g. sumatriptan or naratriptan); an adenosine Al agonist; an adenosine A2 antagonist; a purinergic P2X antagonist, an EP ligand; an NMDA modulator, such as a glycine antagonist; an AMPA modulator; a substance P antagonist (e.g. an NK1 antagonist); a 15 cannabinoid; a nicotinic receptor agonist; an alpha-1 or 2 adrenergic agonist; acetaminophen or phenacetin; a 5-lipoxygenase inhibitor; a leukotriene receptor antagonist; a DMARD (e.g. methotrexate); gabapentin, pregabalin and related compounds; L-dopa and/or dopamine agonists; a catechol-0-methyltransferase inhibitor; a tricyclic antidepressant (e.g. amitryptiline); a neurone stabilising antiepileptic drugs; a monoaminergic uptake inhibitor 20 (e.g. venlafaxine); a matrix metalloproteinase inhibitor; a nitric oxide synthase (NOS) inhibitor, such as an iNOS or an nNOS inhibitor; a free radical scavenger; an alpha-synuclein aggregation inhibitor; a cholinesterase inhibitor, a cholesterol lowering agent; an alpha secretase modulator; a beta-secretase modulator; a beta-amyloid aggregation inhibitor; an inhibitor of the release, or action, of tumor necrosis factor alpha; an antibody therapy, such as 25 monoclonal antibody therapy; an antiviral agent, such as a nucleoside inhibitor (e.g. lamivudine) or an immune system modulator (e.g. interferon); an opioid analgesic, such as morphine; a vanilloid receptor agonist and antagonist; an analgesic, such as a cyclooxygenase-1 and/or cyclooxygenase-2 inhibitor ; a local anaesthetic such as lidocaine and derivatives; a stimulant, including caffeine; an H2-antagonist (e.g. ranitidine); a proton 30 pump inhibitor (e.g. omeprazole); an antacid (e.g. aluminium or magnesium hydroxide; an antiflatulent (e.g. semethicone); a decongestant (e.g. phenylephrine, phenylpropanolamine, pseudoephedrine, oxymetazoline, epinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine, naphazoline, xylometazoline, propylhexedrine, or levo desoxyephedrine); antitussive (e.g. codeine, hydrocodone, carmiphen, carbetapentane, or WO 2008/151702 30 PCT/EP2008/003848 dextramethorphan); a diuretic; or a sedating or non-sedating antihistamine; an antipsychotic agent, including typical and atypical antipsychotics (e.g. haloperidol, risperidone, clozapine); an anti-depressant, such as a selective serotonin re-uptake inhibitors, serotonin and 5 noradrenaline re-uptake inhibitors , MAO inhibitors and tryciclics antidepressant drugs; a mood stabilizer (e.g. lithium, lamotrigine, valproate); an anxiolytic agent (e.g. benzodiazepines, buspirone, beta-adrenergic receptors antagonists); morphine or morphine derivatives; other calcium or sodium channel blockers. 10 It is to be understood that the present invention covers the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in combination with one or more therapeutic agents. The compounds of the present invention are useful in human and veterinary medicaments. It is to be understood that as used herein the terms "treatment" or "treating" whenever not 15 specifically defined otherwise, include prevention, alleviation and cure of pathological affection, in particular, they include both treatment of established symptoms and prophylactic treatment. The compounds of the present invention for their therapeutic or preventive use in the above mentioned pathologies will be preferably used as active ingredients in a pharmaceutical composition. 20 Therefore, a further object of the present invention are pharmaceutical compositions containing a therapeutically effective amount of a compound of the invention or a salt thereof in admixture with a pharmaceutically acceptable carrier. Accordingly, the expression "therapeutically effective" when referred to an "amount", a "dose" or "dosage" of the compounds of this invention is intended as an "amount", a "dose" 25 or "dosage" of any said compounds sufficient for use in both treatment of the established symptoms and the prophylactic treatment of the above said pathological affections. The pharmaceutical compositions object of the present invention may be administered in a variety of immediate and modified release dosage forms, e.g. orally, in the form of tablets, troches, capsules, sugar or film coated tablets, liquid solutions, emulsions or suspensions; 30 rectally, in the form of suppositories; parenterally, e.g. by intramuscular and/ or depot formulations; intravenous injection or infusion; locally and transdermally in form of patch and gel and cream. Suitable pharmaceutically acceptable, therapeutically inert organic and/or inorganic carrier materials useful in the preparation of such composition include, for example, water, gelatin, 35 gum arabic, lactose, starch, cellulose, magnesium stearate, talc, vegetable oils, cyclodextrins, WO 2008/151702 31 PCT/EP2008/003848 polyalkyleneglycols and the like. The composition comprising the phenylethylamino derivatives of formula (I) as above defined can be sterilized and may contain further well known components, such as, for 5 example, preservatives, stabilizers, wetting or emulsifying agents, e.g. paraffin oil, mannide monooleate, salts to adjust osmotic pressure, buffers and the like. For example, the solid oral forms may contain, together with the active ingredient, diluents, e.g. lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, 10 e.g. starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disgregating agents, e.g. a starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs; sweeteners; wetting agents such as lecithin, polysorbates, laurylsulphates; and, in general, non-toxic and pharmacologically inactive substances used in pharmaceutical formulations. Said pharmaceutical preparations may be 15 manufactured in known manner, for example, by means of mixing, granulating, tabletting, sugar-coating, or film-coating processes. The preparation of the pharmaceutical compositions object of the invention can be carried out according to common techniques. The oral formulations comprise sustained release formulations that can be prepared in 20 conventional manner, for instance by applying an enteric coating to tablets and granules. The liquid dispersion for oral administration may be e.g. syrups, emulsions and suspensions. The syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol. Suspensions and emulsions may contain as a carrier, for example, a natural gum, agar, sodium 25 alginate, pectin, methylcellulose, carboxymethyl-cellulose, or polyvinyl alcohol. The suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride. The solutions for intravenous injections or infusion may contain as carrier, for example, 30 sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions. The suppositories may contain, together with the active ingredient, a pharmaceutically acceptable carrier, e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactants or lecithin. 35 The pharmaceutical compositions comprising the phenylethylamino derivatives of formula (I) WO 2008/151702 32 PCT/EP2008/003848 as above defined will contain, per dosage unit, e.g., capsule, tablet, powder injection, teaspoonful, suppository and the like from about 0.1 to about 500 mg of one or more active ingredients most preferably from 1 to 10 mg. 5 Optimal therapeutically effective doses to be administered may be readily determined by those skilled in the art and will vary, basically, with the strength of the preparation, with the mode of administration and with the advancement of the condition or disorder treated. In addition, factors associated with the particular subject being treated, including subject age, weight, diet and time of administration, will result in the need to adjust the dose to an 10 appropriate therapeutically effective level. It is to be understood that while the invention is described in conjunction of the preferred embodiments thereof, those skilled in the art are aware that other embodiment could be made without departing from the spirit of the invention. 15 EXPERIMENTAL PART The 1 H-NMR spectra have been determined in solution of CDCl 3 or DMSO-d 6 with a Varian Gemini 200 MHz spectrometer. The chemical shifts are defined as 8 with CDCl 3 or DMSO-d6 and D 2 0 as inner standard. The HPLC/MS analyses are determined with a Gilson instrument by utilizing a X-Terra RP 18 20 column (5 ptm, 4.6x50 mm) coupled to a UV detector (220 nm) and a Finnigan Aqa mass spectrometer (electron spray, positive ionization mode). Conditions utilized for the analyses: flow: 1.2 ml/min; column temperature: 50 'C; A/B elution gradient (eluent A: 0.1% formic acid in water; eluent B: 0.1% formic acid in acetonitrile): 5-95% of B from 0 to 8.0 minutes, 95% of B from 8.0 to 9.5 minutes. 25 For better illustrating the invention the following examples are now given. Example 1 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethylacetamide hydrochloride 30 The compound was synthesized according to Scheme I Step 1: 2-(3-Hydroxyphenyl)-(tert-butoxycarbonyl)ethylamine Method A 35 To a suspension of 2-(3-benzyloxyphenyl)-ethylamine hydrochloride (12.6 g, 47.7 mmol) in WO 2008/151702 33 PCT/EP2008/003848
H
2 0 (120 ml) and IM NaOH (95 ml), a solution of boc 2 0 (15.6 g, 71.5 mmol) in THF (120 ml) was added dropwise and the mixture was stirred at room temperature. After 16h the organic solvent was removed under reduced pressure and the mixture was extracted with 5 CH 2
C
2 (2x 100 ml). The collected organic phases were dried over Na 2
SO
4 , the solution was filtered and the solvent evaporated under reduced pressure to give a crude oil that was used without further purification. 'H NMR (300 MHz, CDCl 3 ): S. 7.47-7.28 (in, 5H), 7.22 (in, 1H), 6.87-6.77 (m, 3H), 5.05 (s, 2H), 4.52 (bs, 1H), 3.38 (dt, J = 6.5 Hz, J = 6.5 Hz, 2H), 2.77 (t, J = 7.1 Hz, 2H), 1.44 (s, 9H). 10 ESI*MS: calcd for C 20
H
2 5
NO
3 : 327.43; found: 328.1 (MH*). The 2-(3-Benzyloxyphenyl)-(tert-butoxycarbonyl)ethylamine obtained in Step 1 and 10% Pd/C (1.3 g) in MeOH (240 ml), was hydrogenated in a Parr apparatus for 16h at 35 psi. The catalyst was removed by filtration on Celite pad and the solvent was evaporated under 15 reduced pressure. The crude oil was used without further purification. 'H NMR (300 MHz, CDCl 3 ): 8 7.19 (dd, J = 7.8 Hz, J = 7.8 Hz, 1H), 6.82 - 6.66 (in, 3H), 4.56 (bs, 1H), 3.39 (dt, J = 7.0 Hz, J = 6.3 Hz, 2H), 2.76 (t, J = 7.0 Hz, 2H), 1.46 (s, 9H). ESI+MS: called for C1 3
H,
9
NO
3 : 237.30; found: 238.2 (MH*). 20 Method B A 33% solution of HBr in acetic acid (150 ml) was cooled to 0 *C and 3-methoxy phenethylamine (10.0 g, 66.0 mmol) was added portionwise. The mixture was heated to 80 'C and stirred for 16 h. The solvent was evaporated under reduced pressure and the residue was dissolved in water (160 ml). 4 M NaOH (15 ml) was added followed by 2 M of NaOH (130 25 ml). A solution of boc 2 0 (15.8 g, 72.6 mmol) in THF (160 ml) was added dropwise and the mixture was stirred at room temperature for 16 h. The upper organic layer of the resulting mixture was separated and the aqueous layer was extracted with CH 2 Cl 2 (3x100 ml). The combined organic solutions were dried over Na 2
SO
4 , filtered and the solvent was evaporated under reduced pressure. The crude title compound (16.8 g) was obtained as a brown gum that 30 was used in the following steps without further purification. ESI*MS: calcd for C1 3 Hi 9
NO
3 : 237.3; found: 182.1 (MH*- t-butyl, major fragment). Step 2: 2-(3-Butoxyphenyl)-(tert-butoxycarbonyl)ethylamine To a solution in acetone (240 ml), of 2-(3-hydroxyphenyl)-(tert-butoxycarbonyl)ethylamine 35 obtained in Step 1, K 2
CO
3 (19.8 g) and 1-bromobutane (15 ml) were added. The suspension WO 2008/151702 34 PCT/EP2008/003848 was refluxed for 3 days and the solvent was evaporated under reduced pressure. The residue was dissolved in H 2 0 (200 ml) and extracted with CH 2 Cl 2 (2x200 ml). The solvent was eliminated under reduced pressure and the residue was purified by flash chromatography 5 (petroleum ether/EtOAc 85:15) affording 1 (11.3 g, 81% over 3 steps) of the title compound as colorless oil. 'H NMR (300 MHz, CDCl 3 ): 8 7.22 (dd, J = 7.6 Hz, J = 7.6 Hz, 1H), 6.81 - 6.72 (m, 3H), 4.55 (bs, 1H), 3.97 (t, J = 6.3 Hz, 2H), 3.39 (dt, J = 6.5 Hz, J = 6.5 Hz, 2H), 2.78 (t, J = 7.1 Hz, 2H), 1.78 (m, 2H), 1.51 (m, 2H), 1.45 (s, 9H), 0.99 (t, J = 7.3 Hz, 3H). 10 ESI*MS: calcd for C1 7 H27NO 3 : 293.41; found: 294.1 (MH*). Step 3: 2-[2-(3-Butoxyphenyl)-(tert-butoxycarbonyl)ethylamino]-N,N-dimethylacetamide To a suspension of NaH (60%, 2.0 g, 51 mmol) in dry DMF (125 ml) cooled at 0 'C, a solution of 2-(3-butoxyphenyl)-(tert-butoxycarbonyl)ethylamine (7.5 g, 25.5 mmol) in dry 15 DMF (125 ml) was added dropwise. After lh at room temperature, 2-chloro-N,N dimethylacetamide (5.2 ml, 51 mmol) was added and the mixture was stirred for 16h at room temperature. H 2 0 (10 ml) was added and the solvent was evaporated under reduced pressure. The residue was dissolved in H 2 0 (150 ml) and extracted with CH 2 C1 2 (2x150 ml). The collected organic phases were dried over Na 2
SO
4 , filtered and evaporated. The crude was 20 purified by flash chromatography (petroleum ether/EtOAc 4:6) affording the title compound (7.2 g, 75%) as light yellow oil. 'H NMR (300 MHz, DMSO-d6): 8 7.1 (m, 1H), 6.79 - 6.71 (m, 3H), 3.97 (t, J = 6.0 Hz, 2H), 3.96 (s, 2H), 3.40 (dd, J = 8.7 Hz, J = 7.2 Hz, 2H), 2.88 (s, 6H), 2.76 (dd, J = 7.9 Hz, J = 6.4 Hz, 2H), 1.76 (m, 2H), 1.46 (m, 2H), 1.37 (s, 9H), 0.95 (t, J = 7.3 Hz, 3H). 25 ESI*MS: calcd for C 2 1
H
34
N
2 0 4 : 378.52; found: 379.0 (MH*). Step 4: 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethylacetamide hydrochloride A solution of 2-[2-(3-butoxyphenyl)-(tert-butoxycarbonyl)ethylamino]-N,N dimethylacetamide (9.6 g, 25.3 mmol) in HCl/Et 2 O (127 ml) was stirred at room temperature 30 for 16h. The solvent was evaporated under reduced pressure, the residue was ground with a mixture of Et 2 0/iPr 2 O 50/50, filtered and washed with Et 2 0/iPr 2 O to obtain the title compound as white solid (1,71 g, yield 95%). 'H NMR (300 MHz, CDCl 3 ): 8 9.63 (br. s., 1 H), 7.23 (dd, 1 H), 6.83 - 6.91 (m, 2 H), 6.80 (ddd, 1 H), 3.96 (s, 2 H), 3.96 (t, 2 H), 3.32 - 3.44 (m, 2 H), 3.22 - 3.32 (m, 2 H), 2.97 (s, 6 WO 2008/151702 35 PCT/EP2008/003848 H), 1.70 - 1.83 (m, 2 H), 1.41 - 1.58 (m, 2 H), 0.99 (t, 3 H). ESI*MS: called for C 16
H
26
N
2 0 2 : 278.40; found: 279.3 (MH*). 5 Analogously, starting from the appropriate intermediates, the following compounds were prepared: 2-{2-[3-(4,4,4-Trifluorobutoxy)phenyl]-ethylamino}-N,N-dimethylacetamide hydrochloride 'H NMR (300 MHz, DMSO-d6): 5 9.00 (br. s., 2 H), 7.17 - 7.32 (m, 1 H), 6.78 - 6.94 (m, 3 10 H), 4.04 (br. s., 2 H), 3.91 - 4.20 (m, 2 H), 3.08 - 3.22 (m, 2 H), 2.93 - 3.00 (m, 2 H), 2.94 (s, 3 H), 2.90 (s, 3 H), 2.30 - 2.48 (m, 2 H), 1.78 - 2.05 (m, 2 H). ESI*MS: calcd for Ci 6
H
23
F
3
N
2 0 2 (free base): 332.27; found: 333.25 (MH*). 2-[2-(3-Pentyloxyphenyl)-ethylamino]-N,N-dimethylacetamide hydrochloride 15 'H NMR (300 MHz, DMSO-d6): 6 9.03 (br s, 2 H), 7.14 - 7.29 (m, 1 H), 6.70 - 6.88 (m, 3 H), 4.03 (s, 2 H), 3.95 (t, 2 H), 3.06 - 3.21 (m, 2 H), 2.94 (s, 3 H), 2.90 (s, 3 H), 2.81 - 3.02 (m, 2 H), 1.62 - 1.80 (m, 2 H), 1.23 - 1.48 (m, 4 H), 0.90 (t, 3 H). ESI*MS: calcd for C 17
H
28
N
2 0 2 (free base): 292.42; found: 293.25 (MH*). 20 2-[2-(3-Hexyloxyphenyl)-ethylamino]-N,N-dimethylacetamide hydrochloride 'H NMR (300 MHz, DMSO-d6): 8 9.01 (br s, 2 H), 7.23 (dd, 1 H), 6.65 - 6.93 (m, 3 H), 4.03 (s, 2 H), 3.95 (t, 2 H), 3.05 - 3.24 (m, 2 H), 2.94 (s, 3 H), 2.91 - 3.01 (m, 2 H), 2.90 (s, 3 H), 1.57 - 1.84 (m, 2 H), 1.35 - 1.51 (m, 2 H), 1.22 - 1.36 (m, 4 H), 0.70 - 1.01 (m, 3 H). ESI+MS: calcd for C 18
H
30
N
2 0 2 (free base): 306.45; found: 307.32 (MH+). 25 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dipropylacetamide hydrochloride 'H NMR (300 MHz, DMSO-d6): 8 8.88 (br. s., 2 H), 7.15 - 7.30 (m, 1 H), 6.68 - 6.88 (m, 3 H), 4.02 (s, 2 H), 3.96 (t, 2 H), 3.23 - 3.28 (m, 2 H), 3.09 - 3.22 (m, 4 H), 2.87 - 2.98 (m, 2 H), 1.62 - 1.75 (m, 2 H), 1.35 - 1.62 (m, 6 H), 0.94 (t, 3 H), 0.85 (dt, 6 H). 30 ESI*MS: calcd for C 20
H
34
N
2 0 2 (free base): 334.50; found: 335.34 (MH*). 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dibutylacetamide hydrochloride 'H NMR (300 MHz, DMSO-d6 + TFA): 6 8.85 (br. s., 2 H), 7.19 - 7.28 (m, 1 H), 6.62 - 6.88 WO 2008/151702 36 PCT/EP2008/003848 (m, 3 H), 4.01 (t, 2 H), 3.96 (t, 2 H), 3.30 (t, 2 H), 3.06 - 3.24 (m, 4 H), 2.85 - 3.00 (m, 2 H), 1.61 - 1.82 (m, 2 H), 1.40 - 1.55 (m, 6 H), 1.20 - 1.38 (m, 4 H), 0.94 (t, 6 H), 0.89 (t, 3 H). ESIMS: called for C 20
H
38
N
2 0 2 (free base): 362.55; found: 363.35 (MH*). 5 2-[2-(3-Pentyloxyphenyl)-ethylamino]-N,N-dipropylacetamide hydrochloride IH NMR (300 MHz, DMSO-d6 + Na 2
CO
3 ): 8 7.50 (br. s., 1 H) 7.07 - 7.24 (m, 1 H) 6.62 6.83 (m, 3 H) 3.93 (t, 2 H) 3.06 - 3.22 (m, 5 H) 2.58 - 2.81 (m, 5 H) 1.62 - 1.78 (m, 2 H) 1.28 - 1.56 (m, 8 H) 0.68 - 0.99 (m, 9 H). 10 ESI*MS: calcd for C 21
H
36
N
2 0 2 (free base): 348.53; found: 349.28 (MH*). 2-[2-(3-Butoxyphenyl)-ethylamino]-acetamide hydrochloride 'H NMR (300 MHz, DMSO-d6): 5 8.96 (br s, 2 H), 7.87 (br s,1 H), 7.54 (br s,1 H), 7.23 (dd, I H), 6.58 - 6.83 (m, 3 H), 3.96 (t, 2 H), 3.70 (s, 2 H), 3.04 - 3.18 (m, 2 H), 2.82 - 3.01 (m, 2 15 H), 1.57 - 1.80 (m, 2 H), 1.32 - 1.54 (m, 2 H), 0.81 - 1.04 (m, 3 H). ESI*MS: calcd for Ci 4
H
22
N
2 0 2 : 250.34; found: 251.1 (MH+). 2-[2-(3-Butoxyphenyl)-ethylamino]-N-methylacetamide hydrochloride IH NMR (300 MHz, DMSO-d6): 6 8.99 (br s, 2 H), 8.39 (q, 1 H), 7.08 - 7.37 (m, 1 H), 6.65 20 6.95 (m, 3 H), 3.96 (t, 2 H), 3.70 (s, 2 H), 3.04 - 3.25 (m, 2 H), 2.79 - 3.04 (m, 2 H), 2.67 (d, 3 H), 1.57 - 1.82 (m, 2 H), 1.44 (sxt, 2 H), 0.94 (t, 3 H). ESI*MS: called for CI 5
H
24
N
2 0 2 : 264.37; found: 265.2 (MH*). 'H 2-[2-(3-Isopropoxyphenyl)-ethylamino]-N,N-dimethylacetamide hydrochloride 25 'H NMR (300 MHz, DMSO-d6): 6 9.04 (br s, 2 H), 7.12 - 7.32 (m, 1 H), 6.70 - 6.81 (m, 3 H), 4.60 (spt, 1 H), 4.03 (s, 2 H), 3.04 - 3.21 (m, 2 H), 2.94 (s, 3 H), 2.91 - 3.01 (m, 2 H), 2.90 (s, 3 H), 1.26 (d, 6 H). ESIMS: called for Ci 5
H
24
N
2 0 2 : 264.37; found: 265.2 (MH*). 30 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-diethylacetamide hydrochloride 'H NMR (300 MHz, DMSO-d6): 8 8.89 8.98 (br s, 2 H), 7.24 (dd, I H), 6.72 - 6.88 (m, 3 H), 4.03 (s, 2 H), 3.96 (t, 2 H), 3.34 (q, 2 H), 3.26 (q, 2 H), 3.08 - 3.21 (m, 2 H), 2.86 - 3.03 (m, 2 H), 1.59 - 1.78 (m, 2 H), 1.33 - 1.54 (m, 2 H), 1.13 (t, 3 H), 1.07 (t, 3 H), 0.94 (t, 3 H). ESI*MS: calcd for CI 8
H
30
N
2 0 2 : 306.45; found: 307.2 (MH*).
WO 2008/151702 37 PCT/EP2008/003848 2-[2-(3-Butoxyphenyl)-ethylamino]- 1 -pyrrolidin- 1 -yl-ethanone 'H NMR (300 MHz, DMSO-d6): 8 8.94 (s, 2 H), 7.14 - 7.33 (m, 1 H), 6.64 - 6.93 (in, 3 H), 5 4.00 (t, 2 H), 3.88 (s, 2 H), 3.33 - 3.45 (in, 4 H), 3.19 - 3.29 (in, 2 H), 2.96 - 3.05 (in, 2 H), 1.78 - 2.00 (in, 4 H), 1.65 - 1.78 (in, 2 H), 1.37 - 1.56 (m, 2 H), 0.96 (t, 3 H). ESI+MS: calcd for Ci 8
H
28
N
2 0 2 : 304.44; found: 305.2 (MH*). 2-[2-(3-Butoxy-4-fluorophenyl)-ethylamino]-N,N-dimethylacetamide hydrochloride 10 'H NMR (300 MHz, DMSO-d6): 6 8.91 (br s, 2 H) 7.15 (dd, 1 H) 7.05 (dd, 1 H) 6.79 (ddd, 1 H) 3.97 - 4.12 (in, 4 H) 3.09 - 3.21 (in, 2 H) 2.94 (s, 3 H) 2.92 - 2.99 (in, 2 H) 2.90 (s, 3 H) 1.65 - 1.82 (m, 2 H) 1.36 - 1.54 (m, 2 H) 0.87 - 1.01 (m, 3 H). ESI*MS: calcd for CI 6
H
2 5
FN
2 0 2 (free base): 296.38; found: 297.22 (MH*). 15 2-[2-(3-Butoxy-4-methoxyphenyl)-ethylamino]-N,N-dimethylacetamide hydrochloride 'H NMR (300 MHz, DMSO-d6): 6 8.97 (br s, 2 H), 6.90 (d, 1 H), 6.84 (d, 1 H), 6.74 (dd, 1 H), 4.02 (br s, 2 H), 3.94 (t, 2 H), 3.73 (s, 3 H), 3.04 - 3.22 (in, 2 H), 2.94 (s, 3 H), 2.90 (s, 3 H), 2.84 - 2.92 (in, 2 H), 1.57 - 1.84 (in, 2 H), 1.44 (sxt, 2 H), 0.94 (t, 3 H). ESI*MS: called for C1 7
H
28
N
2 0 3 (free base): 308.42; found: 309.21 (MH*). 20 Example 2 2-[2-(3-Butoxyphenyl)-ethylamino]-2,N,N-trimethylpropanamide hydrochloride Step 1: 2-[2-(3-Butoxyphenyl)-ethylamino]-2-methylpropionic acid ethyl ester 25 To a solution of 2-(3-butoxyphenyl)-ethylamine hydrochloride (0.27 g, 1.42 mmol; obtained from the compound of Step 2 of Example 1, according to the standard procedure described in Step 4 of Example 1) in acetonitrile (8 ml), 2-bromo-2-methylpropionic acid ethyl ester (0.27 ml, 1.85 mmol) and triethylamine (0.52 ml, 3.70 mmol) were added. The solution was heated at 100 *C under microwave irradiation for 3h. The mixture was cooled to room temperature 30 and partitioned between water and CH 2 Cl 2 . The organic layer was separated, washed with brine, dried over Na 2
SO
4 , filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography (silica, CH 2 Cl 2 :MeOH from 100:0 to 95:5) affording the title compound (0.17 g, 39% yield) as colourless oil. ESI*MS: calcd for C 18
H
29
NO
3 : 307.44; found: 308.2 (MH*).
WO 2008/151702 38 PCT/EP2008/003848 Step 2: 2-[2-(3-Butoxyphenyl)-ethylamino]-2,NN-trimethylpropanamide hydrochloride To a solution of dimethylamine, 2 M in THF (0.6 ml, 1.1 mmol) in toluene (3 ml) 5 trimethylaluminium, 2 M in hexane (1.4 ml, 2.77 mmol) was added and the mixture was stirred at room temperature for 15 minutes. 2-[2-(3-butoxyphenyl)-ethylamino]-2-methyl propionic acid ethyl ester (0.17 g, 0.55 mmol) in dry toluene (8 ml) was added and the solution was heated to 90 'C and stirred for 24h. The mixture was cooled to room temperature and the solved removed under reduced pressure. The residue was partitioned between water 10 and diethyl ether. The organic layer was separated, washed with brine, dried over Na 2
SO
4 , filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography (first purification: silica, CH 2 Cl 2 :MeOH from 100:0 to 97:3; second purification: silica, EtOAc) affording the title compound that was dissolved in HCl/Et 2 0 and stirred for 20 minutes. The resulting hydrochloride salt was filtered, washed with iPr 2 O and 15 dried at 40 'C under vacuum. The pure title compound (18.5 mg, 20% yield) was obtained as a white solid. 'H NMR (300 MHz, CDCl 3 ): 5 9.39 (bs, 2 H), 7.24 (t, 1 H), 6.71-6.97 (in, 3 H), 3.97 (t, 2 H), 3.13-3.36 (in, 4 H), 3.09 (s, 6 H), 1.90 (s, 6 H), 1.69-1.86 (in, 2 H), 1.51 (sxt, 2 H), 0.99 (t, 3 H). 20 ESI*MS: calcd for C 18
H
30
N
2 0 2 : 306.45; found: 307.32 (MH*). Example 3 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethylpropanamide hydrochloride 25 Step 1: 2-[2-(3-Butoxyphenyl)-(tert-butoxycarbonyl)ethylamino]-N,N-dimethylpropanamide A solution of 2-[2-(3-butoxyphenyl)-(tert-butoxycarbonyl)ethylamino]-N,N dimethylacetamide (0.410 g, 1.1 mmol; prepared according to Step 3 of Example 1) in dry THF (5 ml) was cooled to -78 *C and LiHMDS (lithium hexamethyldisilazide), 1 M in THF, (1.43 ml, 1.4 mmol) was added dropwise. The mixture was stirred 30 min then a solution of 30 methyl iodide (0.187 g, 1.3 mmol) in dry THF (1 ml) was added dropwise. The mixture was stirred for 2h allowing the cooling bath to expire. The solvent was evaporated under reduced pressure and the residue was dissolved in EtOAc (15 ml) and washed with water (2x15 ml). The organic phase was dried over Na 2
SO
4 , filtered and the solvent was evaporated under reduced pressure. The residue was purified by flash chromatography (silica, petroleum 35 ether:EtOAc from 8:2 to 6:4) affording the title compound (0.22 g, 52% yield) as a colourless WO 2008/151702 39 PCT/EP2008/003848 oil. ESI*MS: calcd for C 22
H
36
N
2 0 4 : 392.54; found: 393.3(MH*). 5 Step 2: 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethylpropanamide hydrochloride The title compound was prepared from 2-[2-(3-butoxyphenyl)-(tert butoxycarbonyl)ethylamino]-N,N-dimethyl-propanamide according to the standard procedure described in Step 4 of Example 1. White solid (47% yield). 'H NMR (300 MHz, DMSO-d6): 8 9.16 (br s,1 H), 8.82 (br s,1 H), 7.14 - 7.31 (in, 1 H), 6.64 10 - 6.93 (in, 3 H), 4.39 (q, 1 H), 3.96 (t, 2 H), 3.08 - 3.22 (m, 1 H), 3.00 (s, 3 H), 2.96 - 3.06 (m, I H), 2.87 - 2.96 (m, 2 H), 2.90 (s, 3 H), 1.59 - 1.82 (m, 2 H), 1.37 - 1.53 (m, 2 H), 1.38 (d, 3 H), 0.94 (t, 3 H). ESI*MS: calcd for C 17 1H 28
N
2 0 2 (free base): 292.42; found: 293.25 (MH*). 15 Example 4 2-[2-(3-Butoxyphenyl)-ethylamino]-3-hydroxy-N,N-dimethylpropanamide hydrochloride Step 1: 2-[2-(3-Butoxyphenyl)-(tert-butoxycarbonyl)ethylamino]-3-acetoxy-N,N-dimethyl propanamide 20 The title compound was prepared from [2-[2-(3-butoxyphenyl)-(tert butoxycarbonyl)ethylamino]-N,N-dimethylacetamide and acetic acid bromomethyl ester according to Step 1 of Example 3. Colourless oil (38% yield). ESI*MS: calcd for C 24
H
38
N
2 0 6 (free base): 450.58; found: 451.2 (MH*). 25 Step 2: 2-[2-(3-Butoxyphenyl)-(tert-butoxycarbonyl)ethylamino]-3-hydroxy-N,N-dimethyl propanamide 2-[2-(3-Butoxyphenyl)-(tert-butoxycarbonyl)ethylamino]-3-acetoxy-N,N-dimethylpropan amide (0.19 g, 0.42 mmol) was dissolved in 3 % NH 4 0H/MeOH (15 ml) and stirred at room temperature for 5h. The solvent was evaporated under reduced pressure and the residue was 30 purified by flash chromatography (silica, petroleum ether:EtOAc from 7:3 to 3:7) affording the title compound (0.13 g, 66% yield) as a colourless oil. ESI*MS: calcd for C 22
H
36
N
2 0 5 : 408.54; found: 409.2(MH*). Step 3: 2-[2-(3-Butoxyphenyl)-ethylamino]-3-hydroxy-N,N-dimethylpropanamide hydrochloride 35 The title compound was prepared from 2-[2-(3-butoxyphenyl)-(tert- 40 butoxycarbonyl)ethylamino]-3-acetoxy-N,N-dimethylpropanamide according to the standard procedure described in Step 4 of Example 1. Obtained as white solid (76% yield). 'H NMR (300 MHz, DMSO-d6): 5 8.46 - 9.44 (in, 2 H) 7.10 - 7.33 (in, 1 H) 6.65 - 6.92 (in, 3 5 H) 5.54 (t, I H) 4.44 (t, I H) 3.95 (t, 2 H) 3.65 - 3.88 (m, 2 H) 3.11 - 3.22 (in, I H) 3.03 - 3.09 (in, I H) 3.02 (s, 3 H) 2.91 - 2.99 (in, 2 H) 2.90 (s, 3 H) 1.61 - 1.79 (in, 2 H) 1.35 - 1.53 (m, 2 H) 0.86 - 1.00 (m, 3 H). ESI*MS: calcd for C1 7
H
2 8
N
2 0 3 (free base): 308.42; found: 309.21 (MH*). 10 Example 5 2-[2-(3-Butoxy-4-iethylphenyl)-ethylamino]-N,N-dimethylacetamide hydrochloride Step 1: (3-Hydroxy-4-methylphenyl)-acetonitrile To a solution of 3-methoxy-4-methylphenylacetonitrile (2.0 g, 12.4 mmol) in dry CH 2
CI
2 (50 15 ml) cooled to -78 *C, BBr 3 I M in CH 2
C
2 (27 ml, 27 mmol) was added dropwise. The mixture was stirred overnight allowing the cooling bath to expire. The mixture was slowly poured in ice/water under stirring. When the ice melted, the aqueous phase was extracted with EtOAc and the organic phase was dried over Na 2
SO
4 , filtered and the solvent was evaporated under reduced pressure. The crude title compound (1.7 g, 93% yield) was used in the next step 20 without further purification. Step 2: (3-Butoxy-4-methylphenyl)-acetonitrile To a solution of (3-hydroxy-4-methylphenyl)-acetonitrile (1.7 g, 11.5 mmol) in acetone (100 ml), K 2
CO
3 (7.9 g, 57.5 mmol) and 1-bromo butane (6.1 ml, 57.5 mmol) were added. The 25 suspension was refluxed for 24h and the solvent was evaporated under reduced pressure. The residue was dissolved in CH 2
C
2 and washed with water and brine. The organic layer was dried over Na 2
SO
4 , filtered and the solvent evaporated under reduced pressure. The crude was purified by flash chromatography (petroleum ether:EtOAc 9.5:0.5) affording the title compound (1.43 g. 61% yield) as colourless oil. 30 ESI*MS: calcd for Ci 3
HI
7 NO: 203.29; found: 204.1 (MH*). Step 3: N-[2-(3-Butoxy-4-methylphenyl)-ethyl]-carbamic acid tert-butyl ester To a solution of (3-butoxy-4-methylphenyl)acetonitrile (0.94 g, 5.0 mmol) in methanol (38 ml), nickel chloride hexahydrate (0.12 g, 0.5 mmol) and boc 2 O (2.18 g, 10.0 mmol) were 213494_1 (GHMatters)24/12/2009 40a added. The solution was cooled to 0 0 C and sodium borohydride (1.32 g, 35.0 mmol) was added 2134994_1 (GHMatters)24/12/2009 WO 2008/151702 41 PCT/EP2008/003848 portionwise over 30 minutes. The mixture was stirred overnight allowing the cooling bath to expire. The reaction was quenched by addition of diethylentriamine (0.54 ml, 5 mmol) and stirred for 30 minutes. The solvent was removed under reduced pressure and the residue re 5 dissolved in EtOAc, washed with water, dried over Na 2
SO
4 , filtered and the solvent was evaporated under reduced pressure. The crude was purified by flash chromatography (silica, petroleum ether:EtOAc 90:10) to give the title compound . Colourless oil (80% yield). ESI+MS: calcd for CI 8
H
29
NO
3 : 307.44; found: 308.1 (MH*). 10 Step 4: 2-[2-(3-Butoxy-4-methylphenyl)-ethylamino]-N,N-dimethylacetamide hydro chloride The title compound was prepared from [2-(3-butoxy-4-methylphenyl)-ethyl]-carbamic acid tert-butyl ester according to the standard procedures described in Steps 3 and 4 of Example 1. Obtained as white solid. 15 'H NMR (300 MHz, DMSO-d6): 8 8.93 (br s, 2 H), 7.08 (dd, 1 H), 6.79 (d, 1 H), 6.69 (dd, 1 H), 4.03 (s, 2 H), 3.97 (t, 2 H), 3.08 - 3.19 (in, 2 H), 2.93 (s, 3 H), 2.91 - 2.97 (in, 2 H), 2.90 (s, 3 H), 2.11 (s, 3 H), 1.65 - 1.79 (in, 2 H), 1.39 - 1.54 (in, 2 H), 0.95 (t, 3 H). ESI*MS: calcd for CI 7
H
28
N
2 0 2 (free base): 292.42; found: 293.25 (MH*). 20 Analogously, starting from (2,6-difluoro-3-methoxyphenyl)-acetonitrile the following compound was prepared: 2-[2-(3-Butoxy-2,6-difluorophenyl)-ethylamino]-N,N-dimethylacetamide hydrochloride 'H NMR (300 MHz, DMSO-d6): 8 9.16 (br s, 2 H), 7.07 - 7.18 (in, 1 H), 6.96 - 7.07 (in, 1 H), 25 4.07 (s, 2 H), 4.02 (t, 2 H), 3.08 (s, 4 H), 2.93 (s, 3 H), 2.90 (s, 3 H), 1.63 - 1.76 (m, 2 H), 1.36 - 1.51 (in, 2 H), 0.93 (t, 3 H). ESI*MS: calcd for Ci 6
H
24
F
2
N
2 0 2 (free base): 314.37; found: 315.20 (MH*). 30 Example 6 2-[2-(3-Butoxyphenyl)-2-methylpropylamino]-N,N-dimethylacetamide hydrochloride Step 1: 2-(3-Methoxyphenyl)-2-methylpropionitrile To a solution of (3-methoxyphenyl)-acetonitrile (8.0 g, 0.054 mol) in DMF (25 ml) cooled to WO 2008/151702 42 PCT/EP2008/003848 0 *C, NaH (1.3 g, 0.054 mol) was added. The reaction was stirred for 30 min, and Mel (3.3 mL, 0.054 mol) was added. The reaction was stirred 1h at room temperature. After this period, the reaction mixture was cooled again to 0 *C, NaH (1.3 g, 0.054 mol) was added 5 followed by Mel (3.3 ml, 0.054 mol) after 30 minutes. The reaction was stirred at room temperature overnight. DMF was evaporated and the crude diluted with brine and extracted with Et 2 0. The organic phase was washed with water, dried over Na 2
SO
4 , the solvent was evaporated under reduced pressure and the residue was purified by flash chromatography (petroleum ether:AcOEt 95:5) to give the title compound (4 g, 42% yield) as a colourless oil. 10 ESI*MS: calcd for CI H1 3 NO: 175.23; found: 176.1 (MH*). Step 2: 2-[2-(3-Butoxyphenyl)-2-methylpropylamino]-N,N-dimethylacetamide hydro chloride The title compound was prepared from 2-(3-methoxyphenyl)-2-methylpropionitrile according 15 to the procedure described in Example 5. 'H NMR (300 MHz, DMSO-d6): 8 8.44 (br. s., 2 H), 7.28 (t, 1 H), 6.90 - 7.04 (m, 2 H), 6.77 6.90 (in, 1 H), 3.99 (t, 2 H), 3.88 (s, 2 H), 3.16 (s, 2 H), 2.88 (s, 6 H), 1.64 - 1.78 (in, 2 H), 1.42 - 1.55 (in, 2 H), 1.36 - 1.42 (in, 6 H), 0.90 - 1.04 (in, 3 H). ESI*MS: calcd for C 18
H
30
N
2 0 2 (free base): 306.45; found: 307.26 (MH*). 20 Example 7 2-[2-(3-Butylthiophenyl)-ethylamino]-N,N-dimethylacetamide hydrochloride Step 1: (3-Butylthiophenyl)-acetonitrile To a solution of (3-iodophenyl)-acetonitrile (2.0 g, 8.2 mmol) and acetic acid S-butyl ester 25 (2.4 ml, 24.6 mmol) in n-BuOH (5 ml), Cul (0.156 g, 0.8 mmol), ethylene glycol (0.96 ml, 1.7 mmol) and K 2
CO
3 (2.4 g, 17.3 mmol) were added and the mixture was heated under microwave irradiation to 110 'C for 1h. The reaction mixture was diluted with AcOEt and filtered over a celite pad. The organic phase was washed with water and brine, dried over Na 2
SO
4 and the solvent was evaporated under reduced pressure. The crude was purified by 30 flash chromatography (petroleum ether:AcOEt from 10:0 to 9:1) to give pure title compound as a pale yellow oil (1.0 g, 64% yield), used without further purification in the next step. ESI*MS: calcd for C 12 Hi 5 NS: 205.32, no mass detectable. Step 2: 2-[2-(3-Butylthiophenyl)-ethylamino]-N,N-dimethylacetamide hydrochloride WO 2008/151702 43 PCT/EP2008/003848 The title compound was prepared from (3-butylthiophenyl)-acetonitrile according to the procedure described in Example 5. 'H NMR (300 MHz, DMSO-d6): 8 9.08 (br. s., 2 H), 7.23 - 7.36 (m, 1 H), 7.15 - 7.23 (m, 2 5 H), 6.95 - 7.11 (m, 1 H), 4.03 (s, 2 H), 3.08 - 3.21 (in, 2 H), 2.92 - 3.02 (m, 4 H), 2.94 (s, 3 H), 2.90 (s, 3 H), 1.49 - 1.67 (m, 2 H), 1.30 - 1.49 (m, 2 H), 0.89 (t, 3 H). ESI*MS: calcd for C 1 6
H
26
N
2 0S (free base): 294.46; found: 295.20 (MH*). Example 8 10 2-[2-(3-Butylsulfonylphenyl)-ethylamino]-N,N-dimethylacetamide hydrochloride Step 1: 2-[2-(3-Butylsulfonylphenyl)-(tert-butoxycarbonyl)ethylamino]-N,N dimethylacetamide To a solution of 2-[2-(3-butylthiophenyl)-(tert-butoxycarbonyl)ethylamino]-N,N 15 dimethylacetamide hydrochloride (0.25 g, 0.62 mmol; prepared from the compound of Step 2 of Example 7, by reaction with boc 2 0 according to the procedure described in the first part of Step 1 of Example 1) in acetonitrile (20 ml)/water (10 ml), a mixture of oxone (0.92 g, 1.5 mmol) and NaHCO 3 (0.2 g, 2.3 mmol) was added portionwise over 5 minutes. The mixture was stirred at room temperature for 2h. The mixture was partitioned between water and 20 CH 2 Cl 2 , the organic was washed with water and brine, dried over Na 2
SO
4 and the solvent was evaporated under reduced pressure. The crude was purified by flash chromatography (petroleum ether:AcOEt 3:7) to give pure title compound as a colourless oil (0.20 g, 75% yield). ESI*MS: calcd for C 2 1
H
34
N
2 0 5 S: 426.58; found: 427.1 (MH*). 25 Step 2: 2-[2-(3-Butylsulfonylphenyl)-ethylamino]-N,N-dimethylacetamide hydrochloride The title compound was prepared from 2-[2-(3-butylsulfonylphenyl)-(tert butoxycarbonyl)ethylamino]-N,N-dimethylacetamide according to the standard procedure described in Step 4 of Example 1. 30 'H NMR (300 MHz, DMSO-d6 + TFA): 8 8.84 - 9.10 (m, 2 H), 7.74 - 7.86 (m, 2 H), 7.57 7.71 (m, 2 H), 4.06 (t, 2 H), 3.03 - 3.34 (in, 6 H), 2.95 (s, 3 H), 2.91 (s, 3 H), 1.45 - 1.63 (m, 2 H), 1.24 - 1.42 (m, 2 H), 0.84 (s, 3 H). ESI+MS: calcd for CI 6
H
2 6
N
2 0S (free base): 294.46; found: 295.20 (MH*).
WO 2008/151702 44 PCT/EP2008/003848 Example 9 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethylthioacetamide hydrochloride 5 Step 1: 2-[2-(3-Butoxyphenyl)-(tert-butoxycarbonyl)ethylamino]-N,N-dimethylthioacetamide To a solution of 2-[2-(3-butoxyphenyl)-(tert-butoxycarbonyl)ethylamino]-N,N dimethylacetamide (0.38 g, 1.0 mmol) in dry toluene (20 ml), Lawesson's reagent (0.58 g, 1.2 mmol) was added one-pot and the mixture was heated to reflux and stirred for 2h. The solvent was evaporated under reduced pressure and the residue was purified by flash chromatography 10 (petroleum ether:AcOEt from 9:1 to 8:2) to give pure title compound as a colourless oil (0.11 g, 28% yield). ESI*MS: calcd for C 2 1
H
34
N
2 0 3 S: 394.58; found: 395.1 (MH+). Step 2: 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethylthioacetamide hydrochloride 15 The title compound was prepared from 2-[2-(3-butoxyphenyl)-(tert butoxycarbonyl)ethylamino]-N,N-dimethylthioacetamide according to the standard procedure described in Step 4 of Example 1. Obtained as white solid. H NMR (300 MHz, DMSO-d6): 8 8.88 (s, 2 H), 7.16 - 7.34 (m, 1 H), 6.73 - 6.88 (m, 3 H), 4.17 (s, 2 H), 3.96 (dd, 2 H), 3.43 (s, 3 H), 3.31 (s, 3 H), 3.16 - 3.26 (m, 2 H), 2.92 - 3.04 (m, 20 2 H), 1.62 - 1.76 (m, 2 H), 1.36 - 1.50 (m, 2 H), 0.94 (t, 3 H). ESI*MS: calcd for C 16
H
26 N2OS (free base): 294.46; found: 295.22 (MH*). Example 10 2-[2-(3-Butoxyphenyl)]-(N'-methoxy)ethylamino]-N,N-dimethylacetamide 25 Step 1: 2-(3-Butoxyphenyl)-acetaldehyde To a solution of 2-(3-butoxyphenyl)-ethanol (3.00 g, 15.4 mmol; prepared from 2-(3 hydroxyphenyl)-ethanol according to the procedure described in Step 2 of Example 1) in
CH
2 Cl 2 (100 ml), Dess-Martin periodinane reagent (8.5 g, 20.1 mmol) was added and the 30 reaction was left at room temperature overnight. The solution was poured into a NaHCO 3 saturated solution containing Na 2
S
2
O
3 (35 g), and the mixture was stirred for 30 min. The organic layer was separated, dried over Na 2
SO
4 , filtered and evaporated under reduced pressure.
WO 2008/151702 45 PCT/EP2008/003848 The residue containing the title compound (2.9 g, 99% yield) was used in the next step without further purification. 5 Step 2: 2-(3-Butoxyphenyl)-(N-methoxy)ethylamine To a suspension of 2-(3-butoxypheny)-acetaldehyde (2.00 g, 10.4 mmol) and 0 methoxyamine hydrochloride (1.12 g, 13.4 mmol) in water (13 ml), a solution of Na 2
CO
3 (0.66 g, 6.2 mmol) in water (20 ml) was added dropwise under stirring at 0 *C. The reaction was left at room temperature overnight and then extracted with diethylether. The organic layer 10 was dried over Na 2
SO
4 , filtered and evaporated under reduced pressure. The residue containing the desired oxime intermediate (2.24 g, 10.2 mmol) was dissolved in methanol (60 ml) and acetic acid (8.8 ml, 153.0 mmol) was added. The solution was cooled to 0 *C and NaCNBH 3 was added portionwise. The reaction mixture was stirred at room temperature overnight, then the solvent was removed under reduced pressure and the residue 15 was partitioned between 5% NaHCO 3 solution and ethyl acetate. The organic phase was dried over Na 2
SO
4 , filtered and concentrated to dryness under vacuum. The crude residue was purified by column chromatography, (petroleum ether: ethyl acetate 9:1) to afford 0.88 g (38% yield) of the title compound. 20 Step 3: 2-[2-(3-Butoxyphenyl)]-(N'-methoxy)ethylamino]-NN-dimethylacetamide 2-(3-Butoxyphenyl)-(N-methoxy)ethylamine (0.5 g, 2.25 mmol), obtained as described in Step 2, was dissolved in acetonitrile (15 ml) and ethyldiisopropylamine (1.95 ml, 11.25 mmol) was added followed by 2-chloro-N,N-dimethylacetamide (1.15 ml, 11.25 mmol). The solution was heated at 130 'C under microwave irradiation for 6h. The mixture was cooled to 25 room temperature, the solvent removed under reduced pressure and the residue was partitioned between 5% NaHCO 3 and ethyl acetate. The organic phase was dried over Na 2
SO
4 , filtered and concentrated to dryness under vacuum. The crude residue was purified by column chromatography, (petroleum ether: ethyl acetate 1:1) to afford 0.25 g (36% yield) of the title compound. 30 'H NMR (300 MHz, DMSO-d6 + TFA): 7.17 (t, 1 H), 6.61 - 6.89 (m, 3 H), 3.94 (t, 2 H), 3.56 (s, 2 H), 3.47 (s, 3 H), 2.98 (s, 3 H), 2.89 - 2.97 (in, 2 H), 2.80 (s, 3 H), 2.72 - 2.86 (m, 2 H), 1.58 - 1.77 (m, 2 H), 1.34 - 1.53 (in, 2 H), 0.93 (t, 3 H). ESI*MS: calcd for C 17
H
28
N
2 0 3 (free base): 308.42; found: 309.18 (MH*).
WO 2008/151702 46 PCT/EP2008/003848 Example 11: TTXs-sodium channel influx assay ND7/23 rat dorsal root ganglion-derived cell line endogenously expresses a mixed population 5 of TTXs sodium channels. These cells lack of TTXr sodium channels as shown by the absence of their respective transcripts. ND7/23 cells were grown in DMEM supplemented withl0% FBS and 1mM sodium piruvate. The cells were seeded at 50,000 cells/well on 96 poly-L-lysine-coated plates and further incubated for 18-24h before use. 10 The Membrane Potential Kit Assay (Molecular Devices), based on a negatively charged fluorescent dye able to monitor changes in membrane potential caused by the sodium influx due to the channel opening, was used for the assay. Cells were incubated with the dye loading for 30 minutes at 25'C. Then, lOOnM of the toxin Anemonia sulcata (used as enhancer of the channel opener response) alone or in the presence 15 of TTX (as reference standard) or test compound were added for further 15 minutes. The fluorescence (excitation:530nm, emission: 565 nm wavelength) was measured before and after (40-45 s) the automated injection of the sodium channel opener veratridine (100 PM) using a Victor plate reader (Perkin Elmer). The inhibition curves were calculated from 5 concentrations, each in triplicate, and the IC 50 20 determined using linear regression analysis. The compounds of the present invention inhibit TTXs sodium channels with pharmacologically significant IC 50 values. The results, obtained with some compounds which are representative of the entire class of compounds of the invention, compared with the standards ralfinamide and safinamide, are 25 reported in Table 1. Table 1 Na+ influx Compound
IC
5 0 pM 2-[2-(3-Hexyloxyphenyl)-ethylamino]-N,N- 0.5 dimethylacetamide hydrochloride 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N- 0.5 dipropylacetamide hydrochloride 2-[2-(3-Pentyloxyphenyl)-ethylamino]-N,N- 0.5 47 dimethylacetamide hydrochloride 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N- 0.6 diethylacetamide hydrochloride 2-[2-(3-Butoxyphenyl)-ethylamino]-2,N,N- 0.7 trimethylpropanamide hydrochloride 2-[2-(3-Pentyloxyphenyl)-ethylamino]-N,N- 1.1 dipropylacetamide hydrochloride 2-[2-(3-Butoxyphenyl)-ethylamino}-N,N- 1.1 dimethylpropanamide hydrochloride 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N- 1.2 dibutylacetamide hydrochloride 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N- 1.2 dimethylthioacetamide hydrochloride 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N- 1.5 dimethylacetamide hydrochloride 2-[2-(3-Butoxyphenyl)-ethylamino]-1- 2.1 pyrrolidin- I -yl-ethanone hydrochloride 2-[2-(3-Butoxy-2,6-difluorophenyl)- 2.6 ethylamino]-N,N-dimethylacetamide hydrochloride (S)-(+)-2-[4-(2-Fluorobenzyloxy) benzylamino]-propanamide (ralfinamide)* 9.5 (S)-(+)-2-[4-(3-Fluorobenzyloxy) benzylamino]-propanamide (safinamide)* 7.4 * as the salt with methanesulfonic acid 5 Example 12: Calcium channel influx assay AtT20/Dl6v-F2 mouse pituitary tumour cell line preferentially expresses L-type calcium channels. AtT20 cells were grown in DMEM with 10% of FBS, 4mM glutamine. The cells were seeded 2134994_1 (GHMatters)24112/2009 WO 2008/151702 48 PCT/EP2008/003848 at 200,000 cells/well on 96 poly-L-lysine-coated plates and further incubated for 18-24h, before use. The Ca" Kit Assay (Molecular Devices), which is based on a fluorescent calcium indicator to 5 detect the calcium influx determined by depolarizing conditions, was used for the assay. Cells were incubated with the calcium dye loading for 30 min at 37*C. Then, to-conotoxin alone (1 pM) or in presence of nifedipine (as reference standard) or test compound were added for further 15 min. The fluorescence (excitation: 485-emission: 535 nm wavelength) was measured before and 10 after (30-40 sec) the automated injection of 100 mM KC depolarizing solution using a Victor plate reader (Perkin Elmer). The inhibition curves were calculated from 5 concentrations, each in triplicate, and the IC 50 determined using linear regression analysis. The results, obtained with some compounds which are representative of the entire class of 15 compounds of the invention, compared with the standards ralfinamide and safinamide, are reported in Table 2. Table 2 Compound Ca"+ influx
IC
50 pM 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N dipropylacetamide hydrochloride 1.1 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N dibutylacetamide hydrochloride 1.8 2-[2-(3-Hexyloxyphenyl)-ethylamino]-N,N dimethylacetamide hydrochloride 4.0 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N diethylacetamide hydrochloride 6.7 2-[2-(3-Pentyloxyphenyl)-ethylamino]-N,N dipropylacetamide hydrochloride 6.9 2-[2-(3-Butylthiophenyl)-ethylamino]-N,N dimethylacetamide hydrochloride 7.2 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N dimethylthioacetamide hydrochloride 7.6 49 2-[2-(3-Pentyloxyphenyl)-ethylamino]-N,N dimethylacetamide hydrochloride 8.3 2-{2-[3-(4,4,4-Trifluorobutoxy)phenyl] ethylamino} -N,N-dimethylacetamide 9.3 hydrochloride (S)-(+)-2- [4-(2-Fluorobenzyloxy)-benzylamino] propanamide (ralfinamide)* 26.0 (S)-(+)-2-[4-(3 -Fluorobenzyloxy)-benzylamino] propanamide (safinamide)* 33.0 * as the salt with methanesulfonic acid 5 Example 13: Patch clamp evaluation of Na* currents blockade in rat cortical neurons Cell Preparation and culturing Procedures involving animals and their care were conducted in conformity with institutional guidelines in compliance with national (D.L. n.116, G.U., suppl.40, Feb. 18, 1992) and international laws and policies (EEC Council directive 86/609, OJL358.1, Dec.12 1987; 10 Guide for the Care and Use of Laboratory Animals, U.S. National Research Council, 1996). Cortical neurons were prepared from embryonic Wistar rats (El 7-E19). A female rat at date 17-19 of pregnancy was anesthetized and sacrificed. The fetuses (n= 4-5) were dissected and placed in ice-cold Hank's solution (Hank's solution (Life tech.14170-088) + glucose 30% + Pen-Strep 100x (Life Tech. 15140-122) 100U-100pg/ml and Hepes-NaOH 5mM). The uterus 15 and placenta were removed, the fetuses were decapitated and the heads were placed in ice cold Hank's solution. The skin of the head was removed using a pincer, the scalp was opened cutting laterally from the back till the eyes, and the brain was taken out using a curved pincer. 20 The brain was cut in two halves, the outer connective tissue membrane was removed with a pincer, and, keeping the brain upside down, the cerebellum, the brainstem and the diencephalon was removed using a curved pincer trying to clean as much as possible the inside of the cortex. 2134994_1 (GHMatters)24/1212009 50 Each cortex was cut in smaller parts with a scissors, the pieces were transferred to a 15 ml centrifuge tube using a 5 ml pipette and washed twice with Hank's solution. 5 The solution was removed except 1-2 ml and the tissue was first dissociated with a 5 ml pipette then with two fire-polished Pasteur pipettes (medium and small opening, respectively). After the mechanical dissociation, 5 ml of complete DMEM (Dulbecco's modified Eagle medium) (Gibco 41966-029) + FBS (Hyclone) 10% + Glutamine (Life Tech. 25030-024) 2mM + Pen-Strep 100U-100pg/ml were added, and cell suspension was centrifuged for 5 min 10 at 1000 rpm. Supernatant was removed and 5 ml of complete Neurobasal medium was added (NB medium (Life tech.21103-049) + B27 (Life tech.17504-044) 2% + Glutamine 2mM + Pen-Strep IOOU-100ipg/ml). Cells were counted and diluted in Neurobasal medium to a concentration of 400000 cells per 15 poly-D-lysine 5ptg/ml treated Petri dish. Cortical neurons were used from day 6 h till day I 1* after plating, and once a week Neurobasal medium was changed. 20 Whole Cell Patch Clamp Recordings Experiments on cortical neurons were carried out using standard whole cell patch clamp methods (Hamill et al., PFUGHERS ARCH., 1981 Aug, 391(12), 85-100). Membrane currents were recorded and filtered at 5 kHz with an Axon Axopatch 200B amplifier and data digitized with an Axon Digidata 1322A (Axon Instruments, CA, USA). Protocol playing and 25 data acquisition were controlled online with Axon pClamp8 software. Measuring and reference electrodes were AgCl-Ag electrodes. A Sutter Instrument P-87 Puller (CA, USA) was used for pulling patch clamp pipettes with a resistance of 2-3 MQ from Harward borosilicate glass tubes. Cells were continuously superfused with extracellular solutions, using a solution changer Biologic RSC-200. 30 Voltage protocols and data analyses To test the effect of compounds on sodium currents in cortical neurons, cells were clamped at -90 mV, then a two step protocol was used to determine the voltage dependence of the block. 213494_1 (GHMatters)24/12/2009 50a Sodium currents were activated by a 30ms step pulse to -lOmV (test pulse) from a 2000ms preconditioning potential of -11 OmV (resting condition) and a potential of ~ -50mV (half maximal steady-state condition). 5 Tonic block of resting and depolarized currents at a given drug concentration, was calculated as the difference between the peak Na* current in the control external bath solution and peak currents with the test substance divided by control peak. 2134994_1 (GHMatters)2412I/209 WO 2008/151702 51 PCT/EP2008/003848 Drug concentration-inhibition curves were obtained by plotting tonic blocks in the resting and depolarized condition, versus drug concentrations. Dose-response curves were fitted to the tonic block data, according to the logistic equation: y = A2+(Al-A2)/[l+(x/ICso)p]. Al and 5 A2 are fixed values of 0 and 1 corresponding to 0 and 100% current inhibition, x is the drug concentration, IC 50 is the drug concentration resulting in 50% current inhibition and p is the corresponding slope factor. The apparent affinity of drug for the inactivated state (Ki) was calculated according to the equation 1/Kdep=h/Kr + (1-h)/Ki where Kr is the affinity of drug for the resting/closed state; 10 Kdep is the IC 5 o in the depolarized condition, h and (1-h) are the fractions of channels present at the rest and dep potentials, respectively. Solutions and drugs Control bath solution contained (mM): NaCl 60, CholineCi 60, CaCl2 1.3, MgCl2 2, KCl 2, 15 CdCl2 0.4, NiCl2 0.3, TEACI 20, Hepes 10, Glucose 10. Internal pipette solution consisted of (mM): CsF 65, CsCl 65, NaCl 10, CaCl 2 1.3, MgCl 2 2, Hepes 10, EGTA 10, MgATP 1. Compounds were dissolved as stock solutions (20mM) in DMSO. They were diluted to the final concentrations in the external solution. 20 Results The compounds of this invention are able to block Na+ currents in rat cortical neurons. The results obtained with 2-[2-(3-butoxyphenyl)-ethylamino]-N,N-dimethylacetamide 25 hydrochloride (NW-3509), a representative compound of the chemical class of this invention, compared with our standards safinamide and ralfinamide, are reported in Table 3. Table 3 COMPOUND IC 50
IC
50 Ki resting (Kr) depolarized (PM) (piM) 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N dimethylacetamide hydrochloride 25 0.8 0.4 52 (S)-(+)-2-[4-(3-Fluorobenzyloxy) benzylamino]-propanamide (safinamide)* > 100 (180) 7.0 3.6 (S)-(+)-2-[4-(2-Fluorobenzyloxy) benzylamino]-propanamide (ralfinamide)* > 100 (213) 9.0 4.7 * as the salt with methanesulfonic acid 5 Data expressed as IC 5 o value at iM concentration, as well as the affinity for the inactivated state (Ki) demonstrate that the compound of this invention is a very potent and voltage dependent sodium channel blocker. Example 14: Patch clamp evaluation of Na* currents blockade in ND7/23 cell line 10 Cell line maintenance ND7/23 (ECACC No 92090903 from SIGMA), is a hybrid cell line derived from a neonatal rat DRG fused with the mouse neuroblastoma NI8Tg2 (Wood et al., Proc. Biol.Sci., 1990 Sept., 241(1302),187-194). ND7/23 cells exhibit sensory neuron - like properties and express tetrodotoxin-sensitive (TTX-s) but not tetrodotoxin-resistant (TTX-r) currents (Zhou et al.; 15 J.Pharmacol. Exp. Ther., 2003 Aug., 306(2), 498-504; John et al., Neuropharmacology, 2004 Mar, 46(3), 425-438). The lack of TTX-r currents is consistent with the absence of TTX-r channel transcripts in these cells. The molecular identity of the channels responsible for the TTX-s conductance is unknown but 20 it is presumed that is likely to arise from the activity of a mixed population of sodium channels. Cells are routinously maintained in DMEM with 10% of FBS, 4 mM glutamine,ImM sodium piruvate. The day before the patch clamp experiment cells are detached and seeded at 25 100,000 cells / polylysine-coated 35mm Petri dish. Whole Cell Patch Clamp Recordings Experiments on ND7/23 cells were carried out using standard whole cell patch clamp methods (Hamill et al., PFUGHERS ARCH., 1981 Aug, 391(12), 85-100), as described in previous 213494_1 (GHMatters)24/12/209 53 section. Voltage protocols and data analyses 5 To test the effect of compounds on sodium currents in ND7/23 cells, holding membrane potential was set at -90 mV, then a two step protocol was used to determine the voltage dependence of the block. Sodium currents were activated by a 30 ms step pulse to 0 mV (test pulse) from a 2000 ms preconditioning potential of -11OmV (resting condition) and a potential of ~ -70mV (half maximal steady-state condition). 10 Tonic block of resting and depolarized currents at a given drug concentration was calculated as the difference between the peak Na* current in the control external bath solution and peak currents with the test substance divided by control peak. 15 Drug concentration-inhibition curves were obtained by plotting tonic blocks in the resting and depolarized condition, versus drug concentrations. Dose-response curves were fitted to the tonic block data, according to the logistic equation: y = A2+(Al-A2)/[l+(x/IC 5 o)p]. Al and A2 are fixed values of 0 and I corresponding to 0 and 100% current inhibition, x is the drug concentration, IC 50 is the drug concentration resulting in 50% current inhibition and p is the 20 corresponding slope factor. The apparent affinity of drug for the inactivated state (Ki) was calculated according to the equation 1/Kdep=h/Kr + (1-h)/Ki where Kr is the affinity of drug for the resting/closed state; Kdep is the ICSO in the depolarized condition, h and (1-h) are the fractions of channels present 25 at the rest. and dep. potentials, respectively. Solutions and drugs Control bath solution contained (mM): NaCl 80, Choline HCI 40, CaCl2 1.3, MgCl2 2, KCI 2, CdCl2 0.4, NiCl2 0.3, TEACl 20, Hepes 10, Glucose 10. 30 Internal pipette solution consisted of (mM): CsF 65, CsCI 65, NaCl 10, CaCl 2 1.3, MgCl 2 2, Hepes 10, EGTA 10, MgATP 1. 2134994_1 (GHMatters)24112/2009 54 Compounds were dissolved as stock solutions (20 mM) in DMSO. They were diluted to the final concentrations in the external solution. 5 Results The compounds of this invention are able to block Na* currents in ND7/23 cells. The results obtained with 2-[2-(3-pentyloxyphenyl)-ethylamino]-N,N-dimethylacetamide hydrochloride NW-3525 and 2-[2-(3-butoxy-2-fluorophenyl)-ethylamino]-N,N-diethylacetamide, 10 representative compounds of the chemical class of this invention, compared with our standard ralfinamide, are reported in Table 4. Table 4
IC
50
IC
50 Ki COMPOUND resting (Kr) depolarized (pM) (pLM) 2-[2-(3-Pentyloxyphenyl)-ethylamino]-N,N dimethylacetamide hydrochloride 2.9 0.7 0.5 2-[2-(3-Butoxy-2-fluorophenyl) ethylamino]-N,N-dimethylacetamide 13 1.7 1 (S)-(+)-2-[4-(2-Fluorobenzyloxy) benzylamino]-propanamide (ralfinamide)* 149.0 15.0 8.3 15 * as the salt with methanesulfonic acid Data expressed as IC 50 value at pM concentration, as well as the affinity for the inactivated state (Ki) demonstrate that the two compounds of this invention is a very potent and voltage dependent sodium channel blockers. 20 Example 15: In vitro MAO-B enzyme activity assay Membrane preparation (crude mitochondrial fraction) Male Wistar rats (Harlan, Italy weighing 175-200 g) were sacrificed under light anaesthesia and brains were rapidly removed and homogenized in 8 volumes of ice-cold 0.32 M sucrose 2134994_1 (GHMatters)24112/2009 54a buffer containing 0.1 M EDTA, pH 7.4. The crude homogenate was centrifuged at 2220 rpm for 10 minutes and the supernatant recovered. The pellet was homogenized and centrifuged again. The two supernatants were pooled and centrifuged at 9250 rpm for 10 minutes at +4 5 *C. The pellet was resuspended in fresh buffer and centrifuged at 11250 rpm for 10 minutes at +4 *C. The resulting pellet was stored at -80 *C. In vitro enzyme activity assay The enzyme activity was assessed with a radioenzymatic assay using the substrate 4
C
10 phenylethylamine (PEA) specific for MAO-B. The mitochondrial pellet (500 pg protein) was resuspended in 0.1 M phosphate buffer (pH 7.4). 200 pl of the suspension were added to a 50 d solution of the test compound or buffer, 21349"_1 (GHMatter)24/12/2009 WO 2008/151702 55 PCT/EP2008/003848 and incubated for 30 min at 37 'C (preincubation) then the substrate (50 Pl) was added. The incubation was carried out for 10 minutes at 37 *C (" 4 C-PEA, 0.5 pM). The reaction was stopped by adding 0.2 ml of perchloric acid. After centrifugation, the 5 deaminated metabolites were extracted with 3 ml of toluene and the radioactive organic phase containing the neutral and/or acidic metabolites formed as a result of MAO-B activity was measured by liquid scintillation spectrometry at 90% efficiency. The MAO-B activity was expressed as moles of substrate transformed/mg protein/min. 10 Compounds representative of the entire chemical class of this invention don't show MAO-B inhibition, at relevant concentrations, as reported in Table 5 as ICso values (the concentration of the compound able to inhibit by 50% the MAO-B enzyme activity). As a matter of fact a significative MAO-B inhibition is considered when the IC 50 values are in the sub-micromolar range such as our standards safinamide and ralfinamide. 15 Table 5 MAO-B Compound
IC
50 jiM 2-[2-(3-Butoxyphenyl)-ethylamino]-N-methylacetamide 110 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N dimethylacetamide hydrochloride 231 2-[2-(3-Butoxy-2,6-difluorophenyl)-ethylamino]-N,N dimethylacetamide hydrochloride >300 2-[2-(3-Butoxy-4-methoxyphenyl)-ethylamino]-N,N dimethylacetamide >300 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N dimethylpropanamide hydrochloride >300 (S)-(+)-2-[4-(3-Fluorobenzyloxy)-benzylamino] propanamide (safinamide)* 0.1 (S)-(+)-2-[4-(2-Fluorobenzyloxy)-benzylamino] propanamide (ralfinamide)* 0.2 * as the salt with methanesulfonic acid WO 2008/151702 56 PCT/EP2008/003848 Example 16: Formalin test According to a modified protocol from Rosland et al. (Rosland J. H., Tjolsen A., Maehle B., Hole K. Pain (1990) 42: 235-242), mice were injected subcutaneously (s.c.) with 20 pl of 5 2.7% solution of formalin into the plantar surface of left hindpaw and placed immediately into clear PVC observation chambers (23 x 12 x 13 cm). Pain behaviour was quantified by counting the cumulative licking time (s) of the injected paw. Measurements were taken during the early phase (0-5 min) and late phase (20-40 min) after formalin injection (Tjolsen A., Berge 0. G., Hunskaar S., Rosland J. H., Hole K. Pain (1992) 51: 5-17). 10 The test compound was administered p.o. or s.c. 5-45 minutes before formalin injection in a volume of 10 ml/kg body weight to groups of 10 mice per dose. Control group was treated with vehicle. The orally and subcutaneous administered compounds of the invention can be found active in this experimental model. 15 The results expressed as ED50 value, obtained with one compound administered at 0.6-20 mg/kg p.o. and s.c., which is representative of the entire class of compounds of the invention, and reported in Table 6 demonstrates that this compound has a good analgesic activity. Table 6 Compound
ED
50 (mg/kg) P.O. 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N dimethylacetamide hydrochloride 14.9 (S)-(+)-2-[4-(2-Fluorobenzyloxy) benzylamino]-propanamide (ralfinamide)* 29.3 (S)-(+)-2-[4-(3-Fluorobenzyloxy)- 69.4 benzylamino]-propanamide (safinamide)* 20 * as the salt with methanesulfonic acid Example 17: Spinal nerve ligation model of neuropathic pain Effects on neuropathic pain are tested in the Spinal Nerve Ligation model (SNL) (Kim S. H.
WO 2008/151702 57 PCT/EP2008/003848 and Chung J. M. (Pain (1992) 50: 355-363). Animals: Adult male Wistar rats weighing 175-200 g were used. All animals were housed in groups of 8/10 in a temperature (22±0.5 'C) and relative-humidity (60-70%) controlled room 5 on a 12-h light/dark cycle (lights on between a 6 a.m. to 6 p.m.) and allowed free access to water and standard diet for rodents. Drugs: After measurement of a basal allodynic threshold, test compounds dissolved in distilled water was administered orally at the doses of 0.5-100 mg/kg in a volume of 2 ml/kg. Control rats were treated with vehicle. 10 Spinal nerve ligation: Neuropathy was produced according to a modified method described by Kim S. H. and Chung J. M. (Pain (1992) 50: 355-363). Briefly, the animals were anaesthetized with sodium thiopental 35 mg/kg i.p. (plus additional dose if needed) and after the exposure of the dorsal vertebral column from L4 to S2, the exposed L5 and L6 spinal nerves were tightly ligated with 4-0 silk suture, and the incision was closed. Rats were 15 allowed to recover after surgery for about 5-14 days before testing. Mechanical Allodynia: Mechanical allodynia thresholds were determined according to the method of Chaplan et al. (Chaplan S. R., Bach F. W., Pogrel J. W., Chung J. M. and Yaksh T. L. J. Neurosc. Method. (1994) 53: 55-63). Rats were placed in individual plastic boxes of 24 x 10 x 15 cm on a mesh metal floor and allowed to acclimate for about 30 min before testing. 20 The paw withdrawal thresholds of the hind paws of the rats were determined in response to probing with 8 calibrated von Frey filaments (Stoelting, Wood Dale, IL) with logarithmically incremental stiffness ranging from 0.41 to 15 g (4 to 150mN). Each filament was applied perpendicularly to the plantar surface of the ligated paw of rats. A maximal cut-off of 15g was used. Withdrawal thresholds was determined by sequentially increasing and decreasing the 25 stimulus strength ("up-down" method), analyzed by using a Dixon nonparametric test, and expressed as the mean withdrawal threshold (Dixon W. J. Am. Stat. Assoc. (1965) 60: 967 978). The mechanical allodynia thresholds both in the sham and operated animals was measured before (pre-drug) and at 15, 30, 60, 90, 120, 180, 240, 300, 360 and 420 min after p.o. treatment. A 24 h threshold was also measured in both treatment schedules. The test was 30 carried out between 9 a.m. and 6 p.m. The observers were blind to the experimental and treatment conditions. Thermal hyperalgesia: Thermal hyperalgesia was assessed using the plantar test (Ugo Basile, Varese, Italy). The rats were placed in Plexiglas enclosures on a clear glass plate. With the rat standing relatively still, a radiant heat source beneath the glass floor was aimed at the plantar 35 surface of the hind paw, and the withdrawal latency was measured. Before assessment of WO 2008/151702 58 PCT/EP2008/003848 thermal hyperalgesia, the intensity of the radiant heat was adjusted to yield a baseline latency of about 20 seconds from naive rats with the cutoff of automatically set at 30 seconds to avoid tissue damage. 5 Orally administered representative compounds of this invention were found active in this experimental model. (Figure 1: Effect of 2-[2-(3-butoxyphenyl)-ethylamino]-N,N-dimethylacetamide hydrochloride (NW-3509) orally administered in thermal hyperalgesia in SNL rats. ED50 = 10.58 mg/kg (6.7-16.6). Values represent the mean +SEM of 10 animals per group.) 10 Example 18: Complete Freund's adjuvant model of chronic inflammatory pain Monoarthritis was induced in rats (200 g weight) by an intra-plantar injection into the left hind paw of 100 pd of complete Freund's adjuvant (CFA, Sigma) containing heat-killed and dried Mycobacterium tubercolosis in a mixture of paraffin oil and an emulsifying agent, 15 mannide monooleate. A group of naive rats were used as control. The CFA injection produced an area of localized oedema and inflammation starting from few h after injection, with a progressive reduction in the mechanical withdrawal threshold. Each animal was allowed to develop the arthritis over a period of 8-9 days before testing. Mechanical Allodynia: Mechanical allodynia thresholds were determined according to the 20 method of Chaplan et al. (Chaplan S. R., Bach F. W., Pogrel J. W., Chung J. M. and Yaksh T. L. J. Neurosc. Method. (1994) 53: 55-63). Rats were placed in individual plastic boxes of 24 x 10 x 15 cm on a mesh metal floor and allowed to acclimate for about 30 min before testing. The paw withdrawal thresholds of the hind paws of the rats were determined in response to probing with 8 calibrated von Frey filaments (Stoelting, Wood Dale, IL) with logarithmically 25 incremental stiffness ranging from 0.41 to 15 g (4 to 150mN). Each filament was applied perpendicularly to the plantar surface of the ligated paw of rats. A maximal cut-off of 15g was used. Withdrawal thresholds was determined by sequentially increasing and decreasing the stimulus strength ("up-down" method), analyzed by using a Dixon nonparametric test, and expressed as the mean withdrawal threshold (Dixon W. J. Am. Stat. Assoc. (1965) 60: 967 30 978). The mechanical allodynia thresholds both in the sham and operated animals was measured before (pre-drug) and at 15, 30, 60, 90, 120, 180, 240, 300, 360 and 420 min after p.o. treatment. A 24 h threshold was also measured in both treatment schedules. The test was carried out between 9 a.m. and 6 p.m. The observers were blind to the experimental and treatment conditions. 35 Orally administered representative compounds of this invention were found active in this WO 2008/151702 59 PCT/EP2008/003848 experimental model. Example 19: Acetic acid-induced visceral pain model in mice 5 Visceral pain is still one of the most common forms of pain, which seeks medical care. Despite the conventional belief that visceral pain is a variant of somatic pain, it differs in neurological mechanisms and transmission pathways. Visceral pain is characterized by referral hyperalgesia and also it is not always linked to tissue injury. The acetic acid-induced visceral pain model is widely used in experimental research to 10 produce abdominal contractions ( Korster R et al,. Fed. Pro. (1959) 18: 412; Friese N et al., Life Sci. (1997) 60: 625-634) The model consists of intraperitoneal (i.p.) injection of an irritant that induces a syndrome called 'writhing', which consists of contractions of the abdomen, twisting and turning of the trunk, arching of the back and extension of the hind limbs. 15 Animals and procedure: Male CD1 mice weighing 25-33 g were used. Each treated group was allowed 30 min to habituate to laboratory surroundings in individual polypropylene transparent boxes. The visceral pain was scored by counting the number of writhes for 10 min after i.p. injection of 0.6% acetic acid (10 ml/kg of body weight). The number of writhes after acetic acid administration were evaluated. Both complete body stretching (complete writhe) 20 or partial stretching with a clear contracting of the abdomen (partial writhe) were counted. Separate groups of 10 mice each were administered orally with vehicle (10 ml/kg), or different doses of the tested compound dissolved in vehicle (10 ml/kg ), 5 min before acetic acid injection. Data are expressed as the mean number of writhes during the 10 min observation period. 25 Orally administered representative compounds of this invention were found active in this experimental model reducing the number of writhes induced by acetic acid. (Figure 2: Effect of 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide hydrochloride (NW-3509) orally administered at 20 mg/Kg p.o. in acetic acid induced visceral pain test. ***p<0.01 vs. vehicle t-test. Values represent the mean+SEM of n = 10 animals per group. 30 ***p<0.01 Dunnet's test.) Example 20: Maximal electroshock test (MES) in mice The maximal electroshock test (MES) is used commonly in the screening of anti-epileptic drugs in rodent models. 35 Animals and Apparatus: Male CDI mice weighing 25 g were used. The procedure described 60 by White et aL. (White H. S., Woodhead J. H., Franklin M. R., Swinyard E. A., and Wolf H. H. Antiepileptic Drugs (1995) 4th ed: 99-110, Raven Press, Ltd., New York) was followed. An Ugo Basile electroconvulsive generator (Model ECT UNIT 7801) was used to deliver an 5 electrical stimulus sufficient to produce a hindlimb tonic extensor response in at least 97% of control animals. The stimulus was delivered intra-aurally through clip electrodes in mice (0.7 s of a 40 mA shock, with a pulse train of 80 Hz having a pulse duration of 0.4 ms). The acute effect of compounds administered intraperitoneally (i.p.), subcutaneously (s.c.), intravenously (i.v.) or orally (p.o.) 5-120 minutes before MES induction were examined and compared with 10 a vehicle control group. Ten mice were studied per group. Complete suppression of the hindlimb tonic extensor component of seizures was taken as evidence of anticonvulsant activity. The compounds of the invention were administered p.o. or i.v., at the doses of 0.1 - 100 15 mg/kg. The results, expressed as ED50 values obtained with some compounds representative of the entire chemical class of the invention, are reported in Table 7 and in Table 8, demonstrate that these compounds are active as anticonvulsant drugs. 20 Table 7 Compound % protection ED 50 10 mg/kg p.o. (mg/kg p.o.) 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N- 100 4.3 dimethylacetamide hydrochloride 2-[2-(3-Butoxyphenyl)-ethylamino]-N methylacetamide hydrochloride 30 12.1 2-[2-(3-Butoxy-2,6-difluorophenyl)- 100 2.0 ethylamino]-N,N-dimethylacetamide hydrochloride 2-[2-(3-Pentyloxyphenyl)-ethylamino]-N,N- 100 2.8 dimethylacetamide hydrochloride 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N- 60 6.5 2134994_1 (GHMatters)24/12/2M00 WO 2008/151702 61 PCT/EP2008/003848 dimethylpropanamide hydrochloride 2-[2-(3-Hexyloxyphenyl)-ethylamino]-N,N- 100 4.6 dimethylacetamide hydrochloride Table 8 Compound MES ED 50 mg/kg i.v. 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N dimethylacetamide hydrochloride 0.2 (S)-(+)-2-[4-(2-Fluorobenzyloxy) benzylamino]-propanamide (ralfinamide)* 2.7 (S)-(+)-2-[4-(3-Fluorobenzyloxy) benzylamino]-propanamide (safinamide)* 4.0 5 * as the salt with methanesulfonic acid Example 21: Amphetamine and chlordiazepoxide-induced hyperlocomotion in mice In this model, mice are treated with a mixture of d-amphetamine plus an anxiolytic dose of the benzodiazepine, chlordiazepoxide (Rushton R, Steinberg H. Combined effects of 10 chlordiazepoxide and d-amphetamine on activity of rats in an unfamiliar environment. Nature 1966; 211:1312-3;. R. Arban, G. Maraia, K. Brackenborough, L. Winyard, A. Wilson, P. Gerrard, C. Large,. Evaluation of the effects of lamotrigine, valproate and carbamazepine in a rodent model of mania Behavioural Brain Research, 158: 123-132).The model has been claimed to mimic some aspects of mania in bipolar disorder. Importantly, the hyperactivity 15 induced by the mixture of d-amphetamine and chlordiazepoxide could be prevented by prior administration of the established mood stabilizer, lithium, as well as other mood stabilizers drugs (e.g. magnesium valproate and carbamazepine). Therefore, this model has face and predictive validity as a model of bipolar disorder and represents a valuable tool to determine, if a test compound could be a potential mood stabilizer drug candidate. 20 Amphetamine (AMP) (2.5 mg/kg) plus chlordiazepoxide hydrochloride (CDZ) (3 mg/kg/ip) were administered to male Albino Swiss mice (25-32 g) in a volume of 10 ml/kg. The locomotor activity was recorded using Opto-M3 System (Columbus Instruments) which is multi-channel activity monitor. Opto-M3 system has 10 infrared emitters and respective amount of receivers (0.5" beam spacing), attached to the PC computer and calculating both WO 2008/151702 62 PCT/EP2008/003848 ambulatory activity and total counts. Thus the system differentiates forward locomotion (ambulation) from stereotyped like movement (total counts). Mice were pretreated with the test compound (0.5-20 mg/kg) and 10 min later, with AMP (2.5 mg/kg) or AMP jointly with 5 CDZ (3 mg/kg). After successive 30 min. the mice were treated again with the same dose of the test compound and were placed individually in the motor activity cages. The locomotor activity (ambulation and total activity count) was evaluated for 30 min. Each group consisted of 8-10 mice. Statistical analysis: the data were evaluated by an analysis of variance (ANOVA), followed, 10 when appropriate, by individual comparison with the control using Dunnett's test. Results show that amphetamine and amphetamine-chlordiazepoxide (CDZ) administration induced a significant increase in locomotor activity. Orally administered representative compounds of this invention were found active in this experimental model decreasing amphetamine and amphetamine-chlordiazepoxide induced 15 hyperactivity. (Figure 3: Ambulation over 30 min. a) chlordiazepoxide (3.0 mg/Kg ip); b) 2-[2-(3-butoxyphenyl)ethylamino]-N,N dimethylacetamide hydrochloride (NW-3509) (20.0 mg/Kg po); c) amphetamine (2.5 mg/kg i.p.). 20 Amphetamine alone and the mixture amphetamine + chlordiazepoxide significantly increased locomotor activity **p<0.001 Dunnet's test vs. vehicle. 2-[2-(3-Butoxyphenyl)ethylamino]-N,N-dimethylacetamide hydrochloride (NW-3509) reduced hyperactivity induced by both amphetamine alone and by the mixture of amphetamine and chlordiazepoxide in a statistical significant way ##p<0.001 Dunnet's test 25 vs. amphetamine or amphetamine + chlordiazepoxide. Data represent the mean + SEM of n = 10 mice per group.) Example 22: Morris Water Maze test (amnesia induced by scopolamine in rat) The method which detects antiamnesic activity, follows that described by Morris (Learn. 30 Motiv., 12 239-260, 1981).The Morris Maze consists of a circular water tank (Diameter = 150 cm) filled with water and maintained at 26-28 'C with an escape platform (Diameter = 15 cm) 18 cm from the perimeter and always in the same position 1.5 cm beneath the surface of the water. The water is made opaque by addition of a non-toxic coloring agent (e.g. milk powder) rendering the platform invisible.
63 The animals are given 4 training sessions over 4 consecutive days (Day 1 to Day 4). Each training session consists of 4 trials in the Morris Maze, each separated by 1 minute. For each trial the animal is placed in the maze at one of four starting points equally distributed around 5 the maze and allowed to find the escape platform. The animal is left on the escape platform for 60 seconds before being returned to its home cage. If the animal does not find the platform within 120 seconds the experimenter removes it from the water and places it on the platform for 60 seconds before replacing it in its home cage. During the 4 trials the animals start the maze once from each starting point in a randomly determined order per animal. 10 The trials are video-recorded and the behaviour of animals is analyzed using a video-tracking system (Panlab: SMART). The principal measure taken is the escape latency at each trial. Additional measures are the swim speed and distance travelled. 15 Scopolamine-treated animals (0.5 mg/kg i.p., administered 30 minutes before each session) show amnesia in this task as indicated by the failure to reduce their escape latencies from trial to trial and from session to session. A probe test will be performed on Day 5. The platform is removed from the maze and the animal allowed to swim freely in the maze for 60 seconds. The principal measure taken is the time spent in the target quadrant (i.e. that previously 20 containing the platform), which is compared with the time spent in the other quadrants and with the value expected by chance (i.e. 25% of probe test duration). Twelve scopolamine treated rats are studied per group. The experiment also includes a normal control group receiving saline instead of scopolamine. The test substance is evaluated at 3 doses, administered p.o. 5-60 minutes before the each training session and the probe trial, i.e. 30 25 minutes before scopolamine, and compared with a vehicle control group. The experiment will therefore include 5 groups. Data are analyzed by comparing treated groups with scopolamine control using unpaired Student's t tests. 30 Orally administered representative compounds of this invention were found active in this experimental model. 2134994_1 (GHMatter)24/12/2009 63a Example 23: Cognition model - Novel Object Recognition test The object recognition test consists of a sample trial and a choice trial separated by an inter trial interval (ITI). On the sample trial, two identical objects are presented. On the choice trial, 5 one of the objects presented in sample trial (termed as familiar objects) is replaced by a new object. Rats are able to discriminate between the familiar object and the new object when the 2134994_1 (GHMatters)24/12/20 WO 2008/151702 64 PCT/EP2008/003848 ITI is lh or less, but not with a 24h ITI ( Deschaux 0, et al, 1997, Neurosci. Lett. 222, 159 162 ; Ennaceur A, et al, 1989.,Behav. Brain Res. 33, 197-207; Puma C, Bizot JC, 1998, Neurosci. Lett. 248, 183-186.). Therefore, the object recognition task with a lh ITI allows to 5 detect the amnesic effect of a drug and whether this amnesic effect is reduced by another drug. The object recognition test with a 24h ITI allows to detect a drug-induced enhancement of memory. Numerous studies have been conducted in order to assess memory effects of drugs. For example, past studies demonstrated that nicotine improves memory in the 24-h ITI condition and reduces scopolamine-induced amnesia in the 1-h ITI condition. 10 Methods: The object recognition task is performed as described in Bizot JC, et al, 2005 Prog Neuropsychopharmacol Biol Psychiatry. 29:928-935 Subjects: Naive 8-week old male Wistar rats were used Apparatus: The apparatus of the object recognition task is an open box made of grey opaque Plexiglas (40 cm L, 40 cm W, 40 cm H). The objects to be discriminated (3.5 cm L, 6 cm H) 15 differ in both color and shape. They are a white door button round shape and a grey door button star shape. Apparently, they have no natural significance for rats and they had never been associated with reinforcement. In order to rule out the possibility of scent traces left on the objects and therefore the dependency of the recognition capacity of rats on the olfactory cue, the objects and the ground of the box are washed with clear water and dried between 20 each trial. A video camera is fixed to the ceiling above the box to monitor the animals' activity. Experiments take place over 2 days (scopolamine-induced anmesia) or 3 days (natural forgetting). The test consists of a 15-min habituation trial ( day 1), a 3-min sample trial ( day 2) and a 3-min choice trial ( day 2 or day 3). 25 Scopolamine-induced amnesia experiment. This experiment is conducted on rats randomly subdivided in different groups (n= 12/group) which receive: - control group: 1 intraperitoneal (IP) injection of saline 30 min before the test (sample trial) 1 per-os (PO) injection of saline 15 min before the test and. - Scopolamine group: 1 IP injection of scopolamine (0.1 mg/kg) 30 min before the test and 1 30 PO injection of saline 15 min before the test (sample trial) - Scopolamine + Nicotine group: 1 IP injection of scopolamine (0.1 mg/kg) 30 min before the test and 1 IP injection of nicotine (0.4 mg/kg) 20 min before the test (sample trial) - Scopolamine + representative tested compound groups: 1 IP injection of scopolamine (0.1 mg/kg) 30 min before the test (sample trial) and 1 PO injection of different doses of the tested 35 compound 15 min before the test (sample trial).
WO 2008/151702 65 PCT/EP2008/003848 On Day I The rat is allowed to explore the apparatus for 15 min. (Habituation trial). On day 2 the rat is placed in the apparatus with two identical objects presented in two corners of the box for 3 min ( sample trial). After 1 hr the rat is placed in the apparatus with two objects; one of 5 the objects presented in sample trial (termed as familiar objects) is replaced by a new object. (Choice trial). Natural forgetting experiment: This experiment is conducted on rats randomly subdivided in different groups (n= 12/group) which receive - Control group: I intraperitoneal (IP) injection of saline 20 min before the test and 1 per-os 10 (PO) injection of saline 15 min before the test. - Nicotine group: 1 IP injection of nicotine (0.2 mg/kg) 20 min before the test and 1 PO injection of saline 15 min before the test. - Representative tested compound group: 1 IP injection of saline 20 min before the test and 1 PO injection of tested compound at various doses 15 min before the test. 15 On Day 1 The rat is allowed to explore the apparatus for 15 min. (Habituation trial). On day 2 the rat is placed in the apparatus with two identical objects presented in two comers of the box for 3 min ( sample trial). Twenty four hours later (day 3) the rat is placed in the apparatus with two objects; one of the objects presented in sample trial (termed as familiar objects) is replaced by a new object. 20 Data: The basic measurement is the time spent by the rats in exploring the objects during the sample trial and during the choice trial.. Object recognition task indices include the following parameters: - The total exploration time in the sample trial, - The total exploration time in the choice trial. 25 - The difference of exploration time between the new object and the familiar object in the choice trial (N-F). - The discrimination index, that is 100x(N-F) divided by the total exploration time in the choice trial. Data are analysed by ANOVA and Student's t-test. 30 Orally administered representative compounds of this invention were found active in this experimental model reducing scopolamine-induced amnesia in the object recognition task with a 1-h inter trial interval (1 hr ITI) and improving memory in a natural forgetting situation, i.e. in the object recognition task with a 24 hours inter trial interval (24hr ITI). 35 Example 24: Depression test: Tail Suspension Test in the mouse 66 Tail-suspension test is one of the so-called "behavioural despair" models and are used for the screening of antidepressant drugs. They are based on a common phenomenon: a normal animal submitted to a non-soluble aversive situation alternates between agitation and 5 immobility. The reason of agitation is searching, it is highly energy consuming, while the purpose of immobility is energy conservation. Animals after antidepressant treatment struggle more even in desperate situation, and they spend less time with immobility. Some aspects of neurotic depression can be studied with the aid of these models. 10 The present method detects antidepressant and anxiolytic activity and follows that described by Stdru et al (Psychopharmacology, 85 367-370, 1985). Rodents, suspended by the tail, rapidly become immobile. Antidepressants decrease the duration of immobility, whereas tranquillizing agents increase the duration of immobility. The behaviour of the animal is recorded during 6 minutes automatically using a computerized device (Itematic-TST) 15 developed by Stdru et al (Prog. Neuropsychopharmacol. Exp. Psychiatry, L 659-671, 1987). 6 mice are studied simultaneously. Two parameters are recorded : - Duration of immobility : this parameter is analogous to that used in the "behavioural despair" test (Arch. Int. Pharmacodyn. Ther., 229 327-336, 1977). 20 - Power of movements : this parameter, based on the energy expended by the animal, is independent of the duration of activity. 10 mice are studied per group. The test is not performed blind but the randomization schedule 25 generated by the Itematic-TST ensures a homogeneous distribution of the treatments both in time and in the position of each animal in the apparatus. The test substance is evaluated at 3 doses, administered p.o. 5-60 minutes before the test, and compared with a vehicle control group. Imipramine (128 mg/kg p.o.) and diazepam (8 mg/kg p.o.), administered under the same experimental conditions, are used as reference substances. 30 The experiment therefore includes 6 groups. Data are analyzed by comparing treated groups with vehicle control using unpaired Student's t tests. Orally administered representative compounds of this invention were found active in this 2134994_1 (GHMatters)24/12/2009 67 experimental model. Example 25: Cognitive impairment in schizophrenia method 5 Cognitive impairment is often associated with schizophrenia and it has come to be recognized as a core element of the disorder, bearing on patient's recovery and re-integration into society. Particular interest has recently attracted a pharmacological model of cognitive dysfunctions in schizophrenia, which is based on the effects of glutamate NMDA receptor antagonists such as 10 phencyclidine (PCP) and ketamine (Javitt et al., Am. J. Psychiatry, 1991 Oct., 148(10), 1301 1308) which impair attention and increase "impulsivity" and "compulsive" perseveration in mice performing a complex task (Greco et al., Psychopharmacology (Berl), 2005 Apr., 179(1), 68-76). 15 Materials and Methods Animals: Male DBA/2N mice (Charles River, Italy) were used. The mice weighed 25-30 g at the start of the experiments, and were housed under temperature-controlled conditions (21 *C) with a 12 h light 12 h dark cycle (light on 7:00 am-7:00 pm). Food (Rieper, Italy) was available ad libitum. The animals had two hours of access to water at the end of each day's 20 testing. The five-choice serial reaction time task apparatus: The test apparatus consisted of four 21.6 x 17.8 x 12.7 cm chambers (Med Associates Inc. USA), as previously described (Greco et al., Psychopharmacology (Berl), 2005 Apr., 179(1), 68-76). Stimuli and recording of responses, 25 were managed by a SmartCtrlTM Package 8 In/16 Out (Med Associates Inc. USA) with additional interfacing by MED-PC for Windows (Med Associates Inc. USA). The running program for the 5-CSRT task was custom-written. Behavioural procedures: habituation to liquid reinforcer and nose-poking in the holes. Mice 30 were handled for one week and their body weight recorded. They were then water-deprived by allowing them 2-h access to water in the early evening until their body weight had stabilised (8 days). Then, over the next two days the mice were habituated in their home cages to the reinforcer (10% sucrose solution) used afterwards in the operant procedures. On 21349941 (GHMattes)24/12/2009 67a the following two days mice were habituated to the operant boxes. During this stage, 10% sucrose solution was available in a small bowl placed below the receptacle hole of the box. First, mice had to learn that every 5 sec the liquid reward was available in a small cup in the 5 receptacle hole. During this period head entries were recorded. During the next period, mice were trained to poke their noses into the illuminated holes. Immediately after a poke in the water receptacle a LED at the rear of one of the holes was turned on. A nose-poke in the lighted hole extinguished the light stimulus and the liquid dipper provided a 0.01 mL liquid reward in the receptacle hole. Any response in one of the other four holes had no consequence 10 and was not recorded. The light stimulus was presented in all five holes in random order. A mouse was switched to the 5-CSRT task after it had completed at least 50 rewarded nose-poke 2134994_1 (GHMatters)24/12/2009 WO 2008/151702 68 PCT/EP2008/003848 trials in one 30-min session. The five-choice serial reaction time task. The start of the session was signalled by illumination of the house-light and the delivery of a 0.01 mL liquid reward. Nose poking in 5 the receptacle hole began the first trial. After a fixed delay (the inter-trial interval, ITI), the LED at the rear of one of the holes came on for a short period. The LED stimulus was presented the same number of times in each hole during a complete session, with the order of presentation randomised by the computer. While the light was on, and for a short period afterwards (the limited hold), responses in the hole that was illuminated (correct response) 10 resulted in the liquid reward. Responses in the holes that had not been illuminated (incorrect responses) or failure to respond within the limited hold (omissions) caused the house-lights to be turned off for a short period (time out). Responses in the holes while the house-light was off restarted the time out. After the delivery of the liquid reward, or at the end of time out, the mouse started the next trial by poking its nose into the receptacle hole. Responses made in 15 the holes after a correct response (perseverative responses), or after the end of time out before nose-poking into the receptacle hole, resulted in a period of time out. Responses in the holes during the ITI (anticipatory responses) also resulted in a period of time out. After anticipatory responses a nose-poke into the receptacle hole restarted the current trial. Each daily session consisted of 100 trials or 30 min of testing, whichever was completed sooner, after which all 20 lights were turned off and further responses had no effect. In the first session of the test schedule, the stimulus and limited hold each lasted 1 min and, depending on individual performance, they were progressively reduced to 1 sec. The stimulus duration was reduced in the following sequence: 60, 30, 10, 5, 2.5, 2, 1.5 and 1 sec (baseline). The ITI and time out both lasted 2 sec during the first session and the ITI was raised to 5 sec in subsequent 25 sessions; time out was not changed. Throughout the whole period of training and experiments each mouse had one session per day on a 5-CSRT task. Drugs and treatment schedules. The test compound is dissolved in water and is administered intraperitoneally (i.p.) at the dose of 10 mg/kg. Five minutes after the treatment mice were injected with vehicle (saline) or PCP (1.5 mg/kg) and 10 min later they started the test 30 session. In each experiment the various combination of the test compound with vehicle or PCP are administered according to a Latin-square design. At least 48 h are left between the drug testing days. During these intervening days the mice are tested on the 5-CSRT task to re establish baseline performance and to check for any residual effects of drugs. Statistical analysis: The main dependent variables selected for analysis are: (a) the percentage WO 2008/151702 69 PCT/EP2008/003848 of correct responses (total correct responses/total correct + total incorrect responses x 100); (b) percentage of omissions (total omissions/ total correct responses + total incorrect responses + total omissions x 100); (c) the number of anticipatory responses in the holes 5 during the ITI; (d) the number of perseverative responses in the holes after a correct response. Correct responses and omissions, as percentages, are transformed according to the formula 2arcsin(SQRT (%X/100)), to normalize the distributions in accordance with the ANOVA model (Winer, 1971). The effects of the test compound (n=12) on PCP induced deficits in the 5-CSRT task were 10 analysed independently by a within subjects 2 x 2 ANOVA with factors Drug (test compound) and PCP. Subsequently the treatment group means are compared using apost-hoc Tukey-Kramer test. Statistical software (SAS Institute Inc., USA) was run on Micro VAX 3500 computer (Digital, USA). PCP causes a profound effect on attentional performance of DBA/2N mice increasing 15 anticipatory and perseverative responses. Representative compounds of this invention, administered 10 mg/Kg i.p., reversed PCP induced increase in anticipatory and perseverative responses, supporting the use of this kind of compounds for the treatment of psychiatric disorders. 20 Example 26: Prepulse inhibition of startle in mice and rats. Prepulse inhibition (PPI) is a cross-species phenomenon (ie, it is present in mammals ranging from mice to humans), yet it is relatively absent among schizophrenic patients. The reduced ability to filter out among irrelevant auditory stimulation is a characteristic thought to 25 contribute to certain manifestations of these conditions including inattention, distractibility, and cognitive deficits. The PPI procedure is used to assess the subject's ability to "gate" or filter environmental information. In the acoustic (startle model) of sensorimotor gating a weak acoustic stimulus (prepulse) decrease the reflexive flinching response (startle) produced by a second, more intense, stimulus (the pulse). Drugs like dizocilpine (MK-801) or amphetamine 30 disrupt PPI and represent an animal model of schizophrenia. Antipsychotic drugs are able to prevent PPI deficit. The test is quite useful to screen potential antipsychotic drugs. Similarly some strains of mice such as the DBA/J display a spontaneous impairment of PPI that can be reversed by antipsychotic drugs and are also used as animal model of schizophrenia. 35 PPI in rat: Wistar or Sprague-Dawley rats (weighing 200 to 300 g) or 3-week-old DBA/2J WO 2008/151702 70 PCT/EP2008/003848 mice were used. The startle apparatus (San Diego Instruments, CA) consisted of 12 plastic transparent cages, placed individually in a sound-proof cabinets, equipped with a movable platform floor attached to a sensor recording vertical movements of the platform. Startle 5 reaction was evoked by acoustic stimuli delivered by a loudspeaker suspended above the cages and connected to an acoustic generator. The transient force resulting from the movements of the platform evoked by the startle reaction was recorded with a PC computer during a recording window of 200 ms measured from the onset of the acoustic stimulus, digitalized and stored in the computer for further evaluation. The amplitude of the startle 10 response was measured during the whole recording window (200 ms) and an average value of amplitude was taken for further evaluation. The control and treated rats were placed in the testing cages individually. After 5 min of habituation (background white noise, 65 dB), two types of acoustic stimuli were used in random order: acoustic stimulus alone [120 dB, 40 ins, (P)] or the stimulus proceeded by a prepulse [75 dB, 20 ms (PP)] applied 100 ms before the 15 stimulus. During each experimental session 20 trials of each type were presented with interstimulus interval of 20 s. The amplitudes were averaged for each individual animal, separately for both types of trials (stimulus alone or stimulus preceded by the prepulse). The percent PPI was calculated with the following formula: 100 - [(mean startle amplitude for prepulse + pulse trials/mean startle amplitude for pulse alone trials) x 100] i.e. 100 - (PP/P) x 20 100. A high value of the calculated %PPI indicated that the prepulse inhibited the response to a pulse stimulus, whereas a low value indicated weaker inhibition by prepulse. Deficits of sensorimotor gating was induced by MK-801 (0.2 mg/kg) given ip 5 min before test or amphetamine (2.5 mg/kg) given sc 10 min before test. Orally administered representative compounds of this invention were found active in this experimental model, reversing PPI 25 deficit induced by MK-801 (Figure 4) or by amphetamine. PPI in DBA mice: Male 3-week-old DBA/2J and C57BL/6J mice were used. Detection of acoustic startle response and PPI was performed as described in Bortolato et al Psychopharmacology, 2007, Oct; 194(3): 361-9. In each experiment, mice were assigned to receive either compounds of the invention or 30 vehicle and were tested in the PPI session using a between-subjects design. The percent PPI was calculated with the following formula: 100 - [(mean startle amplitude for prepulse + pulse trials/mean startle amplitude for pulse alone trials) x 100] i.e. 100 - (PP/P) x 100. The magnitude of the acoustic startle response was calculated as the average response to all of the pulse-alone trials, excluding the first and last blocks of five pulse-alone trials 35 presented.
WO 2008/151702 71 PCT/EP2008/003848 Orally administered representative compounds of this invention were found active in this experimental model reducing PPI deficit of BDA/2J mice. (Figure 4: Effect of 2-[2-(3-butoxyphenyl)ethylamino]-N,N-dimethylacetamide hydrochloride 5 (NW-3509) in MK-801 PPI disruption in rats. Data are expressed as mean + SEM of n = 10 animals. p<0.01 indicate statistically significant difference between vehicle and MK-801. *p<0.05 **p<0.01 indicate statistically significant differences between vehicle + MK-801 treated animals and animals treated with 2-[2-(3-butoxyphenyl)ethylamino]-N,N dimethylacetamide hydrochloride (NW-3509). 10 Analysis of variance followed by Dunnet's test.) Example 27: Paradoxical sleep deprivation in rats. The psychopathological and neurobiological relationships between sleep and psychotic phenomena have been evidenced by a number of classical clinical observations and 15 psychological reports. Schizophrenic patients exhibit severe insomnia, together with a number of structural alterations of sleep architecture, such as a reduction in REM sleep latency and duration, as well as a decrease in SWS (Slow Wave Sleep) time. Numerous studies have demonstrated that prolonged sleep deprivation is indeed conducive to a number of transient psychological disorders, including impaired verbal constructions, disorganized thought, 20 depersonalization and perceptual changes, ranging from minor disturbances and abnormal bodily sensations to complex acoustic and visual hallucinations. Typically, these disorders are indistinguishable from psychotic phenomena, but are normally extinguished following a prolonged recuperative sleep. Several studies have documented that following a period of forced sleep deprivation, rats exhibit for a limited time a paradoxical array of behavioral 25 changes, such as stereotyped behavior and hyperactivity. Moreover, sleep deprivation in rats enhances startle reaction and disrupts PPI, this effect is time-dependent and reversible by antipsychotic drugs (Gessa, GL et al. (1995) European Neuropsychopharmacology 5, 89-93). Such phenomena are commonly interpreted as relevant to psychosis, as they are also typically produced by psychotomimetic agents in rats. The model of sleep deprivation in rats can be 30 considered a model of mania. Animals: Sprague-Dawley rats (weighing 200 to 300 g) were used. Methods: The procedure to induce paradoxical sleep deprivation (SD) in rats is based on the platform method (modified from Jouvet, et al (1964). Journal ofPhysiology (Paris), 56, 381). Rats were kept on a small Plexiglas platform (7 cm in diameter) within a deep tank filled with 35 water. Each platform was surrounded by water up to 1 cm, beneath the surface. Chow pellets WO 2008/151702 72 PCT/EP2008/003848 and water bottles were located on a grid on the top of the tank. During the whole SD study, the temperature of the experimental room and the water inside the tank were maintained at 23 1 *C. Control rats are placed in the experimental room, either in their home cages or on 5 water tanks equivalent to those used for SD, but with a 12 cm-diameter platform, which allows them to reach REM sleep without falling into the water. At the end of the SD period (72 hr), rats were immediately dried out and placed either in the startle chambers (for PPI measurement) or in the activity cages (hyperactivity) for behavioral testing. The water in the tank was changed daily throughout the SD period. Control rats were maintained in the same 10 room as the sleep-deprived rats for the duration of their SD. Compounds to be tested were given before PPI or behavioural testing. Data Analysis: For each animal, the mean startle amplitudes for the first and the second halves of the second period of the session (blocks, six pulse-alone trials each) were analyzed with a two-way or three-way analysis of variance (ANOVA), with pretreatment (where 15 present) and treatment as between-subjects factors and blocks as repeated measures. The percent PPI was calculated with the following formula: 100 - [(mean startle amplitude for prepulse + pulse trials/mean startle amplitude for pulse alone trials) x 100] i.e. 100 - (PP/P) x 100 and analyzed in multifactor ANOVAs (with specific design and comparisons noted below for each experiment) with the different combinations of injections for pretreatment and 20 treatment as between-subjects factors and trial types as repeated measures. Post hoc analyses were performed using Tukey's test. Locomotor activity data were analysed using the one- or two-way analysis of variance (ANOVA) for repeated measures when appropriate, followed by Tukey's test as post-hoc tests. Orally or intraperitoneally or subcutaneously administered representative compounds of this 25 invention were found active in this experimental model reducing PPI deficit and hyperactivity induced by sleep deprivation. Example 28: Cocaine-induced behavioural sensitization test Drug addiction is a pathological behaviour characterized by compulsive drug seeking and 30 intake. One animal model of these behavioural changes is the long-lasting increase in locomotor activity induced by repeated administration of psychostimulant drugs in rodents (Robinson T. E. and Berridge K.C. Brain Res. Brain Res. Rev. (1993) 18, 247-91) known as drug-induced behavioural sensitization. The effect of test compounds were evaluated in a model of cocaine-induced behavioural sensitization in rat. 35 Locomotor activity apparatus: Male Wistar rats weighing 200-250 g upon arrival were used.
WO 2008/151702 73 PCT/EP2008/003848 Locomotor activity was measured in sixteen identical metal wire hanging cages each measuring 36 cm (L) x 25 cm (W) x 20 cm (H). Each cage contained two sets of infrared emitter-detector photocells positioned along the long axis 1 cm above the grid floor and 8 cm 5 from the front and back of the cage. Background noise was provided by a white noise generator. Movement within the cages produced photocell interruptions, which were automatically recorded by an IBM-compatible computer. Sensitization procedure and treatment: Animals were habituated to the locomotor activity chambers for 2-3 consecutive days before the experiment. Rats received 5 daily i.p. injections 10 of cocaine (15 mg/kg) or saline and either the test compound (0.1-100 mg/kg) or its vehicle and locomotor activity was recorded for 3 h. Ten days after the last injection of cocaine or saline (day 15), the animals were challenged with 15 mg/kg of cocaine in absence of the test compound and locomotor activity was again monitored for 3 h. By the fifth day of treatment with cocaine, animals pretreated i.p. with vehicle showed an 15 increased locomotor response (20% higher then the first day, p < 0.05). Ten days after the last injection of cocaine or saline, the animals were challenged with 15 mg/kg of cocaine in absence of the test compound and locomotor activity was again monitored for 3 h. The rats previously treated with cocaine and that had not received the test compound are expected to show an increased locomotor activity response to cocaine (30% higher then first day, p 20 <0.05). If the rats that had been pretreated with the test compound during the 5 day-cocaine treatment did not show an increase in locomotor activity the test compound is considered to have an effect in preventing psychostimulant drugs addiction. (Koob G. F., Sanna P. P., Bloom F. E. Neuron (1998) 21: 467-476; Robinson T. E., Berridge K. C. Brain Res Brain Res Rev (1993) 18: 247-291) 25 Statistical analysis: Data (total number of beam breaks in 3 hours) were analyzed using a two way ANOVA with repeated measures on one factor including the four experimental groups (i.e., saline/vehicle, saline/test compound, cocaine/vehicle and cocaine/test compound) and two time points (day 1 and day 5) followed by a simple effects analysis. A second two way ANOVA with repeated measures on one factor was used to compare day 1 and the challenge 30 day followed by a Newman-Keuls post hoc test. Orally administered representative compounds of this invention were found active in this experimental model. Example 29: Acute bladder irritation by acetic acid in rats 35 Experiments were performed using adult anesthetized female Sprague Dawley rats (170-200 WO 2008/151702 74 PCT/EP2008/003848 g). A catheter (PE-50) was inserted via a midline abdominal incision into the bladder through the bladder dome, and then intravescical pressure was measured to monitor bladder activity during continuous infusion of 0.15% acetic acid. Continuous intravescical infusion of acetic 5 acid irritates the bladder and reduces the intercontraction intervals (ICI) in anesthetized rats. ICIs, maximal contraction pressure, and pressure thresholds inducing reflex bladder contraction were measured before and after intravescical infusion of acetic acid in rats treated with compounds of the invention. Intraperitoneally or intravenously administered representative compounds of this invention 10 were found active in this experimental model. Example 30: Intermediate bladder irritation by cyclophosphamide (CYP) in rats 15 Experiments were performed using both adult awake and anesthetized female Sprague Dawley rats (170-200 g). Chemical cystitis was induced by CYP , which is metabolized to acrolein, an irritant eliminated in the urine. CYP (150 mg/kg/i.p.) was administered one day before the experiment. Pre-treatment with CYP causes bladder irritation and very frequent voidings with an ICI of about 150-200 seconds between voids. 20 Intraperitoneally or intravenously administered representative compounds of this invention increased the ICI in both awake and anesthetized rats used in this experimental model. Example 31: Migraine test in rats Animals and surgery: Male Wistar rats (250-350 g) were anesthetized with sodium 25 pentobarbital (50 mg/kg i.p.) dissolved in saline. The trachea and left femoral artery were cannulated for artificial ventilation (55 strokes/min) and for measurement of mean blood pressure (MBP) respectively. The femoral vein was cannulated for the intravenous administration of test agents. Body temperature was maintained at 37-38 'C by automatic control of a heating pad. Animals 30 were placed in a stereotaxic frame and a longitudinal incision was made in the scalp. A burr hole was drilled in the skull and a stainless steel bipolar electrode (Plastic One MS 306) was lowered into left ophthalmic branch of the trigeminal ganglion (3.8 mm dorsal to bregma, 2.5 mm lateral from the midline and 9.5 mm below the dural surface) and secured with dental cement. Correct placement of the electrode was confirmed by a brief electrical stimulation, 35 which cause movement of the jaw due to activation of the trigeminal fiber. Following removal 75 of the brain, the correct position of the electrode into the fiber, was visually checked at the end of each experiment. 5 A second hole was drilled ipsilateral of the electrode (1.5 mm rostral to bregma, and 1.5 mm lateral from the sagittal suture) and a needle probe (tip diameter 0.8 mm) of a laser doppler flowmeter was fixed pointing with its tip onto a branch of the middle cerebral artery (MCA) and Cerebral Blood Flow (CBF) change recorded on-line by the PeriFlux 4001 Laser Doppler system. 10 Artefacts of the laser Doppler reading during electrical stimulation of the trigeminal ganglion due to muscular movements were prevented by a bolus of i.v. injection of the neuromuscular blocker pancuronium bromide (0.6 mg/kg i.v.). 15 Anaesthesia and neuromuscular blockade were maintained all over the experiment with an infusion of sodium pentobarbital and pancuronium (12.5 mg/kg/h + 2.4 mg/kg/h, respectively). Experimental protocol: At the end of the surgery, a pause of thirty minutes was taken in order 20 to stabilize the measured parameters. Rest CBF was increased by electrical stimulation with rectangular pulse of 0.5 ms length, 1 10 Hz, 0.5-1 mA for periods of 30 s. After two averaged pre-drug stimulations, vehicle or drugs were administered. 25 Intravenously administered representative compounds of this invention reduced the increase in blood flow induced by trigeminal stimulation. In the claims which follow and in the preceding description of the invention, except where the 30 context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention. 2134994_1 (GHMattes)24/12/2009
Claims (2)
- 2-[2-(3-Pentyloxyphenyl)-ethylamino]-acetamide 2-[2-(3-Hexyloxyphenyl)-ethylamino]-acetamide 2-[2-(3-Butoxyphenyl)-ethylamino]-N-methylacetamide 2-[2-(3-Pentyloxyphenyl)-ethylamino]-N-methylacetamide 25 2-[2-(3-Hexyloxyphenyl)-ethylamino]-N-methylacetamide 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butylyhiophenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butylsu Ifonylphenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxyphenyl)-(N'-hydroxy)ethylamino]-N,N-dimethylacetamide 30 2-[2-(3-Butoxyphenyl)- (N'-methoxy)ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxyphenyl)- (N'-propoxy)ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethyl-thioacetamide 2-[2-(3 -Butoxyphenyl)-2-methylpropylamino]-N,N-dimethylacetamide 2- {2-[3-(4,4,4-Trifluorobutoxy)phenyl]-ethylamino} -N,N-dimethylacetamide 35 2930290_1 (GHMatters) P82528 AU 3/11/11 79 2-[2-(3-Butylthiophenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxy-2-chlorophenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxy-2-fluorophenyl)-ethylamino]-N,N-dimethylacetamide 5 2-[2-(3-Butoxy-4-methoxyphenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-diethylacetamide 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dipropylacetamide 2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dibutylacetamide 2-[2-(3-Pentyloxyphenyl)-ethylamino]-N,N-dimethylacetamide 10 2-[2-(3-Hexyloxyphenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxyphenyl)-ethylamino]- 1 -pyrrolidin- I -yl-ethan- 1-one 2-[2-(3-Pentyloxyphenyl)-ethylamino]-I -pyrrolidin- 1 -yl-ethan- 1-one 2-[2-(3-Hexyloxyphenyl)-ethylamino]- I -pyrrolidin- 1 -yl-ethan- 1-one 2-[2-(3-Butoxyphenyl)-ethylamino]- N,N-dimethylpropanamide 15 2-[2-(3-Butoxyphenyl)-ethylamino]-3-hydroxy-N,N-dimethylpropanamide 2-[2-(3-Butoxyphenyl)-ethylamino]-3-methoxy-N,N-dimethylpropanamide 2-[2-(3-Butoxyphenyl)-ethylamino]-3-propoxy-N,N-dimethylpropanamide 2-[2-(3-Butoxyphenyl)-ethylamino]-2,N,N-trimethylpropanamide 2-[2-(3-Pentyloxyphenyl)-ethylamino]-2,N,N-trimethylpropanamide 20 2-[2-(3-Hexyloxyphenyl)-ethylamino]-2,N,N-trimethylpropanamide (S)-2-[2-(3-Butoxyphenyl)-ethylamino]-propanamide (S)-2-[2-(3-Butoxyphenyl)-ethylamino]-N-methylpropanamide (S)-2-[2-(3-Butoxyphenyl)-ethylamino]-N,N-dimethylpropanamide (R)-2-[2-(3-Butoxyphenyl)-ethylamino]-propanamide 25 (R)-2- [2-(3 -Butoxyphenyl)-ethylamino]-N-methylpropanamide (R)-2- [2-(3 -Butoxyphenyl)-ethylamino]-N,N-dimethylpropanamide 2-[2-(3-Butoxy-2-trifluoromethylphenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxy-4-trifluoromethylphenyl)-ethylamino]-N,N-dimethylacetamide 2-[2-(3-Butoxy-5-trifluoromethylphenyl)-ethylamino]-N,N-dimethylacetamide 30 if the case, either as single optical isomer in the isolated form or mixture thereof in any proportion and its pharmaceutically acceptable salts. 6) The compound of claim I which is 2-[2-(3-butoxyphenyl)-ethylamino]-N,N dimethylacetamide, 2-[2-(3-butoxy-2,6-difluorophenyl)-ethylamino]-N,N-dimethylacetamide, 2-[2-(3-pentyloxyphenyl)-ethylamino]-N,N-dimethylacetamide, or 2-[2-(3-hexyloxyphenyl)
- 2134994.1 (GHMaters)24/12/2009 80 ethylamino]-N,N-dimethylacetamide, and the pharmaceutical acceptable salts thereof. 7) The compound of claim 6 which is 2-[2-(3-butoxyphenyl)-ethylamino]-N,N 5 dimethylacetamide or a pharmaceutically acceptable salt thereof. 8) The compound of any one of claims 5 to 7, wherein the pharmaceutically acceptable salt is the hydrochloride salt or the methanesulfonate salt. 9) The compound of claim I wherein: X is -S0 2 - ; or 10 Y is OH or O(CI-C 4 )alkyl; or Z is=S;or R is (C 9 -Cio)alkyl or o-trifluoro(C 3 -Cio)alkyl; or R, and/or R 2 are different from hydrogen; or both R 3 and R' 3 are different from hydrogen; or 15 both R 4 and R 5 are different from hydrogen, but do not form a (C 3 -C 6 )cycloalkyl residue when taken together with the adjacent carbon atom; or R 6 and R 7 , taken together with the adjacent nitrogen atom form a monocyclic 5-6 membered saturated heterocycle, optionally containing one additional heteroatom chosen among -0-, -S- and -NR 8 -, where R 8 is hydrogen or 20 (CI-C 6 ) alkyl; with the proviso that when X is -S- or -SO 2 -, then Y is not OH or O(CI-C 4 )alkyl; if the case, either as single optical isomer in the isolated form or mixture thereof in any proportion and its pharmaceutically acceptable salts. 10) Use of a compound of any one of claims 1 to 9 as a medicament. 25 11) Use of a compound of any one of claims I to 9, in the manufacture of a medicament. 12) Use of a compound of any one of claims I to 9 as a medicament active as sodium and/or calcium channel modulator for the treatment of pathologies where the above said mechanism(s) play(s) a pathological role, which is a neurological, cognitive, psychiatric, inflammatory, urogenital or gastrointestinal disorder, said medicament being substantially free 30 from any MAO inhibitory activity or having significantly reduced MAO inhibitory activity. 13) Use of a compound of any one of claims I to 9 in the manufacture of a medicament active as sodium and/or calcium channel modulator for the treatment of pathologies where the above said mechanism(s) play(s) a pathological role, which is a neurological, cognitive, psychiatric, inflammatory, urogenital or gastrointestinal disorder, said medicament being 2134994_1 (GHMatters)24/12/2009 81 substantially free from any MAO inhibitory activity or having significantly reduced MAO inhibitory activity. 14) The use according to claim 12 or 13, wherein the disorder is a neurological disorder 5 selected from pain and migraine. 15) The use according to claim 14, wherein pain is a neuropathic pain syndrome or an inflammatory pain syndrome. 16) The use according to claim 14, wherein pain is an acute or chronic pain. 17) The use according to claim 12 or 13, wherein the disorder is a neurological disorder 10 selected from Alzheimer's disease, Parkinson's disease, epilepsy, restless legs syndrome, stroke or cerebral ischemia. 18) The use according to claim 12 or 13, wherein the disorder is an inflammatory process affecting all body systems such as the muscle-skeletal system, an arthritic condition, a disorder affecting skin and related tissues, a disorder of the respiratory system or a disorder of 15 immune and endocrinological system. 19) The use according to claim 12 or 13, wherein the disorder is a cognitive and/or psychiatric disorder selected from Mild Cognitive Impairment, depression, bipolar disorder, mania, schizophrenia, psychosis, anxiety and addiction. 20) The use according to claim 12 or 13, wherein the disorder is a urogenital disorder. 20 21) The use according to claim 12 or 13, wherein the disorder is a gastrointestinal disorder. 22) The use according to any one of claims 10 to 21, wherein the compound is associated with one or more other therapeutic agents. 23) A pharmaceutical composition containing, as the active ingredient, a compound of any of claims I to 9 together with pharmaceutically acceptable therapeutically inert organic or 25 inorganic carrier materials. 24) The use according to claim 19, wherein said compound is associated with one or more other therapeutic agents according to claim 22, wherein the other therapeutic agent is an antipsychotic agent. 25) The use according to 24, wherein the compound is 2-[2-(3-butoxyphenyl)-ethylamino] 30 N,N-dimethylacetamide or a pharmaceutically acceptable salt thereof and the antipsychotic agent is selected from the group consiting of haloperidol, risperidone and clozapine. 26) The use according to claim 25, wherein the compound is the hydrochloride or methanesulfonate salt of 2-[2-(3-butoxyphenyl)-ethylamino]-N,N-dimethylacetamide and the antipsychotic agent is haloperidol or risperidone. 2134994_1 (GHMatters)24/12/2009 82 27) The use according to claim 18, wherein the disorder of the immune system is multiple sclerosis or a demyelinizating disorder. 28) The use according to any one of claims 12 to 27, wherein the patient affected by the 5 disorder(s) is sensitive to unwanted side-effects due to MAO inhibitory activity. 29) A method for treating a patient affected by a disorder caused by dysfunctions of voltage-gated sodium and/or calcium channel, which comprises the administration to said patient of an effective amount of a compound of any of claims I to 9. 30) The method according to claim 29, wherein the disorder is a neurological, cognitive, 10 psychiatric, inflammatory, urogenital or gastrointestinal disorder. 31) The method according to claim 29 or 30, wherein the disorder is a neurological disorder selected from pain and migraine. 32) The method according to claim 29 or 30, wherein the disorder is a neurological disorder selected from Alzheimer's disease, Parkinson's disease, epilepsy, restless legs syndrome, 15 stroke or cerebral ischemia. 33) The method according to claim 29 or 30, wherein the disorder is a cognitive and/or psychiatric disorder selected from Mild Cognitive Impairment, depression, bipolar disorder, mania, schizophrenia, psychosis, anxiety and addiction. 34) The method according to any one of claims 29 to 33, wherein the effective amount of 20 the compound administered to the patient in need thereof does not exhibit any MAO inhibitory activity or exhibits a significantly reduced MAO-inhibitory activity. 35) The method according to any one of claims 29 to 34, wherein the patient is sensitive to unwanted side-effects due to MAO inhibitory activity. 36) The method according to any one of claims 29 to 35, wherein the effective amount of a 25 compound of any of claims 1 to 9 is administered to a patient in need thereof in conjunction with one or more other therapeutic agents. 37) A compound of general formula (I), a pharmaceutical composition containing the compound, or uses or methods involving the compound, substantially as herein described with reference to the Examples and/or Figures. 2134994_1 (GHMatters)24/12/2009
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07011766 | 2007-06-15 | ||
EPEP07011766.8 | 2007-06-15 | ||
PCT/EP2008/003848 WO2008151702A1 (en) | 2007-06-15 | 2008-05-14 | Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators |
Publications (3)
Publication Number | Publication Date |
---|---|
AU2008261325A1 AU2008261325A1 (en) | 2008-12-18 |
AU2008261325A2 AU2008261325A2 (en) | 2010-04-08 |
AU2008261325B2 true AU2008261325B2 (en) | 2012-12-06 |
Family
ID=38658156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2008261325A Active AU2008261325B2 (en) | 2007-06-15 | 2008-05-14 | Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators |
Country Status (28)
Country | Link |
---|---|
US (8) | US8519000B2 (en) |
EP (1) | EP2155663B1 (en) |
JP (1) | JP5440496B2 (en) |
KR (1) | KR101545124B1 (en) |
CN (1) | CN101687773B (en) |
AR (1) | AR068976A1 (en) |
AU (1) | AU2008261325B2 (en) |
BR (1) | BRPI0813363B8 (en) |
CA (1) | CA2689561C (en) |
CY (1) | CY1119787T1 (en) |
DK (1) | DK2155663T3 (en) |
EA (1) | EA018195B1 (en) |
ES (1) | ES2655704T3 (en) |
HK (1) | HK1138566A1 (en) |
HR (1) | HRP20180324T8 (en) |
HU (1) | HUE038113T2 (en) |
IL (1) | IL202235A (en) |
LT (1) | LT2155663T (en) |
MX (1) | MX2009013119A (en) |
NO (1) | NO2155663T3 (en) |
NZ (1) | NZ581288A (en) |
PL (1) | PL2155663T3 (en) |
PT (1) | PT2155663T (en) |
RS (1) | RS56780B1 (en) |
SI (1) | SI2155663T1 (en) |
TR (1) | TR201802576T4 (en) |
TW (1) | TWI400071B (en) |
WO (1) | WO2008151702A1 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1842328A (en) * | 2003-08-25 | 2006-10-04 | 纽朗制药公司 | Alpha-aminoamide derivatives useful as anti-inflammatory agents |
JP5213265B2 (en) * | 2009-10-08 | 2013-06-19 | 花王株式会社 | Method for evaluating or selecting Lox-1 expression regulator |
PL2723710T3 (en) * | 2011-06-27 | 2017-02-28 | Newron Pharmaceuticals S.P.A. | Fluorinated arylalkylaminocarboxamide derivatives |
CN103804341B (en) * | 2012-11-13 | 2018-04-10 | 中国人民解放军军事医学科学院毒物药物研究所 | Amide derivatives and its medical usage |
CN104761531B (en) * | 2014-01-03 | 2017-12-01 | 中国人民解放军军事医学科学院毒物药物研究所 | Analgesic activities compound and its medical usage |
CA3004448A1 (en) * | 2015-11-12 | 2017-05-18 | Afasci, Inc. | Ion channel inhibitory compounds, pharmaceutical formulations and uses |
CN106316824B (en) * | 2016-08-18 | 2018-10-19 | 广州康瑞泰药业有限公司 | A kind of new method of synthesis 2- fluorine cyclopropane-carboxylic acids |
CN112041296B (en) * | 2018-04-28 | 2023-12-29 | 上海璃道医药科技有限公司 | Aminoacetamides containing benzooxy alicyclic structures and uses thereof |
DE112019004296T5 (en) * | 2018-08-30 | 2021-07-22 | Sabic Global Technologies B.V. | FLAVORING CATALYST WITH IMPROVED ISOMERIZATION, MANUFACTURING PROCESS AND USE OF IT |
EP3725768A1 (en) | 2019-04-17 | 2020-10-21 | Newron Pharmaceuticals S.p.A. | Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives |
EP3725769A1 (en) | 2019-04-17 | 2020-10-21 | Newron Pharmaceuticals S.p.A. | Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990014334A1 (en) * | 1989-05-25 | 1990-11-29 | Farmitalia Carlo Erba S.R.L. | N-PHENYLALKYL SUBSTITUTED α-AMINO CARBOXAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION |
WO2004089353A2 (en) * | 2003-04-11 | 2004-10-21 | Newron Pharmaceuticals, S.P.A. | Methods for treatment of parkinson's disease |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB586645A (en) | 1944-07-19 | 1947-03-26 | Burroughs Wellcome Co | Improvements relating to the synthesis of amino acid derivatives and salts thereof |
GB1254332A (en) | 1969-02-27 | 1971-11-17 | Science Union & Cie | Amino acids and their derivatives and processes for preparing them |
US5051403A (en) | 1989-11-22 | 1991-09-24 | Neurex Corporation | Method of treating ischemia-related neuronal damage |
WO1993013128A1 (en) | 1991-12-30 | 1993-07-08 | Neurex Corporation | Methods of producing analgesia and enhancing opiate analgesia |
GB9500691D0 (en) | 1995-01-13 | 1995-03-08 | Smithkline Beecham Plc | Compounds |
GB9515412D0 (en) | 1995-07-27 | 1995-09-27 | Pharmacia Spa | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives |
GB9518572D0 (en) | 1995-09-12 | 1995-11-15 | Smithkline Beecham Plc | Compounds |
US5845454A (en) * | 1996-04-23 | 1998-12-08 | Malizia; John T. | Drop ceiling hanging system |
CA2251368A1 (en) | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
WO1998054123A1 (en) | 1997-05-30 | 1998-12-03 | Warner-Lambert Company | Substituted peptidylamine calcium channel blockers |
DE19740110A1 (en) | 1997-09-12 | 1999-03-18 | Boehringer Ingelheim Pharma | New hydroxy substituted benzomorphan derivatives |
GB9727523D0 (en) * | 1997-12-31 | 1998-02-25 | Pharmacia & Upjohn Spa | Alpha-aminoamide derivatives useful as analgesic agents |
WO1999055688A1 (en) | 1998-04-27 | 1999-11-04 | Warner-Lambert Company | Substituted diarylalkyl amides as calcium channel antagonists |
US6011035A (en) | 1998-06-30 | 2000-01-04 | Neuromed Technologies Inc. | Calcium channel blockers |
AU4329499A (en) | 1998-07-30 | 2000-02-21 | Warner-Lambert Company | Reduced dipeptide analogues as calcium channel antagonists |
WO2001021621A1 (en) | 1999-09-22 | 2001-03-29 | Ortho-Mcneil Pharmaceutical, Inc. | BENZO-FUSED DITHIEPINO[6,5-b]PYRIDINES, AND RELATED COMPOSITIONS AND METHODS |
DE60103261T2 (en) | 2000-03-23 | 2005-06-02 | Ortho-Mcneil Pharmaceutical, Inc. | THIEPINO [3,2-B] DIHYDROPYRIDINES AND RELATED COMPOSITIONS AND METHOD |
EP1268427A1 (en) | 2000-03-31 | 2003-01-02 | Cocensys, Inc. | Aminopyridines and their use as anticonvulsants and sodium channel blockers |
US6521647B2 (en) | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
SE0102858D0 (en) | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
DE60209152T2 (en) | 2001-09-03 | 2006-08-03 | Newron Pharmaceuticals S.P.A. | PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGON THEREOF AND AN ALPHA AMINOAMIDE |
SI1458386T1 (en) | 2001-12-27 | 2007-08-31 | Ortho Mcneil Pharm Inc | Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder |
EP1438956A1 (en) | 2003-01-16 | 2004-07-21 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful as antimigraine agents |
WO2004087125A1 (en) | 2003-04-02 | 2004-10-14 | Ionix Pharmaceuticals Limited | Amino acid derivatives as inhibitors of mammalian sodium channels |
CN1842328A (en) * | 2003-08-25 | 2006-10-04 | 纽朗制药公司 | Alpha-aminoamide derivatives useful as anti-inflammatory agents |
EP1557166A1 (en) | 2004-01-21 | 2005-07-27 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
EP1588704A1 (en) | 2004-04-22 | 2005-10-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders |
WO2006027052A2 (en) | 2004-09-10 | 2006-03-16 | Newron Pharmaceuticals S.P.A. | (halobenzyloxy) benzylamino-propanamides as sodium and/or calcium channel selective modulators |
ES2556937T3 (en) * | 2005-12-22 | 2016-01-21 | Newron Pharmaceuticals S.P.A. | 2-Phenylethylamino derivatives as modulators of calcium and / or sodium channels |
EP1870097A1 (en) | 2006-06-15 | 2007-12-26 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders |
-
2008
- 2008-05-14 PT PT87494498T patent/PT2155663T/en unknown
- 2008-05-14 DK DK08749449.8T patent/DK2155663T3/en active
- 2008-05-14 PL PL08749449T patent/PL2155663T3/en unknown
- 2008-05-14 EA EA201070018A patent/EA018195B1/en unknown
- 2008-05-14 AU AU2008261325A patent/AU2008261325B2/en active Active
- 2008-05-14 TR TR2018/02576T patent/TR201802576T4/en unknown
- 2008-05-14 RS RS20180061A patent/RS56780B1/en unknown
- 2008-05-14 WO PCT/EP2008/003848 patent/WO2008151702A1/en active Application Filing
- 2008-05-14 NZ NZ581288A patent/NZ581288A/en unknown
- 2008-05-14 NO NO08749449A patent/NO2155663T3/no unknown
- 2008-05-14 LT LTEP08749449.8T patent/LT2155663T/en unknown
- 2008-05-14 US US12/663,926 patent/US8519000B2/en active Active
- 2008-05-14 CA CA2689561A patent/CA2689561C/en active Active
- 2008-05-14 SI SI200831914T patent/SI2155663T1/en unknown
- 2008-05-14 MX MX2009013119A patent/MX2009013119A/en active IP Right Grant
- 2008-05-14 CN CN200880020386.5A patent/CN101687773B/en active Active
- 2008-05-14 HU HUE08749449A patent/HUE038113T2/en unknown
- 2008-05-14 BR BRPI0813363A patent/BRPI0813363B8/en active IP Right Grant
- 2008-05-14 EP EP08749449.8A patent/EP2155663B1/en active Active
- 2008-05-14 KR KR1020107001038A patent/KR101545124B1/en active IP Right Grant
- 2008-05-14 ES ES08749449.8T patent/ES2655704T3/en active Active
- 2008-05-14 JP JP2010511510A patent/JP5440496B2/en active Active
- 2008-05-19 TW TW097118361A patent/TWI400071B/en active
- 2008-06-13 AR ARP080102533A patent/AR068976A1/en active IP Right Grant
-
2009
- 2009-11-19 IL IL202235A patent/IL202235A/en active IP Right Grant
-
2010
- 2010-04-30 HK HK10104274.7A patent/HK1138566A1/en unknown
-
2013
- 2013-03-11 US US13/794,377 patent/US9248116B2/en active Active
- 2013-03-11 US US13/794,555 patent/US9051240B2/en active Active
-
2015
- 2015-02-05 US US14/615,275 patent/US9603832B2/en active Active
- 2015-02-05 US US14/614,758 patent/US9474737B2/en active Active
- 2015-02-05 US US14/615,176 patent/US9474738B2/en active Active
- 2015-02-05 US US14/614,677 patent/US9585869B2/en active Active
- 2015-02-05 US US14/615,227 patent/US9474739B2/en active Active
-
2018
- 2018-01-16 CY CY20181100053T patent/CY1119787T1/en unknown
- 2018-02-22 HR HRP20180324TT patent/HRP20180324T8/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990014334A1 (en) * | 1989-05-25 | 1990-11-29 | Farmitalia Carlo Erba S.R.L. | N-PHENYLALKYL SUBSTITUTED α-AMINO CARBOXAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION |
WO2004089353A2 (en) * | 2003-04-11 | 2004-10-21 | Newron Pharmaceuticals, S.P.A. | Methods for treatment of parkinson's disease |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2008261325B2 (en) | Substituted 2- [2- (phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | |
EP1963280B1 (en) | 2-phenylethylamino derivatives as calcium and/or sodium channel modulators | |
CA2833824C (en) | Fluorinated arylalkylaminocarboxamide derivatives | |
AU2012278193A1 (en) | Fluorinated arylalkylaminocarboxamide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 24 DEC 2009 AND 23 FEB 2010 |
|
FGA | Letters patent sealed or granted (standard patent) |